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ABSTRACT 
 
 
According to the statistics from American Cancer Society, the 5-year survival rate 
for patients with advanced melanoma is as low as 5%. Treatment of advanced melanoma, 
therefore, represents an unmet medical need. In this dissertation, I will show the effort to 
develop new generations of bioavailable tubulin inhibitors targeting the colchicine 
binding site and selective small-molecule survivin inhibitors for treating advanced 
melanoma. Extensive structure-activity relationship (SAR) studies of lead molecules 
ABI-231 and UC-112 have been performed. 
 
Chapter 1 will introduce the current situation of advanced or metastatic 
melanoma, its clinical drug treatments, as well as problems in current drug treatments. 
Microtubule dynamics and survivin will be discussed as promising therapeutic targets for 
developing anticancer drugs. 20S-hydroxyvitamin D3 (20S-OH-D3) will be introduced as 
a promising antiinflammatory scaffold. 
 
Chapter 2 will disclose the SAR study of ABI-231, a previously reported potent 
tubulin inhibitor from our lab. In this chapter, a new synthetic method was developed to 
enable the synthesis of ABI-231 analogues modifying the indole moiety. The novel 
synthetic method involved the synthesis of a key diamine intermediate and imidazoline 
formation. From the new synthetic method, thirty ABI-231 analogues were synthesized 
and tested for activities. Among all analogues, 10ab with a 4-methyl-3-indole moiety and 
10bb with a 4-indole moiety showed the most potent antiproliferative activities against a 
panel of melanoma cell lines. 10ab and 10bb had IC50s of 2.2 and 3.0 nM, respectively. 
The SAR result revealed that modification of the indole moiety in ABI-231 was 
beneficial to activity. 
 
In Chapter 3, we will describe our effort to develop the SAR study of ABI-231 
focusing on modification of the 3,4,5-TMP moiety. This is selected since it is one of the 
most common moieties in current tubulin inhibitors targeting the colchicine binding site. 
To circumvent the use of potentially explosive azide reported in Chapter 2, an alternative 
was established to efficiently generate ABI-231 analogues. This new synthetic method 
involved Suzuki coupling and Grignard reactions to modify the 3,4,5-TMP moiety and to 
produce target compounds in gram-scale. Among the eight analogues synthesized, the 
one containing an unique 3-methoxybenzo[4,5]-dioxene moiety had the strongest 
antiproliferative activity against a panel of melanoma cell lines with an average IC50 of 
1.9 nM. To our best knowledge, it represents the most successful instance of isosterically 
modifying the 3,4,5-TMP moiety in CA-4 derivatives. 
 
Chapter 4 will highlight our effort to synthesize reverse ABI (RABI) analogues 
for SAR study. In this chapter, a novel and concise synthetic route was established to 
access RABI scaffold. RABI scaffold was constructed through a Grignard 
reaction/Suzuki-Miyaura coupling reaction strategy. From this new synthetic method, 
twelve novel RABI analogues were synthesized. Compared to MX-RABI(the previously 
reported most potent RABI), several new RABI analogues showed significantly 
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improved cytotoxicities. In particular, analogue 15i with a 4-indazole moiety showed the 
most potent antiproliferative activity against a panel of melanoma cell lines and had an 
average IC50 of 0.8 nM. This is the first sub-nM anti-tubulin compound in the related 
scaffolds. 
 
Chapter 5 will reveal our latest SAR study of UC-112, a previously reported 
selective survivin inhibitor. Fourteen UC-112 analogues modifying the benzyloxy moiety 
of UC-112 were synthesized. Their corresponding SAR result demonstrated that indole 
moiety was the most favorable (analogue 12a). Subsequent structural optimization of 12a 
by introducing either mono-substituent or di-substituent to the indole moiety led to the 
synthesis of another twenty-four new UC-112 analogues. Several substituted indole 
analogues showed equipotency to that of UC-112 and MX-106. Importantly, new indole 
analogues exhibited significant abilities to overcome multidrug-resistance mediated by P-
gp overexpression. 
 
Chapter 6 is characterized by the establishment of a total synthetic method of 20S-
OH-D3 which showed comparable antiproliferative activity to 1,25α-dihydroxyvitamin 
D3 without hypercalcemic toxic effect upto a concentration of 60 μg/kg in vivo. The total 
synthesis of 20S-OH-D3 involved parallel generation of key intermediates from 
ergocalciferol. The vitamin D3 core structure was constructed through Wittig-Horner 
coupling reaction. Deprotection of SEM and TBS was achieved in one step. 20S-OH-D3 
was furnished in sixteen steps with an overall yield of 0.4%. 
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CHAPTER 1.    INTRODUCTION 
 
 
Advanced Melanoma 
 
Melanoma is the least common form of skin cancers and accounts for only about 
5% in cases. It is, however, the deadliest form of all skin cancers and is responsible for 
approximately 80% deaths of patients with skin cancers. According to the statistics from 
the American Cancer Society, it is estimated that approximately 87,110 new cases of 
melanoma will be diagnosed and about 9,730 deaths will result from melanoma in 2017 
[1]. There are five stages in melanoma progress: stages 0-IV. Melanoma begins within a 
single lesion but can spread to nearby lymph nodes and distant organs such as the lung, 
liver, or brain. Melanoma in stage IV is named advanced or metastatic melanoma. For 
patients who are at the very early stage of melanoma, the 5-year survival rate is over 
98%. Surgery is an effective treatment for patients having melanoma with a low thickness 
in the skin (Breslow depths of up to 1.0 mm) [2]. For patients with advanced melanoma, 
the 5-year survival rate is 5-19% [3]. 
 
In nearly 90% cases of melanoma, mitogen-activated protein kinase (MAPK) 
pathway kinases were reported as activated [4]. MAPK pathway (Figure 1-1) is 
composed of a variety of kinases linking the extracellular signals to the DNA in the 
nucleus. MAPK pathway plays an important role in controlling diverse cellular functions 
including cell growth, differentiation, proliferation and apoptosis [5]. RAS is a G protein 
attached to the inner membrane. Upon receiving the activation signals from upstream 
kinases, GDP on the RAS can be detached. Free RAS can bind to GTP to form RAS-GTP 
complex and become activated. On one hand, the RAS-GTP complex can activate BRAF. 
Activated BRAF subsequently induces the phosphorylations of MEK and ERK in a 
sequential fashion. Phosphorylated ERK can then translocate into the nucleus to exert a 
series of cell-regulating functions [6-8]. On the other hand, the RAS-GTP complex can 
stimulate the phosphoinositide 3-kinase (PI3K) which phosphorylates phospholipid 
phosphatidylinositol 4,5-bisphophate (PIP2) to phospholipid phosphatidylinositol 3,4,5-
trisphophate (PIP3). The intracellular signaling propagator PIP3 can promote the 
phosphorylation of the well-known oncogene AKT. Elevated phosphorylation of AKT 
activates the downstream serine/threonine kinase mTOR, a protein that is of great 
importance in regulating cell growth, metabolism, and proliferation [9-11]. 
Phosphorylated AKT and activated mTOR are related to the death of melanoma patients. 
It is reported that nearly 70% of the malignant melanoma cases have elevated levels of 
phosphorylated AKT and activated mTOR [12, 13]. 
 
 
Drug Treatment for Advanced Melanoma 
 
Currently, drug treatments for melanoma can be divided into three categories: 
targeted therapy, chemotherapy, and immunotherapy. 
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Figure 1-1. Biological driver of melanoma 
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Targeted therapy 
BRAF inhibitors 
 
RAF is a serine/threonine-specific protein kinase. The RAF family consists of 
four family members: ARAF, BRAF, CRAF and RAF1 [14]. BRAF is an oncogenic 
driver, which has been demonstrated in both in vitro and in vivo models [15-17]. It was 
shown in 2002 that nearly 50% of melanomas harbored BRAF mutations. 90% of the 
mutations replaced valine at amino acid 600 with glutamate (V600E) while a small 
portion of mutations substituted the valine with lysine, arginine or aspartic acid 
(V600K,V600R/D) [15]. These mutations in the BRAF gene was demonstrated to be 
responsible for the activation of MAPK pathway [18]. 
 
Vemurafenib, the first BRAF inhibitor, was approved by the FDA in 2011. It is 
applied for the treatment of metastatic or unresectable melanoma harboring the BRAF 
V600E mutation. Unlike nonspecific kinase inhibitors such as sorafenib, in a preclinical 
study vemurafenib was revealed to selectively bind to the activated mutant kinase BRAF 
at the ATP-binding site of V600E to inactivate the ERK phosphorylation [19]. An in vivo 
BRAF V600E xenograft animal model study suggested that vemurafenib markedly 
impeded tumor growth in the absence of significant toxicity. In phase I and II clinical 
studies, vemurafenib treatment significantly reduced the tumor size, improved overall 
survival rate, and enhanced progression-free survival in melanoma patients harboring 
BRAF V600E mutation. It was also reported that the median overall survival reached 
13.6 months on average [20, 21]. For patients harboring BRAF V600K or non-V600K 
mutation, no complete or partial response was observed after treated with vemurafenib. 
Most frequently observed side effects for vemurafenib treatment in Phase II and III 
studies included but were no limited to fatigue, rash, and arthralgia [22]. 
 
Another FDA approved selective BRAF inhibitor is dabrafenib (approved in 
2013). Darafenib has a similar response rate and survival rate to that of vemurafenib. 
Darafenib differs from vemurafenib in adverse effect profile. Whilst drug-specific side 
effects for darafenib include fever, specific side effects for vemurafenib involve 
photosensitivity and aminotransferase elevations [22]. In addition, dabrafenib is less 
likely to induce arthralgia and squamous cell carcinoma than vemurafenib [23]. 
MEK inhibitor 
 
MEK1/2 is a serine/tyrosine/threonine kinase. It is a downstream target of the 
MAPK pathway. This cascade is activated and phosphorylated by RAF kinase at serines 
22 and 218 in the activation loop [24]. The abilities of RAF subtypes to activate MEK 
follow the sequence of BRAF > RAF1 > ARAF > CRAF [25, 26]. Activated MEK 
subsequently stimulates the phosphorylation of ERK. Inhibition of MEK can obstruct cell 
proliferation and promote apoptosis [27]. Trametinib and cobimetinib are FDA approved 
MEK inhibitors. Other MEK1/2 inhibitors such as selumetinib, sinimetinib (MEK162), 
PD-0325901, TAK733, pimasertib, and RO4987655 are currently under clinical 
development. 
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Trametinib (GSK1120212) is the first MEK1/2 inhibitor approved by the FDA 
(approved in 2013). It is applied for treatment of metastatic melanoma with BRAF 
V600E/K mutation. Trametinib is a non-competitive MEK1/2 inhibitor and specifically 
binds to an allosteric binding site instead of the ATP site in MEK. Compared to BRAF 
inhibitors vemurafenib and dabrafenib, trametinib was less effective to improve median 
PFS and to trigger complete or partial response [28, 29] but was less likely to cause 
significant toxicities [30]. In particular, trametinib did not induce cutaneous squamous 
cell carcinoma. In a phase III trial that enrolled 322 patients, trametinib significantly 
prolonged the median PFS and overall survival of the patients with BRAF-mutated 
melanoma compared to chemotherapy treatments such as paclitaxel, or dacarbazine 
(DTIC) [31]. 
 
Cobimetinib is another MEK1/2 inhibitor approved by the FDA recently (2015). 
It is mainly used as a combinational therapy with vemurafenib to treat patients with 
BRAF-mutated metastatic melanoma. In phase III clinical trial that enrolled 495 patients 
with advanced melanoma, the combination of cobimetinib and vemurafenib significantly 
improved the median progression-free survival compared to vemurafenib alone [32]. 
 
Selumetinib is a MEK1/2 inhibitor that was in a phase II clinical trial. The in vitro 
assay displayed that selumetinib specifically bond to an adjacent allosteric binding site 
next to the ATP site in MEK1/2. Selumetinib showed potent antiproliferative activity in 
melanoma cell lines with BRAF V600E mutation and arrested the cell cycle in G1-phase 
[33-35]. In a phase I clinical study, selumetinib was found to markedly inactivate 
phosphorylation of ERK [33]. Nevertheless, in a phase II clinical study, selumetinib was 
unable to induce significant objective response. Current effort on selumetinib is, 
therefore, focusing on improving its clinical efficacy by combining with a BRAF 
inhibitor [36]. 
C-kit inhibitor 
 
C-Kit, a receptor tyrosine kinase protein encoded by the Kit gene, is expressed in 
mature melanocytes. C-Kit binds to its ligand stem cell factor to trigger several signaling 
pathways including the MAPK pathway, the PI3K/AKT pathway, and the JAK-STAT 
pathway. In melanoma, 55% of the c-Kit mutated cells contain the substitution of L576P 
and K642E [37]. Recent studies reveal that c-Kit can induce melanocyte proliferation and 
melanoma survival through activation of the MAPK pathway [38].  
 
Imatinib mesylate is an ATP-competitive inhibitor of c-Kit. In a Phase II study, 
imatinib was demonstrated to show significant antitumor activity, particularly in patients 
with advanced melanoma harboring c-Kit abreactions [39]. It was pointed out that 
metastatic melanoma with c-Kit mutations responded more strikingly to imatinib than 
metastatic melanoma with c-Kit amplifications [40]. An in-depth investigation is 
currently undergoing to explore the effect of imatinib on c-Kit mutated advanced 
melanoma. 
 
Nilotinib, a tyrosine kinase inhibitor, was reported to be effective in imatinib-
resistant gastrointestinal stromal tumors. Recently, in a phase II clinical trial, nilotinib 
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showed a lasting response in patients with metastatic melanoma harboring c-Kit 
mutations [41]. In another phase II study that enrolled patients with metastatic melanoma 
harboring c-Kit mutations, nilotinib tremendously improved one-year survival rate of 
patients and triggered durable response without causing severe adverse effects [41, 42]. 
 
 
Immune checkpoint inhibitors 
 
Cancer cells can develop various mechanisms to evade the surveillance of the 
immune system. The mechanisms include but are not limited to releasing of inhibitory 
cytokines, recruiting immunosuppressive immune cells and upregulating immune 
checkpoints [43]. Therefore, inhibition of the immune checkpoints should re-enable the 
immune system to detect and kill cancer cells. To date, reported targetable checkpoints 
for melanoma treatment include but are not limited to programmed cell death 1 (PD1) 
and cytotoxic T-lymphocyte antigen 4 (CTLA4). PD-1 and CTLA-4 are both negative 
regulators of T cell activation. 
Anti CTLA4 antibodies 
 
Ipilimumab is discovered as a CTLA-4 checkpoint inhibitor. It was approved by 
the FDA in 2011 for the treatment of unresectable or metastatic melanoma. In contrast to 
a treatment group receiving placebo, ipilimumab treatment significantly prolonged PFS 
in patients with stage III melanoma [44]. Improved overall survival and median PFS were 
also observed for ipilimumab treatment [45]. However, due to the excessive immune 
activity caused by ipilimumab, mild to severe adverse effects were present in patients 
treated with ipilimumab [45, 46].  
 
Tremelimumab, another anti CTLA-4 antibody, is currently under clinical 
development. In a phase I/II clinical trial that recruited patients with metastatic 
melanoma, less significant toxicity was observed for patients receiving tremelimumab 
than patients treated with ipilimumab[47]. However, tremelimumab did not markedly 
improve the overall survival in a phase III study when compared to conventional 
chemotherapy [48]. 
Anti PD-1 antibodies 
 
Nivolumab is a monoclonal antibody specific for human PD1. It was approved by 
the FDA in 2014 for the treatment of advanced melanoma. In a phase I study that 
nivolumab was applied to treat patients with advanced melanoma, significant clinical 
efficacy and manageable safety profile were observed. Nivolumab gave an overall 
survival rate of 32%. 1-year, 2-year, 3-year and 4-year overall survival rates for 
nivolumab treatment were 63%, 48%, 42% and 32%, respectively. Immune-related grade 
¾ adverse effects were present in 14% of the patients. In a phase III trial, nivolumab was 
effective for metastatic melanoma that was previously treated with ipilimumab. 
Nivolumab accomplished significantly higher overall survival rate than chemotherapy 
treatment [49]. 
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Pembrolizumab (lambrolizumab or MK-3475) is another anti PD-1 antibody 
approved by the FDA in 2014. Pembrolizumab has a high affinity to the IgG4 isotype. In 
a phase I trial that recruited 135 patients with advanced melanoma, the highest response 
rate (~52%) was observed in the highest dose arm. A median duration progression-free 
survival of > 7 months was seen. 13% of the regimen showed grade3/4 adverse events. 
Manageable adverse effects were accompanied with pembrolizumab treatment [50]. A 
clinical trial enrolling 411 patients indicated that pembrolizumab had an overall response 
rate of 34%, a median progression-free survival of 5.5 months, and an overall survival 
rate of 69% at one-year. For patients with metastatic melanoma who were refractory to 
ipilimumab treatment, pembrolizumab was more effective than chemotherapy to prolong 
progression-free survival [51]. 
 
 
Chemotherapy 
 
Traditional chemotherapeutics used for treating melanoma mainly include 
dacarbazine, temozolomide. While these drugs are very effective for treating melanoma 
at the early stages, their clinical effect is not satisfactory when applied to treat advanced 
melanoma. The tumor is prone to acquire resistance over the course of cancer treatment 
when dacarbazine or temozolomide is used. Furthermore, chemotherapy can cause broad 
drug-related side effects such as fatigue, hair loss, appetite loss, diarrhea and peripheral 
neuropathy. Therefore, in modern cancer treatment, chemotherapy is a less preferred 
strategy to targeted therapy and immunotherapy. 
 
 
Challenges in targeted therapy and immunotherapy 
 
Discovery of the oncogenic mutation in BRAF at codon 600 in the MAPK 
signaling pathway has revolutionized the treatment of advanced or metastatic melanoma 
in the last ten years. Several inhibitors targeting the BRAF mutation V600E or its 
downstreams (ERK and MEK) have been approved by the FDA to treat advanced stage 
melanoma. The years 2011 and 2014 have witnessed the approvals of immune checkpoint 
inhibitors ipilimumab and pembrolizumab. Both targeted therapy and immunotherapy 
have brought more substantial clinical benefits than traditional chemotherapies in treating 
metastatic melanoma. However, there are profound problems within targeted therapy and 
immunotherapy. 
 
Despite the fact that targeted therapies such as BRAF inhibitors (vemurafenib and 
dabrafenib) and MEK inhibitor (trametinib) bring substantial initial tumor regression, 
drug resistance can be acquired in nearly 50% patients after a period of 6–8 months` 
treatment [52, 53]. The mechanism of resistance can be divided into three categories: 
intrinsic, acquired, and adaptive resistance [54]. While intrinsic resistance is 
characterized by no response to therapy, acquired resistance is typified by initially 
significant response followed by drug tolerance and progressive disease [54]. The major 
resistant mechanism is the reactivation of the MAPK pathway. The tumor can re-trigger 
the MAPK pathway by activating the downstream MEK1/2 kinase or upstream RAS 
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kinase mutation, elevating the CRAF level, amplifying the BRAF, overexpressing the 
RAF1 or MAP3K8-(COT)-kinase, ERK1/2 mutation, upregulating the RTK, as well as 
mutating the PI3K pathway gene [55-61]. The mechanism of resistance was discussed in 
detail in recent reviews [62-65]. Although combinational therapies of BRAF inhibitors 
and MEK inhibitors, for instance, vemurafenib and trametinib or dabrafenib and 
trametinib, were demonstrated to be more effective for improving median PFS than 
dabrafenib or vemurafenib monotherapy [66], drug resistance remains a significant 
problem with combinational therapies [67, 68]. 
 
Unlike targeted therapy, immune checkpoint inhibitors do not have the problem of 
drug resistance, but they can cause immune-related adverse events (irAEs). IrAEs are 
distinct from adverse events brought by chemotherapy or targeted therapy. These unique 
adverse events result from unrestrained T cell activation and include dermatologic, 
gastrointestinal, hepatic and endocrine toxicities. These toxicities can be reversed, 
however, if not managed timely, they can upgrade to high-grade adverse events and even 
to life-threatening situations [69]. 
 
 
Tubulin Inhibitors for Treatment of Cancer 
 
 
Microtubule dynamics as a therapeutic target 
 
Microtubules are key elements in eukaryotic cells. They are involved in many 
critical cellular functions, such as cell division, cell shape maintenance, vesicles 
transportation, and motility regulation. Formed from polymerized α/β-tubulin 
heterodimers, microtubules are responsible for the generation of mitotic spindle and 
induction of the movement of chromosomes during cellular mitosis [70-72]. Disruption 
of microtubule dynamics causes cell cycle arrest in the G2/M phase, leading to mitotic 
catastrophe and ultimately cellular apoptosis. Given the important role of microtubules in 
cell growth and division, tubulin dynamics has been a fertile target for developing 
anticancer drugs [73-75]. 
 
 
Binding sites in tubulin 
 
At least four binding sites on tubulin have been reported to date: the taxane site, 
the laulimalide site, the vinca site, and the colchicine site (Figure 1-2). A number of 
approved tubulin inhibitors interact with the taxane site (e.g. paclitaxel, docetaxel, and 
epothilones) or the vinca site (e.g. vinblastine, vincristine) in tubulin. They have been 
highly successful in the clinical treatment for many cancer types including ovarian, lung, 
and breast cancers [76-79]. However, the clinical use of these drugs is often associated 
with several limitations. First, these drugs are usually good substrates for a number of 
ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp or MDR1), 
breast cancer resistance protein (BCRP), and multidrug resistant proteins (MRP1, 
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Figure 1-2. Binding sites in tubulin 
Reprinted with permission from Bentham Science Publishers. Wu XX, Wang QH, Li W. 
Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding 
Site. Anti-cancer agents in medicinal chemistry, 2016, 16:1325-1338. 
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MRP2). Thus multidrug resistance often develops in patients upon an extended period of 
drug administration [80-82]. Second, these drugs have very poor aqueous solubility; 
harmful surfactants such as Cremophor EL are usually required in their formulations 
[83]. Finally, overexpression of β-tubulin isoforms (especially the β-III tubulin isoform) 
and certain mutations in tubulin are associated with the development of resistance for 
most of these agents [84-87]. 
 
 
Tubulin inhibitors approved by FDA or in clinical development 
 
Based on their effects on the microtubule structures at high concentrations, 
microtubule-targeting agents (MTAs) can be divided into two categories: microtubule 
stabilizers and microtubule destabilizers. Figure 1-3 and Figure 1-4 list some notable 
examples of the microtubule-stabilizing agents and microtubule-destabilizing agents, 
respectively. 
 
 
Challenges in developing microtubule targeting agents as anticancer agents  
 
Taxanes and vinca alkaloids have achieved great success in clinical treatment for 
a variety of cancers in the last decades; however, acquired drug resistance develops over 
the course of clinical administration and represented a significant obstacle [88]. 
Mechanistically, cancer cells evade cytotoxic MTAs mainly through the following 
pathways: (1) Overexpression of tubulin β-III isotype. Strong clinical evidence supported 
that overexpression of tubulin β-III isotype was responsible for drug resistance to either 
microtubule stabilizer or microtubule destabilizer in patients with different tumor types 
[89]. Overexpression of tubulin β-III might also inherently promote microtubule 
dynamics and prevent cells from proceeding to anaphase [90]. (2) Upregulation of MRP1, 
MRP2 or MDR1 gene. MDR1 gene is responsible for the encoding of P-gp) [72]. P-gp 
mediated drug efflux has been reported as the major mechanism mediated drug-resistance 
to taxanes in many types of tumors [91]. (3) Overexpressed microtubule-regulating 
proteins. It was demonstrated that increased expression of microtubule-regulating 
proteins can stabilize microtubules and contribute to the occurrence of multidrug 
resistance [72]. (4) Changes in cytoskeletal proteins. Mutation in γ-actin was revealed to 
induce vinblastine-resistance [92]. In addition, downregulation of γ-actin was also related 
to drug resistance in childhood leukemia [93]. (5) Tubulin mutations. Certain mutations 
in tubulin are also known to confer resistance to CBSIs. For example, a K350N mutation 
in tubulin induces conformational change to the colchicine binding site and results in 2-
ME2 resistance [94]. Besides these mechanisms, there were other factors that might 
mediate drug resistance to tubulin inhibitors [72, 95]. However, it does not mean that 
these mechanisms induce resistance exclusively, in fact, these mechanisms often work 
collectively. 
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Figure 1-3. Microtubule-stabilizing agents 
 
 
 
 
 
 
Figure 1-4. Microtubule-destabilizing agents 
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Targeting colchicine binding site in tubulin for development of anticancer agents 
 
The colchicine binding site, one of the many well-documented binding sites in 
tubulin, locates at the interface between α and β-tubulin monomers [96]. Colchicine 
binding site inhibitors (CBSIs) mechanistically decrease cellular motility, alter cell 
morphology, impair protein assembly, and arrest mitosis [97, 98]. A number of 
preclinical studies have proven that CBSIs are effective to suppress the overexpression of 
β-tubulin isotype β-III tubulin. CBSIs are also demonstrated to surmount drug-resistance 
mediated by P-gp, MRP1, MRP2 [99-101]. Thus, despite the fact that there are currently 
no FDA-approved tubulin inhibitors interacting with the colchicine binding site [96, 102], 
colchicine binding site represents a great promise and has been extensively investigated. 
There are many CBSIs have entered clinical trials for cancer treatment, for instance, 
ABT-751, ZD6126, CA-4P, AVE8062, OXi4503 and NPI-2358 [103], some of which are 
listed in Figure 1-5. 
 
 
Survivin as a Therapeutic Target for Cancer Treatment 
 
 
Survivin as a therapeutic target 
 
Due to its important role in anti-apoptosis, cell proliferation, and angiogenesis, 
survivin is regarded as a highly promising therapeutic target for the development of 
anticancer agents [104]. 
 
Survivin is the smallest member of the family of Inhibitor of Apoptosis Proteins 
(IAPs). Survivin is almost absent in normal tissues but is highly overexpressed in tumors 
[105]; it is therefore considered as a significant cancer specific biomarker [106]. 
Although the anti-apoptotic effect of survivin is well accepted, the mechanism regarding 
to how survivin mediates inhibition of apoptosis remains debatable. On one hand, it is 
believed that like other IAP family members survivin can directly bind to caspases and 
subsequently block their apoptotic activities [107, 108]. On the other hand, it was 
reported that survivin exerted its anti-apoptotic effect by indirectly inhibiting caspases. It 
has been demonstrated that survivin can bind to XIAP, another member of IAPs, to 
protect XIAP from ubiquitination and degradation. This eventually blocks activation of 
caspase-9 and apoptosis [109]. Additionally, survivin is shown to bind to the 
mitochondrial protein SMAC and antagonize its pro-apoptotic ability [110]. 
Overexpression of survivin is reported to associate with multidrug resistance as well as 
radiation resistance [111, 112]. Resistance to therapies such as cisplatin and vincristine 
can be developed easier in tumor cells with high expression of survivin than in tumor 
cells with low expression of survivin [113].  
 
Selective expression of survivin in tumor cells is validated; the benefit of down-
regulating survivin expression to treat cancer is therefore obvious. Current strategies 
employed to block the anti-apoptotic ability of survivin in tumor cells include but are not 
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Figure 1-5. Colchicine binding site inhibitors in clinical trials 
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limited to introducing recombinant cell-permeable dominant-negative survivin protein 
[114, 115], obstructing protein translation using antisense oligonucleotides [116], and 
small-molecule survivin antagonists [117, 118]. 
 
 
Major survivin inhibitors 
 
To date, a few survivin inhibitors have been developed [119-129], the majority of 
which are listed in Figure 1-6. 
 
 
Challenges in developing survivin inhibitors as anticancer agents 
 
Only a small amount of survivin inhibitors has been reported in the last decade, it 
is therefore not illustrative enough to unlock the potential of survivin for anticancer drug 
development. Despite the fact that the crystal structure of survivin was obtained in early 
of the 2000s [130], targeting survivin for direct binding affinity is challenging because no 
druggable site in survivin has been disclosed to date [130]. Due to that survivin interacts 
with many other molecules such as Hsp90, Smac, caspases, and INCENP, it is therefore 
difficult to specify the drug target and evaluate the drug efficacy. Furthermore, although 
the level of survivin in benign cells is dramatically lower than in malignant tumor cells, it 
is of significant importance to evaluate the lasting effect of shutting off survivin by 
survivin inhibitors in normal tissue [105]. 
 
 
Vitamin D3 for Cancer Treatment 
 
 
1α,25-dihydroxyvitamin D3 and its limit 
 
Vitamin D3 is mainly obtained from photoconversion of 7-dehydrocholesterol on 
the skin. After photoconversion, 7-dehydrocholesterol is converted to pre-vitamin D3 that 
is subsequently isomerized to vitaminD3. The storage form of vitamin D3, 25-
hydroxyvitamin D3 (25-OH-D3), is generated through metabolism of vitamin D3 in the 
liver by 25-hydroxylase (CYP2R1 or CYP27A1) [131]. 25-OH-D3 is metabolized by 1α-
hydroxylase (CYP27B1) in the kidney to form the active form of vitamin D3, 1α,25-
dihydroxyvitamin D3 [1,25(OH)2D3, calcitriol] [132]. 1,25(OH)2D3 exerts its extensive 
biological functions through activation of nuclear vitamin D receptor (VDR), which is 
distributed in almost all tissues of the body. Those biological functions include but are 
not limited to antiproliferative effects [133-135], induction of apoptosis [136, 137], 
antiinflammation [138-140], antiangiogenesis [140, 141] and antimetastatic effects [142, 
143]. The 1,25(OH)2D3 represents a promising scaffold for cancer treatment; however, 
applications of 1,25(OH)2D3 for treatment were greatly hampered by hypercalcemia at 
pharmacological concentrations [144]. 
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Figure 1-6. Structures of the major survivin inhibitors 
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20S-hydroxyvitamin D3 as a promising therapy for cancers 
 
Mammalian cytochrome P450 side-chain cleavage enzyme (P450scc or 
CYP11A1) cleaves the side chain of cholesterol to produce pregnenolone (precursor of 
all steroids) [145, 146]. P450scc also hydroxylates vitamin D3 in a sequential fashion 
[146-150] starting from C20 to form 20S-hydroxyvitamin D3 [20S-(OH)D3] which is 
subsequently converted to di- and trihydroxy metabolites [147, 149-152]. Functional 
studies showed that 20S-(OH)D3 not only stimulated keratinocyte differentiation 
program but also inhibited NF-κB activity in human keratinocytes [153]. In addition, 
20S-(OH)D3 has shown antiinflammatory activities, strong antiproliferative effects, 
antileukemia and tumorostatic effects [153-157], protective effects against ultra-violet B 
(UVB) induced damage [158], as well as antifibrotic activity in vivo [159]. These 
activities are mediated either through activation of the VDR [153, 160] or inhibition of 
RORα and RORγ transcriptional activities [161]. More importantly, while 20S-(OH)D3 
has comparable antiproliferative potency with 1,25(OH)2D3 which has strong 
hypercalcemic toxicity at a concentration of 1μg/kg, 20S-(OH)D3 is not hypercalcemic at 
concentrations as high as 60 μg/kg [154, 156, 158, 162]. However, to obtain proper 
quantity of 20S-(OH)D3 amenable for medicinal chemistry program is challenging. 
Therefore, a chemical synthesis that can prepare the amount of 20S-(OH)D3 and enable 
SAR investigation of this scaffold is of prime importance. 
 
 
Discussion 
 
Targeted therapy and immune therapy have achieved substantial success in 
treating metastatic melanoma. Since 2010, BRAF inhibitors (vemurafenib and 
dabrafenib), MEK1/2 inhibitors (trametinib and cobimetinib), anti PD-1 antibodies 
(nivolumab and pembrolizumab) and anti CTLA4 antibody (lpilimumab) have been 
approved by the FDA for the treatment of advanced melanoma. Nevertheless, patients 
with advanced melanoma rapidly acquire drug-resistance after a 6-month treatment with 
targeted therapy. Clinical responses to immune therapy are sometimes reported to be 
unsatisfactory [163]. IrAEs resulted from unrestrained T cell activation are challenging 
and might be fatal if not managed timely [164, 165].  
 
Unlike anticancer chemical alone, an antibody-drug conjugate (ADC) resorts to 
its monoclonal antibody to selectively target antigen on the surface of a tumor instead of 
normal tissue. As a result, ADC can minimize drug exposure to healthy cells and shows 
significantly less systemic toxicities or off-target side effect than anticancer chemical 
alone. Development of a successful ADC is challenging. There are demanding 
requirements for not only antigen on the surface of tumor but also each part of the ADC. 
ADC consists of anticancer chemical (payload or warhead), stable monoclonal 
antibodies, as well as synthetic linkers. The antigen should be mostly if not exclusively 
expressed in tumor instead of healthy tissue. The antibody should be selective to the 
antigen on the tumor to exclude off-target effect to healthy tissue. The antibody is also 
expected to have favorable stability in blood circulation in order to minimize the 
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destruction of ADC and maximize the concentration of payload that reaches the tumor. 
This stability requirement also applies to the synthetic linker. 
 
As the cytotoxic part, the payload is crucial in ADC. Currently, two types of 
cytotoxic chemicals are mainly subjected to the construction of ADCs: DNA-damaging 
agents and microtubule inhibitors. Generally, the payload is required to show cytotoxicity 
in sub-nanomolar range because (1) only limited percentile of injected antibody can be 
localized to solid tumor (0.003–0.08% injected dose per gram of tumor); (2) there are 
limited quantities of antigens on tumor surface; (3) the drug-to-antibody ratio is low (3.5-
4) [166-168]. Although the available pool of cytotoxic chemical is large, the conjugable 
toxins with “super” potency (sub-nanomolar) are of a limited amount. Thus, the 
discovery of highly potent inhibitors for different targets is still warranted. In addition, 
the ability of toxin to circumvent multidrug-resistance is desirable in order to prolong the 
clinical use.  
 
Because of the critical role of microtubules in many cellular functions, disruption 
of microtubule dynamics is regarded as an attractive strategy for cancer treatment. MTAs 
including paclitaxel, docetaxel, and vincristine have achieved great success in the last 
decade. However, drug resistance resulting from ABC transporters or overexpression of 
β-III tubulin/ MAPs is a major problem for taxanes and vinca alkaloids. Drug discovery 
based on MTAs has experienced long-term infertility due to significant off-target 
toxicity. The interest in MTAs is not revived until the FDA approved trastuzumab 
emtansine in February 2013. Trastuzumab emtansine is applied to the treatment of 
HER2-postive metastatic breast cancer and is a MTA-based ADC.  
 
ABI-231 is a potent CBSI discovered by our group in 2012 [169]. It has an 
average IC50 of 5.2 nM against a panel of melanoma and prostate cancer cell lines. It 
targets the colchicine binding site in tubulin and mechanistically inhibits the microtubule 
polymerization. Importantly, this molecule is effective in drug-resistant cell lines 
mediated by overexpression of P-gp and tubulin β-III isotype. ABI-231, therefore, 
represents a promising scaffold for developing anti-cancer agents and is worthy in-depth 
investigation. However, the in-depth SAR investigation of this promising scaffold is 
hampered by an inefficient synthetic method, through which ABI-231 was achieved 
within five steps with an overall yield of 0.28%. Hence, an efficient synthetic method that 
can rapidly generate ABI-231 analogues for SAR evaluation is needed. According to the 
reported molecular modeling (Figure 1-7) [169], ABI-231 forms three H-bonding 
interactions with tubulin protein. The interactions include the H-bond between methoxy 
and α-THR179 residue, H-bond between NH on imidazole and β-VAL238 as well as NH 
on indole with β-ASN167. The molecular modeling suggests the existence of an 
unoccupied pocket in the vicinity of the indole of ABI-231. We hypothesize that by 
introducing a small functional group to the indole of ABI-231 the ligand-receptor 
interaction can be strengthened. With this hypothesis in mind, we have established new 
generations of synthetic methods to access a variety of novel ABI-231 analogues and 
RABI analogues. ABI-231 analogues with more potent antiproliferative activities than 
ABI-231 have been achieved by introducing substituent to the indole moiety or by  
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Figure 1-7. Molecule modeling result of ABI-231 in tubulin (PDB: 3HKD) 
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isosterically modifying the 3,4,5-trimethoxyphenyl (3,4,5-TMP) in ABI-231. The first 
RABI analogue with sub-nM activity has also been obtained. These efforts will be shown 
in Chapter 2 to 4. 
 
UC-112 is discovered as a selective survivin inhibitor through virtual screening 
by our group in 2014 [126]. It has a low micromolar range IC50 against a panel of 
melanoma cancer cell lines and is selective to survivin over other IAP family members 
such as XIAP, cIAP-1, cIAP-2 and livin. A significant tumor growth inhibitory efficacy 
is observed for UC-112 at a dose of 20mg/kg in an A375 human melanoma xenograft 
model in vivo. Subsequent SAR study of UC-112 has manifested that modifying either 
the 8-hydroquinoline or the pyrrolidine is detrimental to the activity; introducing 
hydrophobic substituent to the para-position of the benzyloxy is beneficial to the activity. 
We hypothesize that the benzyl ether moiety in UC-112 might be too flexible and 
reducing the flexibility of this benzyloxy tail can increase the antiproliferative activity of 
this scaffold (Figure 1-8). With theses hypotheses in mind, we have synthesized thirty-
six UC-112 analogues replacing the benzyloxy in UC-112 with different moieties. Most 
of the new analogues show more potent activities than prototype UC-112. Importantly, 
the new analogues display significant abilities to circumvent P-gp mediated drug-
resistance. The effort on investigating SAR of UC-112 will be shown in Chapter 5. 
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Figure 1-8. Proposed modification of UC-112 by reducing the flexibility of 
benzyloxy moiety 
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CHAPTER 2.    STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF ABI-231 
LEADS TO IMPROVED ACTIVITIES AGAINST MICROTUBULE 
POLYMERIZATION 
 
 
Introduction 
 
Microtubules are cylindrical polymers that are of great importance for many 
cellular functions in the normal cells such as cell division, cell shape maintenance, and 
cell motility. Microtubules are dynamically involved in the formation of the mitotic 
spindle and play a critical role in the proliferation of cancer cells [91, 170, 171]. For these 
reasons, microtubule dynamic is among the most promising therapeutic targets for the 
development of cancer treatment [171]. MTAs can interfere with the microtubular 
functions to disrupt the formation of the mitotic spindle, eventually leading to mitotic 
arrest at the metaphase/anaphase transition. Numerous MTAs have been discovered in the 
last decades and several of them have been approved by the FDA for the treatment of 
different cancer types, such as breast cancer, lung cancer, ovarian cancer, etc. [172]. 
MTAs are generally classified into two categories based on their effect on microtubule at 
high concentrations: microtubule-stabilizing and microtubule-destabilizing agents. 
Microtubule-stabilizing agents bind to tubulin polymer and enhance microtubule 
polymerization. Microtubule-stabilizing agents include, for instance, epothilone, 
ixabepilone, paclitaxel, and docetaxel. Microtubule-destabilizing agents inhibit 
polymerization of microtubule and contain such as colchicine, combretastatins A-4 (CA-
4) and vinca alkaloids [173]. 
 
The MTAs have achieved great success in cancer treatment in the last decade. 
Drug-resistance is, however, acquired over the course of treatment and becomes a 
tremendous obstacle. Since 22 million new cancer cases are estimated to be diagnosed 
worldwide in the coming two decades, the importance of developing anticancer agents to 
treat resistant phenotypes is apparent [174, 175]. Mechanisms to mediate drug-resistance 
against MTAs include but are not limited to overexpression of membrane-bound drug 
efflux proteins such as P-gp, overexpression of β-tubulin isotypes, and microtubule 
mutations [72, 176]. Epothilones are natural products isolated from the So ce90 strain of 
the myxobacterium sorangium cellulosum. Some of the epothilones have been approved 
by the FDA for cancer treatment while some are currently at late stages of clinical trials. 
Different from taxanes and vinca alkaloids, epothilones are not substrates of ATP-binding 
cassette (ABC) transporters and are able to inhibit the overexpression of tubulin β-III 
isotype [177-179]. 
 
As one of the many well-documented binding sites in tubulin, colchicine binding 
site locates at the interface between α and β-tubulin heterodimers [96]. CBSIs 
mechanistically decrease cellular motility, alter cell morphology, impair protein 
assembly, and arrest mitosis [97, 98]. Colchicine, a secondary metabolite isolated from 
natural source, binds to the colchicines binding site in tubulin. Colchicine has wide-scope 
mechanisms of action. It, unfortunately, shows systemic toxicities and induces 
multiorgan dysfunction in a clinical trial for cancer treatment [97]. Other than colchicine 
 21 
and its derivatives, a number of other CBSIs have also been discovered in the last decade. 
Encouragingly, extensive preclinical studies have proven that CBSIs are effective to 
suppress overexpression of tubulin β-III isotype and surmount drug-resistance mediated 
by P-gp, MRP1, MRP2 [99-101].  
 
In our preceding investigations, we have described the discovery of SMART 
scaffold. SMARTs exhibited nanomolar range antiproliferative activity against a panel of 
cancer cell lines (Figure 2-1) [180]. Replacing the substituted benezenes in SMARTs 
with anilines provided the PATs. The PATs showed equipotency to that of SMARTs. 
Subsequent structural modification of the SMART scaffold by replacing the sulfur in 
thiazole with NH resulted in the discovery of ABI-I/II (2-aryl-4-benzoyl-imidazole) 
pharmacophores. ABI-I/IIs showed not only potent activity but also improved 
bioavailability in comparison with SMARTs (shown in Figure 2-1) [181, 182]. Follow-
up modification of the ABI-I/II gave ABI-III pharmacophore (Figure 2-1) [169, 183]. 
From the perspective of chemical structure, ABI-IIIs differed from ABI-I/IIs in having 
bicyclic heterocylces, which are versatile moieties in medicinal chemistry program [184]. 
From the perspective of bioactivity, ABI-IIIs exhibited more potent antiproliferative 
activity (IC50s as low as single-digit nanomolar range) than ABI-I/IIs. Rotation of the 
imidazole ring in ABI-I/IIs led to the establishment of reverse ABIs (RABIs, shown in 
Figure 2-1). RABIs had average IC50s as low as 14 nM [185]. Substituting the imidazole 
and carbonyl linker in ABI-IIIs with bicyclic heterocycles provided the IBIs (shown in 
Figure 2-1). IBIs displayed similar potency to that of ABI-IIIs. All SMARTs, ABIs, 
RABIs and IBIs have been demonstrated to share the same mechanism of action: binding 
to the colchicine binding site in tubulin and inhibiting the tubulin polymerization. 
Importantly, they were all effective to multidrug-resistant cell lines and can overcome P-
gp mediated drug resistance [169, 182, 183]. Among these SMARTs, ABIs, RABIs and 
IBIs, ABI-231 (shown in Figure 2-1) displayed the optimum activity and had an average 
IC50 value of 5.2 nM against a panel of cancer cell lines. Molecular modeling study 
revealed the existence of unoccupied pockets in the vicinity of the indole moiety of ABI-
231. This pocket might serve as an opportunity to strengthen the ligand-protein 
interaction [169]. With this hypothesis in mind, we are prompted to conduct 
comprehensive SAR study of ABI-231 by introducing “indole rotation” and different 
functional groups to the indole moiety. 
 
 
Experimental Section 
 
 
General chemistry 
 
Tetrahydrofuran was distilled from sodium-benzophenone. All other solvents and 
chemical reagents were obtained from commercial sources and directly used without 
further purification. Glassware was oven-dried before use. All reactions were performed 
under an argon atmosphere. TLC was performed on silica gel 60 GF254 and monitored 
under UV light or visualized using phosphomolybdic acid reagent. Flash chromatography  
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Figure 2-1. Examples of microtubule inhibitors that target colchicine binding sites 
in tubulin 
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was performed on 230-400 mesh silica gel (Fisher Scientific). Melting points were 
recorded on a MPA100 Automated Melting Point Apparatus. NMR spectra were obtained 
on a Bruker Ascend 400 (Billerica, MA) spectrometer or a Varian Inova-500 
spectrometer (Agilent Technologies, Santa Clara, CA). HR-MS were obtained on Waters 
Acquity UPLC linked to Waters Acquity Photodiode Array Detector and Waters Acquity 
Single Quadrupole Mass Detector. Chemical shifts are given in ppm with 
tetramethylsilane (TMS) as an internal reference. All coupling constants (J) are given in 
Hertz (Hz). 
 
 
Chemical synthesis 
 
Synthesis of 3-((tert-butyldimethylsilyl)oxy)-3-(3,4,5-
trimethoxyphenyl)propane-1,2-diol (2). To a solution of 3,4,5-trimethoxybenzaldehyde 
(30 g, 0.153 mol) in anhydrous THF (100 mL) at 0 oC under argon was added 
vinylmagnesium bromide solution (168 ml, 0.168 mol, 1.0 M in THF) dropwise, the 
resulting mixture was stirred for an hour. On completion reaction was quenched with 
saturated NH4Cl. The mixture was then extracted with ethyl acetate, washed with brine 
and dried with anhydrous Na2SO4. The combined extracts were evaporated under vacuum 
to give crude oil which was used directly for next step without purification. Imidazole 
(15.6 g, 0.229 mol) and tert-butyldimethylsilyl chloride (34.4 g, 0.229 mol) was 
sequentially added to a solution of the above crude oil in dichloromethane (150 mL) in a 
round bottom flask with stirring under argon. The resulting suspension was stirred for 2 
hours. Water was then added and the mixture was extracted with dichloromethane, 
washed with brine and dried with anhydrous Na2SO4. The combined extracts were 
evaporated to give crude oil mixture which was purified by flash chromatography on 
silica. Elution with hexane/ethyl acetate (10:0-10:1) gave racemic mixture 2 as yellowish 
oil (44.1 g, 85%).  
 
Synthesis of 3-((tert-butyldimethylsilyl)oxy)-3-(3,4,5-
trimethoxyphenyl)propane-1,2-diol (3). To a solution of the compound 2 (44.0 g, 0.13 
mol) in acetone (150 mL) was added N-methylmorpholine N-oxide (22.9 g, 0.195 mol) 
and osmium tetroxide (40 mg, 0.157 mmol) in tert-butanol (5 mL) at room temperature 
with stirring. After 48 hour, acetone was removed under vacuum, water and ethyl acetate 
was then added and the organic phase was separated, washed with brine and dried with 
Na2SO4. Evaporation under vacuum gave the oily residue which was purified with flash 
chromatography on silica. Elution with hexane/ethyl acetate (2:1-1:1) gave diol 3 as 
colorless oil (45.1 g, 93%).  
 
Synthesis of 3-((tert-butyldimethylsilyl)oxy)-3-(3,4,5-
trimethoxyphenyl)propane-1,2-diyl dimethanesulfonate (4). To a solution of 
compound 3 (45.0 g, 0.12 mol) and Methanesulfonyl chloride (23.4 ml, 0.30 mol) in 
anhydrous dichloromethane (100 mL) in a round bottom flask at 0 °C under argon, 
trimethylamine (36.9 ml, 0.26 mol) was added dropwise with vigorous stirring. The 
resulting mixture was stirred for overnight, water was then added and the reaction 
mixture was extracted with dichloromethane, washed with brine and dried with 
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anhydrous Na2SO4. The combined extracts were evaporated under vacuum to give the 
oily crude which was purified with flash chromatography on silica. Pure mesylates 4 was 
eluted out with hexane/ethyl acetate (3:1-2:1) as colorless oil (45.2 g, 71%). 1H NMR 
(400 MHz, Chloroform-d) δ 6.61 – 6.56 (m, 2H), 4.93 (dd, J = 19.9, 5.3 Hz, 1H), 4.79 
(ddd, J = 7.0, 4.8, 2.4 Hz, 1H), 4.53 – 4.41 (m, 1H), 4.36 (dd, J = 11.5, 2.4 Hz, 1H), 3.89 
– 3.77 (m, 9H), 3.04 – 2.75 (m, 6H), 0.90 (d, J = 5.0 Hz, 9H), 0.12 (d, J = 13.5 Hz, 3H), -
0.07 (d, J = 1.4 Hz, 3H). HRMS: calculated for C20H37O10S2Si [M+H]+ 529.1597, found 
529.1562. 
 
Synthesis of tert-butyl(2,3-diazido-1-(3,4,5-
trimethoxyphenyl)propoxy)dimethylsilane (5). To a solution of mesylates 4 (45.0 g, 
0.085 mol) in anhydrous N,N-dimethylformamide (100 mL) in a round bottom flask 
under argon, sodium azide (30 g, 0.46 mol) was added in portions with stirring. The 
resulting mixture was refluxed for overnight. The precipitate was filtered off and washed 
with dichloromethane. The combined filtration was evaporated under vacuum to give the 
oily crude which was purified with flash chromatography on silica. Pure azides 5 was 
eluted out with hexane/ethyl acetate (4:1-3:1) as colorless oil (20.8 g, 58%). 1H NMR 
(400 MHz, Chloroform-d) δ 6.55 (d, J = 9.6 Hz, 2H), 4.64 (dd, J = 6.3, 4.7 Hz, 1H), 3.85 
(dd, J = 2.4, 1.5 Hz, 9H), 3.61 – 3.04 (m, 3H), 0.90 (d, J = 1.0 Hz, 9H), 0.10 (d, J = 9.4 
Hz, 3H), -0.13 (d, J = 4.1 Hz, 3H). HRMS: calculated for C18H31N6O4Si [M+H]+ 
423.2176, found 423.2177. 
 
Synthesis of 3-((tert-butyldimethylsilyl)oxy)-3-(3,4,5-
trimethoxyphenyl)propane-1,2-diamine (6). A suspension of azides 5 (20.0 g, 0.047 
mol) and 10% Pd/C (0.2 g) in ethylacetate-methanol (1:1, 50 ml) was hydrogenated 
overnight, the reaction mixture was filtered off and washed with dichloromethane-
methanol (1:1). The combined filtration was evaporated under vacuum to give the oily 
crude which was purified with flash chromatography on silica. Pure diamine 7 was eluted 
out with dichloromethane/methanol (15:0-15:1) as slightly yellowish oil (10.6 g, 61%). 
1H NMR (400 MHz, Chloroform-d) δ 6.51 (d, J = 13.4 Hz, 2H), 4.45 (dd, J = 34.5, 5.1 
Hz, 1H), 3.83 (d, J = 1.2 Hz, 9H), 2.97 – 2.46 (m, 3H), 0.90 (d, J = 10.8 Hz, 9H), 0.04 (d, 
J = 8.5 Hz, 3H). -0.17 (d, J = 8.5 Hz, 3H). HRMS: calculated for C18H35N2O4Si [M+H]+ 
371.2366, found 371.2369. 
 
General procedure for Boc protection of indolecarboxyaldehydes 7aa-7at and 
7ba-7be. To a solution of the indoles (1.34 mmol) and 4-dimethylaminopyridine (65 mg, 
0.54 mol) in anhydrous dichloromethane (5 mL) under argon was added di-tert-butyl 
dicarbonate (351 mg, 1.61 mmol) with stirring. After 1 hour, water was then added and 
the reaction mixture was extracted with dichloromethane, washed with brine and dried 
with Na2SO4. Evaporation under vacuum gave the crude solid residue which was purified 
with flash chromatography on silica. Elution with hexane/ethyl acetate (10:1-3:1) gave 
pure boc-protected indolecarboxyaldehydes 7aa-7at and 7ba-7be as white to yellowish 
solids. 
 
General procedure for cyclolization to form imidazoline 8aa-8at and 8ba-8be. 
A solution of compound 6 (370 mg, 1.0 mmol) and boc-protected indole (1.1 mmol) in 
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anhydrous dichloromethane (10 mL) was stirred for one hour under argon, then N-
bromosuccinimide (151 mg, 0.85 mmol) was added at ice temperature and reaction was 
warmed to room temperature. After 4 hours, the reaction was quenched with saturated 
sodium thiosulfate solution and extracted with dichloromethane for three times, washed 
with brine and dried with Na2SO4. The combined extracts were evaporated to give crude 
oil, which was purified with flash chromatography on silica. Elution with 
dichloromethane/ethyl acetate (10:1-1:2) gave diaisostereomers 8aa-8at and 8ba-8be as 
transparent oil. 
  
General procedure for removal of TBS protecting group. To a stirred solution 
of compound 8aa-8at (0.5 mmol) in THF (5.0 mL) was added tetra-n-butylammonium 
fluoride (1.0 M in THF, 1.0 ml, 1.0 mmol) under argon. The reaction was quenched with 
water, extracted with ethyl acetate for three times, washed with brine and dried with 
Na2SO4. The combined extracts were evaporated to give crude oil, which was purified 
with flash chromatography on silica. Elution with ethyl acetate/methanol (1:0 – 5:1) 
afforded pure compound 9aa-9at and 9ba-9be as colorless oil.  
 
General procedure for synthesis of 10ab-10at and 10ba-10be. To a stirred 
solution of compound 9 (0.3 mmol) in anhydrous dichloromethane (1.0 mL) was added 
trifluoroacetic acid (1.0 mL) under argon at room temperature. After 1 hour, solvent was 
removed under vacuum to give crude solid which was directly used for next step without 
purification. To a stirred solution of the above crude in anhydrous dimethyl sulfoxide (2.0 
mL) under argon was added 2-iodoxybenzoic acid (252 mg, 0.9 mmol) at room 
temperature. The reaction mixture was stirred for overnight, extracted with ethyl acetate 
for three times, washed with brine and dried with Na2SO4. The combined extracts were 
evaporated to give crude solid, which was purified with flash chromatography on silica. 
Elution with hexane/ethyl acetate (4:1) gave pure compound 15 as yellowish solid. 
 
General procedure for synthesis of 10au-10aw and 10ay. To a stirred solution 
of compound 10af or 10ak or 10ao or 10as (0.05 mmol) in EtOAc-MeOH (3 mL, 1:1) 
was added catalytic equivalent of 10% Pd/C (0.0025 mmol) under argon at room 
temperature. The reaction was then charged with hydrogen and monitored by TLC. Until 
the disappearance of starting material, the reaction mixture was filtered through celite and 
was with EtOAc. The combined solvents were evaporated to give crude solid, which was 
purified with flash chromatography on silica. Elution with Hexanes/ethyl acetate (1:1-
1:4) gave pure compound 10au-10aw and 10ay as yellowish solid. 
 
Synthesis of 10ax. To a stirred solution of compound 10aq in dioxane (1 mL) 
was added saturated LiOH solution (1mL) and reaction was heated at 50oC until the 
disappearance of starting material. The solvent was removed under reduced pressure and 
the crude was purified with flash chromatography on silica. Elution with DCM/MeOH 
(20:1-5:1) gave pure compound 10ax as yellowish solid. 
 
(2-(2-phenyl-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10aa). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.15 – 8.06 (m, 1H), 7.79 (s, 1H), 7.59 – 7.53 (m, 2H), 
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7.47 – 7.41 (m, 4H), 7.22 (dddd, J = 20.6, 8.1, 7.1, 1.2 Hz, 3H), 3.89 (s, 6H), 3.87 (s, 
3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 183.45, 153.73, 142.58, 138.59, 
136.68, 133.65, 132.38, 129.72, 129.63, 129.13, 128.11, 123.63, 121.59, 121.06, 111.94, 
111.89, 107.17, 61.19, 56.78.  HRMS: calculated for C27H24N3O4 [M+H]+ 454.1767, 
found 454.1771. 
 
(2-(4-methyl-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ab). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 7.78 (s, 1H), 7.36 (s, 1H), 7.22 (d, J = 16.4 Hz, 3H), 7.08 
(t, J = 7.6 Hz, 1H), 6.93 – 6.84 (m, 1H), 3.88 (d, J = 2.0 Hz, 9H), 2.50 (s, 3H). 13C NMR 
(101 MHz, Methylene Chloride-d2) δ 184.41, 153.78, 148.55, 142.68, 137.13, 136.97, 
135.76, 133.67, 133.22, 131.08, 127.41, 127.24, 125.09, 125.06, 123.30, 122.79, 110.14, 
110.09, 107.17, 106.73, 106.69, 61.21, 56.82, 21.07. HRMS: calculated for C22H22N3O4 
[M+H]+ 392.1610, found 392.1603. 
 
2-(4-fluoro-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ac). obtained as a yellowish solid. 1H NMR (400 
MHz, Chloroform-d) δ 8.04 (s, 1H), 7.71 (s, 1H), 7.24 (d, J = 8.1 Hz, 1H), 7.19 (s, 2H), 
7.14 (td, J = 8.0, 5.2 Hz, 1H), 6.91 (dd, J = 12.7, 7.8 Hz, 1H), 3.90 (d, J = 1.1 Hz, 9H). 
13C NMR (101 MHz, Chloroform-d) δ 181.51, 167.73, 156.38, 154.01, 153.47, 143.21, 
139.62, 131.22, 130.90, 129.80, 128.82, 124.35, 111.77, 109.92, 107.33, 107.12, 106.31, 
61.08, 56.46. HRMS: calculated for C21H19FN3O4 [M+H]+ 396.1360, found 396.1364. 
 
(2-(4-bromo-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ad). obtained as a yellowish solid. (EtOAc).1H NMR 
(400 MHz, Methylene Chloride-d2) δ 7.77 (s, 1H), 7.68 (s, 1H), 7.42 (d, J = 8.1 Hz, 1H), 
7.34 (d, J = 7.6 Hz, 1H), 7.26 (s, 2H), 7.06 (t, J = 7.9 Hz, 1H), 3.91 (s, 6H), 3.87 (s, 3H). 
13C NMR (101 MHz, Methylene Chloride-d2) δ 184.36, 153.80, 146.48, 142.67, 138.16, 
133.68, 129.87, 125.75, 124.76, 123.88, 113.25, 112.31, 112.25, 107.15, 106.35, 61.20, 
56.84. HRMS: calculated for C21H19BrN3O4 [M+H]+ 456.0559, found 456.0560. 
 
(2-(4-methoxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ae). obtained as a yellowish solid. 1H NMR (400 
MHz, Chloroform-d) δ 9.91 (s, 1H), 8.75 (s, 1H), 7.90 (s, 1H), 7.41 (d, J = 8.4 Hz, 1H), 
7.30 (s, 2H), 7.26 (s, 2H), 6.70 (d, J = 8.4 Hz, 1H), 4.26 (s, 3H), 4.01 (s, 3H), 4.00 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 181.65, 153.51, 151.42, 145.59, 143.17, 138.93, 
131.25, 130.44, 128.59, 127.66, 124.71, 113.49, 107.27, 106.23, 102.57, 99.65, 61.05, 
56.41, 56.09. HRMS: calculated for C22H22N3O5 [M+H]+ 408.1559,found 408.1564. 
 
(2-(4-(benzyloxy)-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10af). obtained as a yellowish solid. 1H NMR (400 MHz, 
Methylene Chloride-d2) δ 11.96 (s, 1H), 10.50 (s, 1H), 8.07 (d, J = 2.6 Hz, 1H), 7.58 – 
7.51 (m, 2H), 7.47 – 7.21 (m, 5H), 7.11 (d, J = 4.2 Hz, 2H), 6.74 (p, J = 4.7 Hz, 1H), 5.48 
(s, 2H), 4.25 – 3.89 (m, 6H), 3.87 (d, J = 0.8 Hz, 3H). 13C NMR (101 MHz, Methylene 
Chloride-d2) δ 183.51, 153.73, 151.84, 142.38, 139.56, 136.73, 134.10, 129.41, 129.04, 
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128.66, 126.85, 124.00, 114.88, 107.16, 107.09, 103.65, 71.70, 61.15, 56.78. HRMS: 
calculated for C28H26N3O5 [M+H]+ 484.1872, found 484.1870. 
 
(2-(5-methyl-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ag). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.03 (s, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.79 (s, 1H), 7.36 
(dd, J = 8.4, 1.5 Hz, 1H), 7.27 (s, 2H), 7.09 (d, J = 8.4 Hz, 1H), 3.92 (d, J = 1.6 Hz, 6H), 
3.88 (d, J = 1.6 Hz, 3H), 2.62 – 2.40 (m, 3H). 13C NMR (101 MHz, Methylene Chloride-
d2) δ 184.33, 153.77, 149.36, 142.51, 135.52, 134.01, 131.13, 126.56, 125.50, 125.01, 
120.34, 112.08, 107.14, 106.03, 61.22, 56.79, 21.80. HRMS: calculated for C22H22N3O4 
[M+H]+ 392.1610, found 392.1611. 
 
(2-(5-fluoro-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ah). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.00 – 7.91 (m, 2H), 7.80 (s, 1H), 7.41 (dd, J = 8.9, 4.5 
Hz, 1H), 7.30 (s, 2H), 7.01 (td, J = 9.0, 2.5 Hz, 1H), 3.92 (s, 6H), 3.88 (s, 3H).  13C NMR 
(101 MHz, Methylene Chloride-d2) δ 184.61, 160.45, 158.11, 153.75, 142.54, 134.00, 
133.81, 127.77, 125.96, 125.85, 113.26, 113.17, 111.74, 111.48, 107.28, 106.92, 106.88, 
106.21, 105.96, 61.22, 56.79. HRMS: calculated for C21H19FN3O4 [M+H]+ 396.1360, 
found 396.1364. 
 
(2-(5-chloro-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ai). obtained as a yellowish solid. 1H NMR (400 MHz, 
Acetone-d6) δ 10.93 (s, 1H), 8.64 (d, J = 2.2 Hz, 1H), 8.29 (s, 1H), 7.92 (s, 1H), 7.54 (d, J 
= 8.7 Hz, 2H), 7.23 (dd, J = 8.7, 2.1 Hz, 1H), 3.97 (s, 6H), 3.85 (s, 3H). 13C NMR (101 
MHz, Acetone-d6) δ 183.80, 154.15, 142.94, 136.18, 136.03, 134.44, 127.60, 127.20, 
126.71, 123.53, 121.78, 114.04, 114.00, 107.96, 107.57, 60.71, 56.67. HRMS: calculated 
for C21H19ClN3O4 [M+H]+ 412.1064, found 412.1068. 
 
(2-(5-bromo-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10aj). obtained as a yellowish solid. 1H NMR (400 MHz, 
Methylene Chloride-d2) δ 8.44 (dd, J = 1.9, 0.8 Hz, 1H), 7.90 (s, 1H), 7.80 (s, 1H), 7.39 – 
7.26 (m, 4H), 3.93 (s, 6H), 3.88 (s, 3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 
184.63, 153.78, 148.24, 142.61, 135.92, 133.91, 127.33, 127.10, 126.19, 123.58, 114.77, 
113.96, 107.29, 106.30, 61.23, 56.84. HRMS: calculated for C21H19BrN3O4 [M+H]+ 
456.0559, found 456.0555. 
 
(2-(5-(benzyloxy)-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ak). obtained as a yellowish solid. 1H NMR (400 
MHz, Acetone-d6) δ 10.69 (s, 1H), 8.24 (dd, J = 9.5, 2.5 Hz, 2H), 7.93 (s, 1H), 7.59 – 
7.46 (m, 4H), 7.46 – 7.35 (m, 3H), 7.35 – 7.28 (m, 1H), 6.98 (dd, J = 8.8, 2.5 Hz, 1H), 
5.16 (s, 2H), 3.95 (s, 6H), 3.82 (s, 3H). 13C NMR (101 MHz, Acetone-d6) δ 183.75, 
155.14, 154.15, 142.92, 138.97, 134.58, 133.03, 132.88, 129.20, 128.58, 128.47, 127.12, 
126.57, 126.40, 114.10, 113.23, 113.18, 107.92, 107.32, 105.98, 71.25, 60.71, 60.54, 
56.69. HRMS: calculated for C28H26N3O5 [M+H]+ 484.1872, found 484.1875. 
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(2-(6-methyl-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10al). obtained as a yellowish solid. 1H NMR (400 MHz, 
Methylene Chloride-d2) δ 8.06 (d, J = 8.2 Hz, 1H), 7.88 (s, 1H), 7.83 (s, 1H), 7.25 (s, 2H), 
7.21 (s, 1H), 7.05 (d, J = 8.0 Hz, 1H), 3.87 (d, J = 3.0 Hz, 9H), 2.41 (s, 3H). 13C NMR 
(101 MHz, Methylene Chloride-d2) δ 183.51, 153.86, 148.33, 142.82, 137.43, 133.85, 
133.46, 132.01, 125.84, 123.74, 123.03, 120.50, 112.28, 107.08, 106.16, 61.20, 56.83, 
21.90. HRMS: calculated for C22H22N3O4 [M+H]+ 392.1610, found 392.1613. 
 
(2-(6-fluoro-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10am). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.27 – 8.17 (m, 1H), 7.88 (d, J = 2.1 Hz, 1H), 7.79 (d, J 
= 2.5 Hz, 1H), 7.30 (d, J = 2.1 Hz, 2H), 7.15 (dt, J = 9.6, 2.4 Hz, 1H), 6.98 (ddd, J = 9.6, 
8.8, 2.4 Hz, 1H), 3.91 (d, J = 2.2 Hz, 6H), 3.87 (s, 3H). 13C NMR (101 MHz, Methylene 
Chloride-d2) δ 184.67, 161.98, 159.62, 153.76, 148.67, 142.55, 137.37, 137.25, 134.00, 
126.67, 126.64, 122.14, 122.10, 122.00, 110.09, 109.85, 107.27, 106.71, 98.65, 98.40, 
61.23, 56.77. HRMS: calculated for C21H19FN3O4 [M+H]+ 396.1360, found 396.1357. 
 
(2-(6-bromo-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10an). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.17 (d, J = 8.5 Hz, 1H), 7.87 (s, 1H), 7.80 (s, 1H), 7.59 
(d, J = 1.9 Hz, 1H), 7.30 (d, J = 10.4 Hz, 3H), 3.90 (s, 6H), 3.88 (s, 3H). 13C NMR (101 
MHz, Methylene Chloride-d2) δ 184.48, 153.73, 148.37, 142.54, 137.94, 133.90, 126.73, 
124.56, 124.45, 124.42, 122.51, 116.67, 115.32, 115.27, 107.20, 106.91, 61.21, 56.77. 
HRMS: calculated for C21H19BrN3O4 [M+H]+ 456.0559, found 456.0558. 
 
(2-(6-(benzyloxy)-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10ao). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 9.54 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 7.0 Hz, 
2H), 7.49 – 7.20 (m, 7H), 7.00 – 6.84 (m, 2H), 4.98 (s, 2H), 3.86 (s, 3H), 3.84 (s, 6H). 
13C NMR (101 MHz, Methylene Chloride-d2) δ 183.92, 156.66, 153.75, 142.52, 137.89, 
137.81, 133.88, 129.02, 128.41, 128.12, 124.92, 122.11, 120.08, 112.30, 107.17, 107.13, 
96.74, 70.92, 61.17, 56.75. HRMS: calculated for C28H26N3O5 [M+H]+ 484.1872, found 
484.1870. 
 
(2-(6-methoxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone  (10ap). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.12 (dd, J = 8.7, 0.6 Hz, 1H), 7.79 (d, J = 5.8 Hz, 2H), 
7.27 (s, 2H), 6.94 (d, J = 2.2 Hz, 1H), 6.88 (dd, J = 8.8, 2.3 Hz, 1H), 3.91 (s, 6H), 3.87 (s, 
3H), 3.83 (s, 3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 184.25, 157.54, 153.75, 
149.09, 142.51, 137.98, 133.96, 125.15, 121.60, 119.63, 111.53, 107.14, 106.61, 95.58, 
95.52, 61.20, 56.78, 56.06. HRMS: calculated for C22H22N3O5 [M+H]+ 408.1559,found 
408.1566. 
 
Methyl 3-(4-(3,4,5-trimethoxybenzoyl)-1H-imidazol-2-yl)-1H-indole-6-
carboxylate (10aq). obtained as a yellowish solid. 1H NMR (400 MHz, DMSO-d6) δ 
13.21 (s, 1H), 11.98 (s, 1H), 8.52 (d, J = 8.4 Hz, 1H), 8.45 (s, 1H), 8.15 (s, 1H), 8.00 (s, 
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1H), 7.77 (d, J = 8.4 Hz, 1H), 7.49 (s, 2H), 3.91 (s, 6H), 3.88 (s, 3H), 3.79 (s, 3H). 13C 
NMR (101 MHz, DMSO-d6) δ 182.97, 166.98, 152.62, 141.15, 135.65, 133.24, 129.07, 
128.45, 127.98, 127.74, 127.50, 123.27, 120.91, 120.60, 117.93, 113.86, 106.82, 106.36, 
60.14, 55.98, 51.84. HRMS: calculated for C23H22N3O6 [M+H]+ 436.1509, found 
436.1506. 
 
(2-(7-methyl-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone  (10ar). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.09 (dt, J = 7.7, 0.9 Hz, 1H), 7.92 (s, 1H), 7.81 (s, 1H), 
7.28 (s, 2H), 7.14 (dd, J = 8.1, 7.1 Hz, 1H), 7.05 (dt, J = 7.2, 1.0 Hz, 1H), 3.90 (s, 6H), 
3.88 (s, 3H), 2.51 (s, 3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 184.19, 153.74, 
149.12, 142.49, 136.79, 136.65, 133.95, 126.24, 126.08, 124.99, 124.96, 123.86, 121.99, 
121.95, 121.75, 118.53, 107.15, 107.08, 107.03, 61.18, 56.76, 16.91. HRMS: calculated 
for C22H22N3O4 [M+H]+ 392.1610, found 392.1615. 
 
(2-(7-(benzyloxy)-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10as). obtained as a yellowish solid. 1H NMR (400 MHz, 
Methylene Chloride-d2) δ 9.29 (s, 1H), 7.95 (d, J = 2.9 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 
7.84 (s, 1H), 7.54 – 7.47 (m, 2H), 7.44 – 7.33 (m, 3H), 7.30 (s, 2H), 7.15 (t, J = 7.9 Hz, 
1H), 6.82 (dd, J = 7.8, 0.7 Hz, 1H), 5.24 (s, 2H), 3.90 (s, 6H), 3.87 (s, 3H). 13C NMR 
(101 MHz, Methylene Chloride-d2) δ 183.55, 153.81, 146.12, 142.59, 137.54, 133.81, 
129.15, 128.74, 128.43, 127.78, 126.94, 125.29, 122.36, 114.16, 107.82, 107.07, 104.86, 
70.93, 61.17, 56.81. HRMS: calculated for C28H26N3O5 [M+H]+ 484.1872, found 
484.1868. 
 
(2-(7-methoxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10at). obtained as a yellowish solid. 1H NMR (400 MHz, 
Methylene Chloride-d2) δ 7.88 (s, 1H), 7.85 – 7.77 (m, 2H), 7.28 (s, 2H), 7.17 (t, J = 7.9 
Hz, 1H), 6.74 (dd, J = 7.9, 0.8 Hz, 1H), 3.98 (s, 3H), 3.91 (s, 6H), 3.88 (s, 3H). 13C NMR 
(101 MHz, Methylene Chloride-d2) δ 184.15, 153.77, 147.11, 142.55, 133.91, 127.59, 
126.64, 125.67, 122.28, 113.43, 107.26, 107.12, 103.42, 61.20, 56.79, 56.01. HRMS: 
calculated for C22H22N3O5 [M+H]+ 408.1559,found 408.1556. 
 
(2-(4-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10au). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 8.02 (s, 1H), 7.72 (d, J = 3.4 Hz, 1H), 7.31 – 7.14 (m, 
3H), 7.07 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 7.3 Hz, 1H), 6.58 (d, J = 7.7 Hz, 1H), 3.91 (s, 
6H), 3.88 (s, 3H). HRMS: calculated for C21H20N3O5 [M+H]+ 394.1403,found 394.1405. 
 
(2-(5-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10av). obtained as a yellowish solid. 1H NMR (400 
MHz, DMSO-d6) δ 12.88 (d, J = 58.5 Hz, 1H), 11.48 – 10.98 (m, 1H), 8.84 (d, J = 12.5 
Hz, 1H), 8.25 (d, J = 2.8 Hz, 1H), 7.89 (d, J = 3.5 Hz, 1H), 7.83 (q, J = 2.0, 1.3 Hz, 1H), 
7.24 (dd, J = 8.6, 2.3 Hz, 1H), 7.18 (s, 1H), 6.69 (ddd, J = 11.2, 8.7, 2.5 Hz, 1H), 3.84 (dd, 
J = 47.9, 6.9 Hz, 9H). HRMS: calculated for C21H20N3O5 [M+H]+ 394.1403,found 
394.1404. 
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(2-(6-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-
trimethoxyphenyl)methanone (10aw). obtained as a yellowish solid. 1H NMR (400 
MHz, Methylene Chloride-d2) δ 7.89 (s, 1H), 7.79 (s, 1H), 7.71 (dd, J = 8.0, 0.9 Hz, 1H), 
7.27 (s, 2H), 7.09 (t, J = 7.9 Hz, 1H), 6.70 (dd, J = 7.7, 0.8 Hz, 1H), 3.92 (s, 6H), 3.88 (s, 
3H). HRMS: calculated for C21H20N3O5 [M+H]+ 394.1403,found 394.1401. 
 
3-(4-(3,4,5-trimethoxybenzoyl)-1H-imidazol-2-yl)-1H-indole-6-carboxylic 
acid (10ax). obtained as a yellowish solid. 1H NMR (400 MHz, DMSO-d6) δ 13.79 – 
13.14 (m, 1H), 12.38 (d, J = 75.1 Hz, 1H), 8.83 – 8.41 (m, 2H), 8.15 (s, 1H), 8.10 – 7.84 
(m, 2H), 7.74 (dd, J = 13.7, 8.4 Hz, 1H), 7.20 (s, 1H), 3.86 (dd, J = 50.2, 10.6 Hz, 9H). 
HRMS: calculated for C22H20N3O6 [M+H]+ 422.1352, found 422.1355. 
 
(2-(1H-indol-2-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone 
(10ba). obtained as a yellowish solid. 1H NMR (400 MHz, Chloroform-d) δ 10.31 (s, 1H), 
8.18 (d, J = 7.7 Hz, 1H), 7.89 (s, 1H), 7.63 (t, J = 8.9 Hz, 2H), 7.51 (t, J = 7.6 Hz, 1H), 
7.34 (d, J = 8.2 Hz, 1H), 7.27 (d, J = 4.9 Hz, 7H), 7.15 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H), 
3.99 (s, 3H), 3.91 (s, 6H). 13C NMR (101 MHz, DMSO-d6) δ 182.28, 152.72, 141.89, 
141.11, 139.01, 136.94, 133.12, 129.21, 128.44, 127.86, 122.31, 120.75, 119.66, 111.90, 
107.32, 106.16, 101.99, 100.14, 60.12, 56.00. HRMS: calculated for C21H20N3O4 [M+H]+ 
378.1454, found 378.1458. 
 
(2-(1H-indol-4-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone 
(10bb). obtained as a yellowish solid. 1H NMR (400 MHz, Chloroform-d) δ 11.06 (s, 1H), 
8.80 (s, 1H), 7.94 (s, 1H), 7.69 (d, J = 7.4 Hz, 1H), 7.47 (dt, J = 8.2, 0.9 Hz, 1H), 7.33 (t, 
J = 2.9 Hz, 2H), 7.26 (d, J = 1.7 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 
6H). 13C NMR (101 MHz, Chloroform-d) δ 183.67, 153.30, 142.36, 136.84, 133.00, 
126.16, 125.49, 121.97, 120.82, 119.18, 113.41, 106.78, 102.88, 61.15, 56.45. HRMS: 
calculated for C21H20N3O4 [M+H]+ 378.1454, found 378.1453. 
 
(2-(1H-indol-5-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone 
(10bc). obtained as a yellowish solid. 1H NMR (400 MHz, Methylene Chloride-d2) δ 9.34 
(s, 1H), 8.28 (d, J = 1.6 Hz, 1H), 7.83 (dd, J = 8.6, 1.7 Hz, 1H), 7.80 (s, 1H), 7.51 (d, J = 
8.6 Hz, 1H), 7.31 (dt, J = 2.7, 1.2 Hz, 1H), 7.26 (s, 2H), 6.61 (dt, J = 3.0, 1.3 Hz, 1H), 
3.91 (s, 6H), 3.88 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 183.52, 153.35, 142.35, 
137.06, 133.13, 128.33, 125.77, 120.90, 120.78, 119.55, 111.83, 106.70, 103.64, 61.15, 
56.43. HRMS: calculated for C21H20N3O4 [M+H]+ 378.1454, found 378.1459. 
 
(2-(1H-indol-6-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone 
(10bd). obtained as a yellowish solid. 1H NMR (400 MHz, Chloroform-d) δ 11.02 (s, 1H), 
8.77 (s, 1H), 7.95 (s, 1H), 7.79 – 7.65 (m, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.36 (t, J = 2.8 
Hz, 1H), 7.32 – 7.16 (m, 4H), 3.97 (s, 3H), 3.92 (s, 6H). 13C NMR (101 MHz, 
Chloroform-d) δ 183.29, 153.36, 151.90, 142.38, 138.95, 136.83, 132.97, 131.17, 126.23, 
125.52, 122.01, 120.72, 119.32, 113.51, 106.55, 102.84, 61.16, 56.45. HRMS: calculated 
for C21H20N3O4 [M+H]+ 378.1454, found 378.1453. 
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(2-(1H-indol-7-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone 
(10be). obtained as a yellowish solid. 1H NMR (400 MHz, Chloroform-d) δ 8.58 (s, 1H), 
8.24 (d, J = 7.5 Hz, 1H), 7.93 (d, J = 3.6 Hz, 1H), 7.87 (dd, J = 7.8, 0.8 Hz, 1H), 7.72 (s, 
2H), 7.60 (t, J = 7.7 Hz, 1H), 7.02 (d, J = 3.7 Hz, 1H), 3.97 (d, J = 0.9 Hz, 9H). 13C NMR 
(101 MHz, Chloroform-d) δ 186.04, 153.10, 143.96, 143.25, 142.87, 142.05, 132.31, 
132.01, 128.20, 125.87, 124.94, 123.97, 121.35, 120.31, 112.94, 110.91, 108.31, 61.14, 
56.49. HRMS: calculated for C21H20N3O4 [M+H]+ 378.1454, found 378.1452. 
 
 
Cell culture and reagents 
 
Human melanoma carcinoma cell lines A375, M14, and WM-164 (American 
Type Culture Collection or ATCC, Manassas, VA, USA) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Corning, Manasas, VA) supplemented with 10% 
(v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawernceville, GA) and 1% 
antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Murine melanoma 
B16F10 cells (ATCC, Manassas, VA, USA) were cultured in Minimum essential medium 
(Invitrogen, Carlsbad, CA), supplemented with 5% heat-inactivated Hyclone FBS 
(Thermo Scientific, Rockford, IL), 1 % antibiotic-antimycotic mixture (Sigma-Aldrich, 
St. Louis MO), 1% Mem-sodium pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin 
(Invitrogen, Carlsbad, CA), L-Glutamine (2mM final concentration) (Invitrogen, 
Carlsbad, CA), and 1% Mem NEAA (Invitrogen, Carlsbad, CA). All cell lines were 
authenticated by ATCC by short tandem repeat profiling.  Cultures were maintained to 
80-90% confluency at 37°C in a humidified atmosphere containing 5% CO2. Compounds 
were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to make a 
stock solution of 20 mM. Compound solutions were freshly prepared by diluting stocks 
with cell culture medium before use.  
 
 
Cytotoxicity assay 
 
A375, M14, and WM-164 were seeded in 96-well plates at a concentration of 
1,000–5,000 cells per well, depending on growth rate of the cell line. After overnight 
incubation, the media was replaced and cells were treated with the test compounds at 10 
concentrations ranging from 0.03 nM to 1μM plus a vehicle control for 72 h in four 
replicates. Following treatment, the MTS reagent (Promega, Madison, WI) was added to 
the cells and incubated in dark at 37°C for at least 1 hour. Absorbance at 490 nm was 
measured using a plate reader (DYNEX Technologies, Chantilly VA). Percentages of cell 
survival versus drug concentrations were plotted, and the IC50 (concentration that 
inhibited cell growth by 50% of untreated control) values were obtained by nonlinear 
regression analysis using GraphPad Prism (GraphPad Software, San Diego, CA). 
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Chemistry 
 
ABI-231 belongs to the third generation of ABIs developed in our lab. It is 
composite of a 3,4,5-trimethoxybenzoyl moiety, a 3-indole moiety, as well as a imidazole 
linker. In the previous SAR studies of ABI-I/II and RABI scaffold, attempts to improve 
their antiproliferative activities against cancer cell lines by modifying the 3,4,5-
trimethoxybenzoyl moiety were not successful [169, 182, 185, 186]. Considering the 
structural similarity between ABI-231 and ABI-I/II, we hypothesize that the 3,4,5-
trimethoxybenzoyl moiety is essential for the activity of ABI-231. Based on the 
molecular modeling result as shown in Figure 1-7, we also hypothesize that introduction 
of substituent to the indole can utilize the unoccupied pocket in the vicinity of the indole 
to enhance the binding affinity of the ABI-231 to tubulin protein. With these hypotheses 
in mind, we have synthesized ABI-231 analogues with modification of the indole moiety. 
Thirty new ABI-231 analogues are furnished. 
 
The previously published synthetic method accessed ABI-231 by resorting to an 
imidazole formation/nucleophilic substitution strategy. This method provided ABI-231 
with an overall yield of 0.28% over five steps, which is not amenable for SAR 
investigation of ABI-231. Hence, to investigate the SAR of ABI-231, it is of 
imperativeness to establish a synthetic method that can efficiently and rapidly generate 
ABI-231 and its analogues. Our proposed synthetic strategy is illustrated in Scheme 2-1. 
To construct the ABI-231 scaffold, we resort to imidazoline cyclization. The imidazoline 
can be formed from a diamine intermediate 6 and indolylcarboxyaldehydes according to a 
reported methodology [187]. We envisage that the imidazoline formation can provide 
resourceful ABI-231 analogues with modifications of the indole moiety because 
indolylcarboxyaldehydes are broadly commercially available. In this proposed method, 
accumulation of a large quantity of the diamine intermediate 6 is crucial. 
 
Diamine 6 can be derived from alkene 1 through a series of well-known and high-
yielding functional group interconversions including Upjohn dihydroxylation, mesylation 
and hydrogenation. 6 was obtained in six steps as depicted in Scheme 2-2. Starting 
material 3,4,5-trimethoxybenzaldehyde was treated with Grignard reagent 
vinylmagnesium bromide to generate the racemic mixture 1, which was protected with 
TBS to give 2 (87% for 2 steps). 2 was then subjected to Upjohn reaction in the presence 
of a catalytic equivalent of OsO4 to form a mixture diastereoisomers 3 in 82% yield. 
Diazide 5 was synthesized in two steps by following reported procedures [188]: 
mesylation of the diol 3 yielded mesylates 4 in 86% yield; 4 was then refluxed with 
sodium azide in DMF carefully to give azides 5 in 67% yield. Hydrogenation of diazide 5 
provided diamine 6 in 53% yield in the presence of Pd/C (10%). 
 
Synthesis of ABI-231 analogues with substituted 3-indolyls was outlined in 
Scheme 2-3. Indolecarboxyaldehyde was protected with Boc to give 7. 7 then reacted 
with diamine 6 in the presence of N-bromosuccinimide in DCM at ice temperature to 
form imidazoline 8. 8 was subjected to the deprotection of TBS and Boc in the presence 
of TBAF and TFA to provide 9. Simultaneous oxidation of imidazoline and secondary  
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Scheme 2-1. Retrosynthetic analysis of ABI-231 and its analogues 
 
 
 
 
 
 
Scheme 2-2. Synthesis of the intermediate 6 
Reagents and conditions: (a): vinylmagnesium bromide, THF, 0oC to rt; (b): tert-
butyldimethylsilyl chloride, imidazole, DCM, rt; (c): OsO4, NMO, Acetone/t-BuOH, rt; 
(d): MsCl, TEA, DCM, rt; (e): NaN3, DMF, reflux; (f): H2, Pd/C (10%), EtOAc-MeOH, 
rt. 
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Scheme 2-3. Synthesis of ABI-231 analogues with 3-indolyls 
Reagents and conditions: (a): (Boc)2O, DMAP, DCM, rt; (b): NBS, DCM, 0oC to rt; (c): 
TBAF, THF, rt; (d): TFA, DCM, rt; (e): IBX, DMSO,rt; (f): H2, Pd/C (10%), EtOAc-
MeOH(1:1), rt; (g): LiOH, Dioxane-H2O, r.t; 10-20% over 4 steps. 
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alcohol in 9 to imidazole and carbonyl was accomplished in the presence of 3.0-5.0 
equivalents of 2-iodoxybenzoic acid (IBX) by referring to a reported method, in which 
imidazoline was oxidized to imidazole using 1.0 equivalent of IBX [189]. Analogues of 
ABI-231 10a-10t were given in 10-20% yield over four steps. Hydrogenation of 10af, 
10ak, 10ao and 10as afforded 10au, 10av, 10aw and 10ay, respectively. Saponification 
of 10aq provided 10ax. Analogs 10ba-10be with indole rotation were synthesized by 
following similar procedures as outlined in Scheme 2-4. 
 
In summary, we have established an efficient synthetic route for ABI-231 and its 
analogues. This novel method necessitated the synthesis of a key diamine intermediate 6 
and imidazoline formation. 6 was obtained from commercially available 3,4,5-
trimethoxybenzaldehyde with an overall yield of 22% in six steps. Rapid generation of 
ABI-231 analogues modifying the indole moiety was successfully carried out through 
cyclization between 6 and commercially available indolylcarboxyaldehydes. Thirty ABI-
231 analogues were prepared from 6 in fours steps with an overall yield of 10-20%. 
 
 
Results 
 
All analogues of ABI-231 were evaluated for their cytotoxicities in human 
melanoma cell lines including A375, WM1641 and M14. Colchicine was used as a 
positive control. ABI-231 was used as a prototype for comparison. The antiproliferative 
effects of the compounds were evaluated by MTT assay. IC50s were reported in nM and 
calculated from at least three independent experiments, each performed in duplicates. 
Their in vitro growth inhibitory effects were shown in Table 2-1 and Table 2-2. ABI-231 
had an average IC50 value of 7.0 nM and was comparable to our previously reported data 
[169]. 
 
 
In vitro growth inhibitory effects of ABI-231 analogues with 3-indolyls 
 
Substitution at the 2-position of the indole ring. Compared to the prototype 
ABI-231, analogue 10aa with a bulky phenyl group on the 2-position of indole moiety 
showed markedly reduced activity. 10aa had an average IC50 value of more than 1 μM 
against a panel of melanoma cell lines. This indicated that only small substituent on the 
indole can be tolerated. It is worthy noting that attempts to synthesize analogues with 
electron-donating functional groups on the 2-position of indole were not successful. For 
example, the reaction as depicted in Figure 2-2 was performed to obtain 2-methyl-3-
indole analogue. This reaction can only provide the target imidazoline in less than 10% 
yield. The low yield of this reaction is probably due to that the electron-donating property 
of the 2-methyl can attenuate reactivity of the 3-carboxaldehyde. 
 
Substitution at the 4-position of the indole ring. Six analogues including 10ab-
10af and 10au were synthesized in this series. The best inhibitory effect was observed for 
4-methyl analogue 10ab. 10ab exhibited 3-fold improvement of potency compared to 
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Scheme 2-4. Synthesis of ABI-231 analogues with rotation of indolyls 
Reagents and condictions:(a): (Boc)2O, DMAP, DCM, rt; (b): NBS, DCM, 0oC to rt; (c): 
TBAF, THF, rt; (d): TFA, DCM, rt; (e): IBX, DMSO, rt; 10-20% over 4 steps. 
  
 37 
Table 2-1. In vitro growth inhibitory effects (nM) of ABI-231 analogues with 3-
indolyls (n=3) 
 
Compound A375 M14 WM164 
10aa >1000 >1000 >1000 
10ab 1.8 ± 0.2 1.7 ± 0.2 3.2 ± 0.3 
10ac 7.2 ± 0.7 8.2 ± 0.9 44.5 ± 15.6 
10ad 13.8 ± 1.7 10.4 ± 1.2 67.1 ±14.5 
10ae >1000 >1000 >1000 
10af >1000 >1000 >1000 
10au 9.2 ± 1.4 8.6 ± 0.8 19.1 ± 1.8 
10ag 277.7 ± 36.3 177.4 ± 16.3 552.3 ± 108.3 
10ah 19.2 ± 1.5 18.0 ± 1.3 80.9 ± 16.6 
10ai 61.8 ± 9.3 64.9 ± 4.3 159.5 ± 24.1 
10aj 164.2 ± 16.7 104.3 ± 5.9 441.7 ± 110.0 
10ak >1000 >1000 >1000 
10av >1000 >1000 >1000 
10al 21.1 ± 3.9 21.7 ± 4.7 23.7 ± 6.1 
10am 17.5 ± 3.0 5.8 ± 0.8 10.3 ± 1.2 
10an 67.8 ± 10.5 41.2 ± 7.5 55.4 ± 7.4 
10ao >1000 >1000 >1000 
10aw >1000 >1000 >1000 
10ap 793.4 ± 89.9 879.8 ± 88.2 >1000 
10aq >1000 196.1 >1000 
10ax >1000 >1000 >1000 
10ar 13.1 ± 1.3 10.8 ± 1.0 61.3 ± 11.0 
10as >1000 >1000 >1000 
10ay >1000 >1000 >1000 
10at 38.3 ± 3.7 34.1 ± 3.5 115.4 ± 25.0 
ABI-231 8.1 ± 1.6 5.6 ± 0.9 7.2 ± 0.9 
Colchicine 14.1 ± 2.2 16.6 ± 1.5 10.8 ± 1.9 
  
 38 
Table 2-2. In vitro growth inhibitory effects (nM) of ABI-231 analogues with 
rotation of indolyls (n=3) 
 
Compound A375 M14 WM164 
10ba 137.7 ± 23.7 72.3 ± 7.8 55.8 ± 9.5 
10bb 3.6 ± 1.0 3.7 ± 0.8 1.6 ± 0.3 
10bc 8.6 ± 3.3 18.5 ± 3.7 6.1 ± 1.2 
10bd 8.0 ± 1.0 6.1 ± 1.1 3.8 ± 0.5 
10be 285.5 ± 28.7 240.6 ± 21.1 435.8 ± 38.3 
ABI-231 8.1 ± 1.6 5.6 ± 0.9 7.2 ± 0.9 
Colchicine 14.1 ± 2.2 16.6 ± 1.5 10.8 ± 1.9 
 
 
 
 
 
 
Figure 2-2. Synthesis of an intermediate for 2-methyl-3-indole ABI-231 analogue 
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prototype ABI-231 and had an average IC50 value of 2.2 nM against three melanoma cell 
lines. Analogue 10ac with a small size halogen 4-F displayed equipotent antiproliferative 
activity to that of ABI-231 and had an average IC50 value of 7.7 nM. In contrast, 
analogue 10ad having a large size halogen 4-bromo was 2-fold less potent than ABI-231 
and had an average IC50 value of 12.1 nM. For analogues 10ae with a 4-methoxy group 
and 10af with a 4-benzoxy group, remarkable reduction of activity were observed. Their 
IC50s were more than 1 μM. Analogue 10au that derived from deprotection of 10af 
showed restored antiproliferative activity from an average IC50 of more than 1 μM to 12.3 
nM. These findings illustrated the importance of the size of substituent on 4-position, 
which strongly correlated with our hypothesis that only small functional groups can be 
accommodated in the pocket in the vicinity of the indole moiety. 
 
Substitution at the 5-position of the indole ring. In this series, the best activity 
was observed in the 5-fluoro analogue 10ah. 10ah had an average IC50 of 39.4 nM. 
Analogue 10ak bearing a bulky benzyloxy showed completely lost antiproliferative 
activity. Overall, analogues with functional groups on 5-position of the indole in ABI-231 
showed markedly decreased antiproliferative activities in comparison with 4-position 
substituted analogues. For example, 5-fluoro analogue 10ah and 5-bromo analogue 10aj 
were 2-fold and 10-fold less potent than 10ac and 10ad, respectively. 5-methyl analogue 
10ag and 5-hydroxy analogue 10av possessed approximately 100-fold decreased 
antiproliferative activity compared to 10ab and 10au.  
 
Substitution at the 6-position of the indole ring. In the series of 6-position 
substituted 3-indolyl analogues, the best activity was observed for the 6-fluoro analogue 
10am, which had an average IC50 of 11.2 nM. Similar to the series of 4-position 
substituted and 5-position substituted 3-indolyl analogues, analogues with bulky 
substituents such as 10ao, 10ap, 10aq lost activities and all had IC50s of more than 1 μM. 
For halogen functional groups, fluoro was more favorable than bromo. Hydrogenation of 
the benzyloxy to hydroxy on the 6-position did not provide any significant activity 
improvement (10aw). 6-methyl analogue 10al was 10-fold less potent than 4-methyl 
analogue 10ab whilst it displayed approximately 10-fold higher potency than 5-methyl 
analogue 10ag. 
 
Substitution at the 7-position of the indole ring. Among the 7-postion 
substituted 3-indolyl analogues, 10ar with a methyl substitution possessed the most 
potent inhibitory effect (average IC50 = 28.4 nM). Interestingly, 10at with a 7-methoxy 
substituent showed better anticancer activity (average IC50 = 62.6 nM) than analogues 
with methoxy on the other positions in the indole moiety. 
 
To summarize the SAR of analogues with 3-indolyls, small substituents (e.g. 
methyl, fluoro) benefits the inhibitory effect while bulky groups (e.g. phenyl, benzyloxy, 
methoxy, bromo) abolishes the antiproliferative activities. In terms of the substituting 
positions of the functional group on the indole, the activity trend follows: 4- > 7- > 6- > 
5-postion. 
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In vitro growth inhibitory effects of ABI-231 analogues with rotation of indolyls 
 
Hwang et al have disclosed a series of indolyl-imidazopyridines as CBSIs in 2015 
[190]. Their SAR study revealed that replacing the 2-indole with 4-, 5- or 6-indole 
significantly affected the antiproliferative activities. In view of the structural similarity 
between ABI-231 and indolyl-imidazopyridines, we hypothesize that rotating the 3-
indole in ABI-231 to 2, 4, 5, 6, or 7-indole will have an influence on the activity. To test 
this hypothesis, five ABI-231 analogues were synthesized (Scheme 2-4) and their in vitro 
growth inhibitory effects were shown in Table 2-2. In this series, 5- and 6-indolyl 
analogues 10bc and 10bd showed comparable antiproliferative activities to that of ABI-
231and had average IC50s of 11.1 and 6.0 nM, respectively. 2- and 7-indolyl analogues 
10ba and 10be were significantly less potent than ABI-231. 10ba and 10be both had 
IC50s of more than 100 nM. Replacement of the 3-indolyl in ABI-231 with 4-indolyl 
resulted in 10bb. 10bb showed approximately 1-fold improvement of activity compared 
to ABI-231 and had an average IC50 of 3.0 nM against three melanoma cell lines. 
 
To summarize the SAR of analogues with “indole rotation”, rotating the indole in 
ABI-231 affects the antiproliferative activities. Among 10ba-10be and ABI-231, 4-indole 
analogue 10bb shows the most potent activity and has an average IC50 of 3.0 nM. 
 
 
Discussion 
 
Previously, our group has disclosed ABI-231 as a potent tubulin inhibitor. ABI-
231 showed antiproliferative activity in the nanomolar range. Importantly, ABI-231 was 
not a substrate of P-gp and was effective to inhibit the expression of β-III tubulin isotype. 
Therefore, ABI-231represents a promising scaffold. According to the published 
molecular modeling result of ABI-231, we hypothesize that introduction of a small 
substituent to the indole moiety on ABI-231 may strengthen its binding affinity to tubulin 
protein. We also hypothesize that rotation of the indole in ABI-231 will affect the activity 
based on the SAR result of indolyl-imidazopyridines published by Hwang et al. 
 
To overcome the earlier limitations, a novel synthetic method is established for 
ABI-231 and its analogues. In this method, the core structure of ABI is furnished through 
an imidazoline formation from a crucial diamine intermediate and commercially available 
indolylcarboxyaldehydes; simultaneous oxidation of the alcohol and imidazoline to 4-
carbonylimidazole in the presence of IBX is firstly reported. This new method is 
amicable for a gram-scale synthesis of ABI-231 and can rapidly generate ABI-231 
analogues for SAR investigation. Thirty new ABI-231 analogues are accomplished from 
the newly established synthetic method. The SAR result demonstrates that small 
substituent such as methyl or fluoro is favorable, which is highly correlated with our 
hypothesis that only small functional group can be accommodated in the target pocket. 
Among the thirty analogues, 10ab (4-methyl-3-indolyl analogue) and 10bb (4-indolyl 
analogue) exhibit the most potent antiproliferative activities and have average IC50s of 
2.2 and 3.0 nM, respectively. 
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The X-ray crystal structure of the most potent analogue 10ab in complex with 
tubulin has been successfully obtained by our collaborators at Sichuan University in 
China. The crystallographic data and structure refinement statistics for 10ab is shown in 
Table 2-3. The co-crystal structure of 10ab in complex with tubulin is shown in Figure 
2-3. The result shows that 10ab binds to the colchicine binding site locating at the 
interface of α and β-tubulin heterodimers. 10ab forms three H-bond interactions with 
tubulin: the carbonyl with the residue β-Asp249 in a distance of 3.4 Å; the imidazole NH 
with the residue α-Thr179 in a distance of 2.9 Å; indole NH with residue β-Asn347 
through a water “bridge”. The crystal structure suggests that a methylene or NH between 
the indole and imidazole moiety may force the indole moiety to move toward the β-
Asn347 residue. This movement may allow the formation of a direct H-bond interaction 
between the indole and β-Asn347 without resorting to a water “bridge”. This is worthy 
investigating in future effort on structural modification of ABI-231. 
 
In conclusion, we have established an efficient synthetic method for ABI-231 
analogues modifying the indole moiety. Thirty new ABI-231 analogues have been 
synthesized. The most potent analogue 10ab has an average IC50 of 2.2 nM and is 3.2-
fold more potent than ABI-231. 
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Table 2-3. Crystallographic data and structure refinement statistics for 10ab 
 
Ligand 10ab 
X-ray source SSRF-BL19U1 
Data collection 
Wavelength (Å) 0.97853 
Resolution range (Å) 50 – 2.80 (2.85 – 2.80)a 
Space group P 212121 
Unit cell (Å, °) 105.2, 157.0, 182.6 
Total reflections 503678 
Unique reflections 75002 
Multiplicity 6.7 (6.3) 
Completeness (%) 100 (100) 
Mean I/sigma (I) 19.3 (3.0) 
Rmerge 0.109 (0.576) 
Structure refinement 
R-factor/ R-freeb 0.2174/ 0.2567 
RMS (bonds) 0.007 
RMS (angles) 1.205 
No. of atoms 17520 
Macromolecules 17435 
Ligand 60 
Waters 25 
Average B-factor 55.92 
Macromolecules 55.91 
Ligands (TAJ) 62.6 
Waters 44.0 
Ramachandran plot statistics 
Most favored regions (%) 92.3 
Allowed regions (%) 7.5 
Generously allowed regions (%) 0.2 
Disallowed regions (%) 0.0 
 
Note: a The values for the data in the highest resolution shell are shown in parentheses.     
b R-free = ?Test||Fobs| ?|Fcalc||/?Test |Fobs|, where ?Test? is a test set of about 5% 
of the total reflections randomly chosen and set aside prior to refinement for the structure. 
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Figure 2-3. Co-crystal structure of 10ab in complex with tubulin 
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CHAPTER 3.    STRUCTURAL MODIFICATION OF THE 3,4,5-
TRIMETHOXYPHENYL MOIETY IN ABI-231 LEADS TO IMPROVED 
ANTIPROLIFERATIVE ACTIVITIES 
 
 
Introduction 
 
Inhibition of microtubules assembly from α and β-tubulin heterodimers is an 
attractive and effective target for developing anticancer therapy. MTAs interrupt the cell 
cycle and result in mitotic arrest at the metaphase/anaphase transition, and eventually 
induce apoptosis of cancer cells [91, 191]. Although MTAs have achieved great success 
in cancer treatment, acquired drug-resistance represented a significant obstacle [88]. 
Therefore, MTAs that are able to surmount multidrug-resistance mechanisms is 
imperatively needed for treatment of resistant phenotypes. 
 
CBSIs have shown significant abilities to overcome P-gp or MRP-mediated drug 
resistance [99, 102]. A number of CBSIs are also proven to effectively inhibit the 
overexpression of tubulin β-III isotype in cancer cells [100]. Thus, colchicine binding site 
in tubulin represents a promising therapeutic target. Some of the notable examples of 
CBSIs are outlined in Figure 3-1. Of these CBSIs, they share a common moiety, 3,4,5-
trimethoxyphenyl (3,4,5-TMP). 3,4,5-TMPs are structurally crucial for many CBSIs to 
exert their maximum antiproliferative activities [101, 102, 192, 193]. Attempts to modify 
3,4,5-TMPs are reported not successful. In colchicine and its derivatives, 3,4,5-TMPs 
play important roles in increasing the binding affinities and maintaining the suitable 
molecular conformations [194]. 3,4,5-TMPs in CA-4 and its derivatives are also 
indispensable in a similar manner. Structural modifications of CA-4 and its derivatives 
are mainly performed on either the double bond linkage or the 3-hydroxy-4-
methoxyphenyl moiety, but rarely on the 3,4,5-TMP moiety [101].  
 
In the search for novel MTAs, we have previously described the discovery of a 2-
aryl-4-benzoyl-imidazole (ABI-I) pharmacophore that had desirable drug-like properties 
and exhibited potent antiproliferative activity against a panel of cancer cell lines [182]. 
Subsequent structural modifications of the benzoyl moiety, the aryl moiety, as well as the 
imidazole fragment in the ABI-I scaffold, result in other pharmacophores, including ABI-
IIs, ABI-IIIs, RABIs, and IIPs. ABI-231 belongs to ABI-IIIs and had an indole moiety. It 
shows the most potent antiproliferative activity and had an average IC50 value of 5.2 nM 
against a panel of cancer cell lines [169, 183, 185, 190]. ABI-231 is not a substrate of P-
gp and displays a dramatic effect in inhibiting tubulin β-III isotype in a pancreatic cancer 
cell model with overexpression of different β-tubulin isotypes (unpublished data). ABI-
231, therefore, is of great promise for developing anticancer therapy. 
 
In Chapter 2, the co-crystal structure of the most potent 4-methyl-3-indole 
analogue in complex with tubulin suggests that there are extensive H-bond interactions 
between each moiety of the ABI-231 with the tubulin protein except for the 3,4,5-TMP 
moiety. The crystal structure also reveals that there is a methionine residue nearby the  
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Figure 3-1. Examples of microtubule inhibitors with 3,4,5-TMP moieties targeting 
colchicine binding sites in tubulin 
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3,4,5-TMP moiety. We hypothesize that optimization of the 3,4,5-TMP moiety in ABI-
231 can potentially introduce a hydrophobic interaction to the methionine residue in 
tubulin. With this hypothesis, we have carried out the SAR investigation of ABI-231 by 
modifying the 3,4,5-TMP moiety. In this chapter, we will disclose the establishment of a 
novel synthetic route to ABI-231 analogues modifying the 3,4,5-TMP moiety. This 
synthetic method involves a Suzuki coupling/Grignard reaction strategy and can 
efficiently generate ABI-231 analogues in gram-scale. This novel method can circumvent 
the involvement of potentially explosive azide reported in the last chapter. Among the 
eight synthesized ABI-231 analogues, the one containing a unique 3-methoxybenzo[4,5]-
dioxene moiety exhibits the strongest antiproliferative activity against a panel of 
melanoma cell lines and has an average IC50 of 1.9 nM. To our best knowledge, it 
represents the most successful instance of modifying the 3,4,5-TMP moiety in CA-4 
derivatives isosterically. Currently, the mechanistic study and in vivo efficacy evaluation 
of these novel ABI-231 analogues are undergoing. 
 
 
Experimental Section 
 
 
General chemistry 
 
Tetrahydrofuran was distilled from sodium-benzophenone. All other solvents and 
chemical reagents were obtained from commercial sources and directly used without 
further purification. Glassware was oven-dried before use. All reactions were performed 
under an argon atmosphere. TLC was performed on silica gel 60 GF254 and monitored 
under UV light or visualized using phosphomolybdic acid reagent. Flash chromatography 
was performed on 230-400 mesh silica gel (Fisher Scientific). Melting points were 
recorded on a MPA100 Automated Melting Point Apparatus. NMR spectra were obtained 
on a Bruker Ascend 400 (Billerica, MA) spectrometer or a Varian Inova-500 
spectrometer (Agilent Technologies, Santa Clara, CA). HR-MS were obtained on Waters 
Acquity UPLC linked to Waters Acquity Photodiode Array Detector and Waters Acquity 
Single Quadrupole Mass Detector. Chemical shifts are given in ppm with 
tetramethylsilane (TMS) as an internal reference. All coupling constants (J) are given in 
Hertz (Hz).  
 
 
Chemical synthesis 
 
General procedure for synthesis of alkylated methyl benzoate 1a, 1b and 4. 
To a solution of the methyl 3-methoxy-4,5-dihydroxybenzoate (2.5 mmol) in acetonitrile 
(10 mL) was added potassium carbonate (6.0 mmol) and dibromomethane (2.75 mmol) or 
1,3-dibromopropane (2.75 mmol) or allyl bromide (6.0 mmol). The mixture was reflux 
for overnight and then cooled to room temperature; the precipitate was filtered off and 
washed with dichloromethane. The combined filtration was evaporated under vacuum to 
give the oily crude which was further purified with flash chromatography on silica. 
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Elution with hexane/ethyl acetate (5:1-2:1) gave 1a, 1b and 4 as colorless oil (yields: 
42% for 1a, 36% for 1b and 93% for 4). 
 
Methyl 7-methoxybenzo[d][1,3]dioxole-5-carboxylate (1a). 1H NMR (400 
MHz, Chloroform-d) δ 7.32 (d, J = 1.4 Hz, 1H), 7.19 (d, J = 1.4 Hz, 1H), 6.04 (s, 2H), 
3.93 (s, 3H), 3.87 (s, 3H). HRMS: calculated for C10H11O5 [M+H]+ 211.0606, found 
211.0607. 
 
Methyl 9-methoxy-3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylate (1b). 
1H NMR (400 MHz, Chloroform-d) δ 7.31 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 
4.39 – 4.22 (m, 6H), 3.88 (s, 3H), 2.22 (q, J = 5.8 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H). 
HRMS: calculated for C12H15O5 [M+H]+ 239.0919, found 239.0917. 
 
Methyl 3,4-bis(allyloxy)-5-methoxybenzoate (4). 1H NMR (400 MHz, 
Chloroform-d) δ 7.27 (s, 2H), 6.12 – 5.99 (m, 2H), 5.42 (dq, J = 17.3, 1.6 Hz, 1H), 5.34 – 
5.24 (m, 2H), 5.17 (ddt, J = 10.3, 1.9, 1.1 Hz, 1H), 4.59 (ddt, J = 6.1, 5.0, 1.5 Hz, 4H), 
3.87 (d, J = 0.7 Hz, 6H). HRMS: calculated for C15H19O5 [M+H]+ 279.1232, found 
279.1236. 
 
General procedure for the synthesis of benzoic acids 2a, 2b and 7. To a 
solution of the methyl benzoate 1a, 1b or 6 (1.0 mmol) in dioxane (5 mL) was added 
solution of lithium hydroxide (1.5 mmol) in water (3ml). The mixture was stirred at 50oC 
until the TLC indicated the completion of the reaction. The solvents were removed under 
reduced pressure and the resulted residue was partitioned between water (10 ml) and 
DCM (10ml), pH value was adjusted to 5 using 1M HCl solution. The organic solvents 
were then combined, dried over Na2SO4, filtered and evaporated under reduced pressure. 
The crude was purified with flash chromatography on silica. Elution with hexane/ethyl 
acetate (4:1-1:1) gave 2a, 2b and 7 as colorless oil (yields: 88% for 2a, 91% for 2b and 
84% for 7).  
 
7-methoxybenzo[d][1,3]dioxole-5-carboxylic acid (2a). 1H NMR (400 MHz, 
Acetone-d6) δ 11.11 (s, 1H), 7.34 (d, J = 1.5 Hz, 1H), 7.15 (d, J = 1.5 Hz, 1H), 6.10 (s, 
2H), 3.93 (s, 3H). HRMS: calculated for C9H9O5 [M+H]+ 197.0450, found 197.0451. 
 
9-methoxy-3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid (2b). 1H 
NMR (400 MHz, Chloroform-d) δ 10.87 (s, 1H), 7.39 (d, J = 2.0 Hz, 1H), 7.31 (d, J = 2.0 
Hz, 1H), 4.41 (t, J = 5.8 Hz, 2H), 4.29 (t, J = 5.9 Hz, 2H), 3.90 (s, 3H), 2.25 (p, J = 5.8 
Hz, 2H). HRMS: calculated for C11H13O5 [M+H]+ 225.0763, found 225.0765. 
 
8-methoxybenzo[b][1,4]dioxine-6-carboxylic acid (7). 1H NMR (400 MHz, 
Acetone-d6) δ 7.25 (d, J = 1.8 Hz, 1H), 6.91 (d, J = 1.8 Hz, 1H), 6.15 (d, J = 3.6 Hz, 1H), 
6.12 (d, J = 3.6 Hz, 1H), 3.86 (s, 3H). HRMS: calculated for C10H9O5 [M+H]+ 209.0450, 
found 209.0447. 
 
General procedure for synthesis of benzoyl chloride 3a, 3b and 8. To a 
solution of the benzoic acid 2a, 2b or 7 (0.8 mmol) in DCM (5 mL) was added thionyl 
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chloride (1.5 ml). The mixture was stirred at 50oC for 3 hours. The solvents were then 
removed under reduced pressure and the corresponding crude benzoyl chloride was 
directly used for next step.  
 
Synthesis of methyl methyl 3-methoxy-4,5-bis(prop-1-en-1-yloxy)benzoate 
(5). To a solution of 4 (279 mg, 1.0 mmol) in toluene (5 mL) was added 
carbonylchlorohydridotris(triphenylphosphine)ruthenium(II) (95 mg, 0.1 mmol). The 
mixture was refluxed for 36hr. Water was then added and the reaction mixture was 
extracted with ethyl acetate, washed with brine and dried with anhydrous Na2SO4. The 
combined extracts were evaporated under vacuum to give crude product which was 
purified with flash chromatography on silica. Elution with hexane/ethyl acetate (8:1-3:1) 
gave 5 as colorless oil (218 mg, 78%). 1H NMR (400 MHz, Chloroform-d) δ 7.35 (s, 2H), 
6.47 – 6.11 (m, 2H), 5.44 – 4.60 (m, 2H), 3.90 (d, J = 2.0 Hz, 6H), 1.80 – 1.55 (m, 6H). 
HRMS: calculated for C15H19O5 [M+H]+ 279.1232, found 279.1234. 
 
Synthesis of methyl 8-methoxybenzo[b][1,4]dioxine-6-carboxylate (6). To a 
solution of 5 (200 mg, 0.72 mmol) in toluene (5 mL) was added Grubbs` catalyst 2nd 
generation (95 mg, 0.072 mmol). The mixture was refluxed for 24hr. Water was then 
added and the reaction mixture was extracted with ethyl acetate, washed with brine and 
dried with anhydrous Na2SO4. The combined extracts were evaporated under vacuum to 
give crude product which was purified with flash chromatography on silica. Elution with 
hexane/ethyl acetate (8:1-3:1) gave 6 as colorless oil (131 mg, 82%). 1H NMR (400 
MHz, Chloroform-d) δ 7.14 (d, J = 1.9 Hz, 1H), 6.89 (d, J = 1.9 Hz, 1H), 5.91 (d, J = 3.6 
Hz, 1H), 5.83 (d, J = 3.6 Hz, 1H), 3.81 (d, J = 0.9 Hz, 6H). HRMS: calculated for 
C11H11O5 [M+H]+ 223.0606, found 223.0607. 
 
Synthesis of 2,4,5-tribromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
imidazole (9). To a stirred solution of 2,4,5-tribromoimidazole (9.5 g, 31.1 mmol) in 
anhydrous THF (100 mL) at ice temperature was added sodium hydride (1.5g, 40.6 
mmol) in portions under argon. The mixture was stirred for 1 hr at this temperature and 
was added 2-(trimethylsilyl)ethoxymethyl chloride (6.7 ml, 35.8 mmol) dropwise. 
Reaction was then warmed to room temperature and stirred for another 1.5 hr. Water was 
then added at ice temperature carefully and the reaction mixture was extracted with ethyl 
acetate, washed with brine and dried with Na2SO4. The combined extracts were 
evaporated under vacuum to give the oily residue which was purified with flash 
chromatography on silica.  Elution with hexane/ethyl acetate (10:0-10:1) gave 9 as 
slightly yellowish solid (12.6 g, 93%). 1H NMR (400 MHz, Chloroform-d) δ 5.30 (s, 2H), 
3.65 – 3.49 (m, 2H), 0.94 – 0.87 (m, 2H), -0.03 (s, 9H). HRMS: calculated for 
C9H16Br3N2OSi [M+H]+ 432.8582, found 432.8588. 
 
Synthesis of 10 and 16. To a mixture of 1-(Phenylsulfonyl)-3-indolylboronic acid 
pinacol ester (5.0 g, 13.1 mmol) or 15, 9 (6.8 g, 15.7 mmol), and sodium carbonate (2.8 
g, 26.1 mmol) in toluene (50 ml), methanol (5 ml) and (2.5 ml) was added 2-
dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (935 mg, 2.0 mmol) and 
tris(dibenzylideneacetone)dipalladium (600 mg, 0.66 mmol) under argon. The mixture 
was refluxed for overnight. Water was then added and the reaction mixture was extracted 
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with ethyl acetate, washed with brine and dried with anhydrous Na2SO4. The combined 
extracts were evaporated under vacuum to give crude product which was purified with 
flash chromatography on silica. Elution with hexane/ethyl acetate (15:1-4:1) gave 10 or 
16 as pale-yellow solid (for 10: 34% yield; for 16: 31% yield). 
 
3-(4,5-dibromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)-1-
(phenylsulfonyl)-1H-indole (10). 1H NMR (400 MHz, Chloroform-d) δ 8.20 (s, 1H), 
8.17 (dt, J = 7.7, 1.1 Hz, 1H), 8.05 – 8.00 (m, 1H), 7.92 – 7.85 (m, 2H), 7.58 – 7.51 (m, 
1H), 7.47 – 7.36 (m, 3H), 7.32 (td, J = 7.7, 1.1 Hz, 1H), 5.35 (s, 2H), 3.80 – 3.68 (m, 2H), 
1.09 – 0.98 (m, 2H), 0.05 (s, 9H). HRMS: calculated for C23H26Br2N3O3SSi [M+H]+ 
609.9831, found 609.9822. 
 
4-(4,5-dibromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)-1-
(phenylsulfonyl)-1H-indole (16). 1H NMR (400 MHz, Chloroform-d) δ 8.11 (dd, J = 8.4, 
1.0 Hz, 1H), 7.86 (dd, J = 8.0, 1.4 Hz, 2H), 7.64 (d, J = 3.7 Hz, 1H), 7.57 – 7.50 (m, 2H), 
7.41 (dt, J = 20.0, 7.8 Hz, 3H), 6.97 (d, J = 3.7 Hz, 1H), 5.25 (s, 2H), 3.49 (dd, J = 8.8, 
7.6 Hz, 2H), 0.85 (dd, J = 8.8, 7.6 Hz, 2H), -0.06 (s, 9H). HRMS: calculated for 
C23H26Br2N3O3SSi [M+H]+ 609.9831, found 609.9834. 
 
General procedure for synthesis of 11a-11f, 17 and 23. To a stirred solution of 
compound 10 or 16 or 21 (1.0 mmol) in anhydrous THF (3.0 mL) under argon was added 
isopropylmagnesium chloride lithium chloride complex solution (1.3 M in THF, 0.92 ml, 
1.2 mmol) at room temperature. The mixture was stirred for 1 hr and was added benzoyl 
chlorides (1.3 mmol) in anhydrous THF (mL). Reaction was kept stirring at room 
temperature for 1 hour and then refluxed for 30 minute. Saturated NH4Cl solution was 
then added to quench the reaction. Reaction mixture was extracted with ethyl acetate, 
washed with brine and dried with Na2SO4. The combined extracts were evaporated under 
vacuum to give the crude product which was purified with flash chromatography on 
silica. Elution with hexane/ethyl acetate (10:1-3:1) gave pure 11a-11f, 17 and 22 as pale-
yellow to yellowish solids (yields: 31-48%). 
 
(4-bromo-2-(1-(phenylsulfonyl)-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)methanone (11a). 1H NMR (400 MHz, Chloroform-d) δ 8.30 (s, 1H), 8.19 (ddd, J = 
7.7, 1.3, 0.7 Hz, 1H), 8.05 (dt, J = 8.4, 1.0 Hz, 1H), 7.97 – 7.87 (m, 2H), 7.59 – 7.54 (m, 
1H), 7.49 – 7.32 (m, 6H), 5.62 (s, 2H), 4.42 – 4.33 (m, 2H), 4.30 (dt, J = 5.7, 1.6 Hz, 2H), 
3.64 – 3.53 (m, 2H), 0.98 – 0.90 (m, 2H), -0.07 (s, 9H). HRMS: calculated for 
C32H33BrN3O6SSi [M+H]+ 694.1043, found 694.1045. 
 
Benzo[d][1,3]dioxol-5-yl(4-bromo-2-(1-(phenylsulfonyl)-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)methanone (11b). 1H NMR (400 
MHz, Chloroform-d) δ 8.29 (s, 1H), 8.19 (ddd, J = 7.9, 1.4, 0.7 Hz, 1H), 8.05 (dt, J = 8.3, 
1.0 Hz, 1H), 7.95 – 7.87 (m, 2H), 7.59 – 7.50 (m, 2H), 7.49 – 7.32 (m, 5H), 6.90 (dd, J = 
8.2, 1.3 Hz, 1H), 6.10 (s, 2H), 5.62 (s, 2H), 3.66 – 3.50 (m, 2H), 0.99 – 0.90 (m, 2H), -
0.06 (s, 9H). HRMS: calculated for C31H31BrN3O6SSi [M+H]+ 680.0886, found 680.0881. 
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(4-bromo-2-(1-(phenylsulfonyl)-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(8-methoxy-2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)methanone (11c). 1H NMR (400 MHz, Chloroform-d) 
δ 8.34 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 8.04 (dd, J = 8.4, 1.0 Hz, 1H), 7.97 – 7.89 (m, 
2H), 7.56 (t, J = 7.4 Hz, 1H), 7.49 – 7.39 (m, 3H), 7.35 (td, J = 7.6, 1.1 Hz, 1H), 7.20 – 
7.11 (m, 3H), 5.62 (s, 2H), 4.41 (dd, J = 3.8, 1.8 Hz, 2H), 4.30 (dd, J = 3.8, 1.8 Hz, 2H), 
3.95 (s, 3H), 3.62 – 3.53 (m, 2H), 0.96 – 0.89 (m, 2H), -0.08 (s, 9H). HRMS: calculated 
for C33H35BrN3O7SSi [M+H]+ 724.1148, found 724.1144. 
 
(4-bromo-2-(1-(phenylsulfonyl)-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(7-methoxybenzo[d][1,3]dioxol-5-
yl)methanone (11d). 1H NMR (400 MHz, Chloroform-d) δ 8.30 (s, 1H), 8.20 (ddd, J = 
7.9, 1.4, 0.7 Hz, 1H), 8.05 (dt, J = 8.2, 1.0 Hz, 1H), 7.94 – 7.90 (m, 2H), 7.60 – 7.53 (m, 
1H), 7.48 – 7.33 (m, 4H), 7.22 (d, J = 1.5 Hz, 1H), 7.12 (d, J = 1.5 Hz, 1H), 6.11 (s, 2H), 
5.63 (s, 2H), 3.95 (s, 3H), 3.65 – 3.57 (m, 2H), 1.00 – 0.91 (m, 2H), -0.06 (s, 9H). HRMS: 
calculated for C32H33BrN3O7SSi [M+H]+ 710.0992, found 710.0999. 
 
(4-bromo-2-(1-(phenylsulfonyl)-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(9-methoxy-3,4-dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)methanone (11e). 1H NMR (400 MHz, Chloroform-d) δ 
8.30 (s, 1H), 8.23 – 8.17 (m, 1H), 8.05 (dt, J = 8.4, 1.0 Hz, 1H), 7.94 – 7.89 (m, 2H), 7.60 
– 7.53 (m, 1H), 7.49 – 7.32 (m, 4H), 7.22 (d, J = 2.0 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 
5.63 (s, 2H), 4.46 (t, J = 5.7 Hz, 2H), 4.30 (t, J = 5.9 Hz, 2H), 3.93 (s, 3H), 3.64 – 3.56 (m, 
2H), 2.28 (p, J = 5.8 Hz, 2H), 0.99 – 0.90 (m, 2H), -0.06 (s, 9H). HRMS: calculated for 
C34H37BrN3O7SSi [M+H]+ 738.1305, found 738.1313. 
 
(4-bromo-2-(1-(phenylsulfonyl)-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(8-methoxybenzo[b][1,4]dioxin-6-
yl)methanone (11f).  1H NMR (400 MHz, Acetone-d6) δ 8.54 (s, 1H), 8.35 (ddd, J = 8.0, 
1.3, 0.7 Hz, 1H), 8.18 – 8.09 (m, 3H), 7.79 – 7.73 (m, 1H), 7.72 – 7.63 (m, 2H), 7.52 
(ddd, J = 8.4, 7.3, 1.4 Hz, 1H), 7.44 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H), 7.31 (d, J = 1.9 Hz, 
1H), 6.92 (d, J = 1.9 Hz, 1H), 6.24 (d, J = 3.6 Hz, 1H), 6.20 (d, J = 3.6 Hz, 1H), 5.81 (s, 
2H), 3.93 (s, 3H), 3.76 – 3.67 (m, 2H), 1.06 – 0.95 (m, 2H), 0.00 (s, 9H). HRMS: 
calculated for C33H33BrN3O7SSi [M+H]+ 722.0992, found 722.0989. 
 
(4-bromo-2-(1-(phenylsulfonyl)-1H-indol-4-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(8-methoxybenzo[b][1,4]dioxin-6-
yl)methanone (17). 1H NMR (400 MHz, Chloroform-d) δ 8.16 (d, J = 8.3 Hz, 1H), 7.88 
(dd, J = 8.4, 1.3 Hz, 2H), 7.68 (d, J = 3.7 Hz, 1H), 7.59 – 7.53 (m, 2H), 7.48 – 7.39 (m, 
3H), 7.13 (d, J = 1.9 Hz, 1H), 6.96 (d, J = 3.7 Hz, 1H), 6.88 (d, J = 1.8 Hz, 1H), 6.00 (d, J 
= 3.6 Hz, 1H), 5.91 (d, J = 3.5 Hz, 1H), 5.50 (s, 2H), 3.90 (s, 3H), 3.34 – 3.27 (m, 2H), 
0.76 – 0.67 (m, 2H), -0.15 (s, 9H). HRMS: calculated for C33H33BrN3O7SSi [M+H]+ 
722.0992, found 722.0996. 
 
(4-bromo-2-(4-methyl-1-(phenylsulfonyl)-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(8-methoxybenzo[b][1,4]dioxin-6-
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yl)methanone (23). 1H NMR (400 MHz, Chloroform-d) δ 7.92 – 7.83 (m, 4H), 7.54 (dd, 
J = 8.3, 6.5 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.25 – 7.20 (m, 1H), 7.10 (d, J = 1.9 Hz, 1H), 
7.01 (d, J = 7.5 Hz, 1H), 6.84 (s, 1H), 6.00 – 5.91 (m, 1H), 5.88 (dd, J = 3.3, 1.8 Hz, 1H), 
5.36 (d, J = 1.8 Hz, 2H), 3.87 (d, J = 1.7 Hz, 3H), 3.39 – 3.29 (m, 2H), 2.18 (s, 3H), 0.79 
– 0.66 (m, 2H), -0.14 (d, J = 1.5 Hz, 9H). HRMS: calculated for C34H35BrN3O7SSi 
[M+H]+ 736.1148, found 736.1155. 
 
General procedure for synthesis of 12a-12f, 18 and 24. To a suspension of 11a-
11f or 17 or 23 (0.5 mmol), potassium carbonate (276 mg, 2.0 mmol), and 
triphenylphosphine (26 mg, 0.1 mmol) in n-BuOH (3 mL) was added palladium acetate 
(5.6 mg, 0.025 mmol). The mixture was heated to reflux for 4 hr. n-BuOH was removed 
under reduced pressure. The residue was partitioned between water (10 ml) and EtOAc 
(10ml). The combined organic solvents were then evaporated under reduced pressure. 
The crude was purified with flash chromatography on silica. Elution with hexane/ethyl 
acetate (10:1-3:1) gave pure 12a-12f, 18 and 24 as pale-yellow to yellowish solids 
(yields: 76-89%). 
 
(2-(1H-indol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-
yl)(benzo[d][1,3]dioxol-5-yl)methanone (12b). 1H NMR (400 MHz, Chloroform-d) δ 
9.35 (s, 1H), 8.30 – 8.17 (m, 1H), 7.94 (d, J = 2.8 Hz, 1H), 7.74 (s, 1H), 7.51 (dd, J = 8.1, 
1.7 Hz, 1H), 7.41 (dd, J = 7.2, 1.7 Hz, 2H), 7.29 – 7.18 (m, 3H), 6.91 (d, J = 8.1 Hz, 1H), 
6.08 (s, 2H), 5.88 (s, 2H), 3.78 – 3.64 (m, 2H), 1.00 – 0.86 (m, 2H), -0.06 (s, 9H). HRMS: 
calculated for C25H28N3O4Si [M+H]+ 462.1849, found 462.1852. 
 
(2-(1H-indol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(8-
methoxy-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone (12c). 1H NMR (400 MHz, 
Chloroform-d) δ 9.24 (s, 1H), 8.19 (d, J = 7.2 Hz, 1H), 7.95 (s, 1H), 7.81 (s, 1H), 7.50 – 
7.42 (m, 1H), 7.30 – 7.20 (m, 2H), 7.18 (d, J = 2.0 Hz, 1H), 7.11 (d, J = 2.0 Hz, 1H), 5.88 
(s, 2H), 4.42 (dd, J = 3.9, 1.7 Hz, 2H), 4.33 (dd, J = 3.7, 1.7 Hz, 2H), 3.96 (s, 3H), 3.77 – 
3.64 (m, 2H), 1.00 – 0.87 (m, 2H), -0.05 (s, 9H). HRMS: calculated for C27H32N3O5Si 
[M+H]+ 506.2111, found 506.2113. 
 
(2-(1H-indol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(7-
methoxybenzo[d][1,3]dioxol-5-yl)methanone (12d). 1H NMR (400 MHz, Chloroform-d) 
δ 8.79 (s, 1H), 8.35 – 8.25 (m, 1H), 8.03 (d, J = 2.8 Hz, 1H), 7.77 (s, 1H), 7.46 – 7.42 (m, 
1H), 7.30 – 7.27 (m, 1H), 7.20 (d, J = 1.5 Hz, 1H), 7.13 (d, J = 1.5 Hz, 1H), 6.10 (s, 2H), 
5.91 (s, 2H), 3.96 (s, 3H), 3.80 – 3.70 (m, 2H), 0.94 (d, J = 8.3 Hz, 2H), -0.05 (s, 9H).  
HRMS: calculated for C26H30N3O5Si [M+H]+ 492.1955, found 492.1957. 
 
(2-(1H-indol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(9-
methoxy-3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methanone (12e). 1H NMR (400 
MHz, Chloroform-d) δ 8.66 (s, 1H), 8.36 – 8.23 (m, 1H), 8.05 (d, J = 2.8 Hz, 1H), 7.79 (s, 
1H), 7.51 – 7.40 (m, 1H), 7.33 – 7.24 (m, 4H), 7.22 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 2.0 
Hz, 1H), 5.92 (s, 2H), 4.44 (t, J = 5.7 Hz, 2H), 4.32 (t, J = 5.9 Hz, 2H), 3.92 (s, 3H), 3.81 
– 3.71 (m, 2H), 2.34 – 2.20 (m, 2H), 1.00 – 0.91 (m, 2H), -0.04 (s, 9H). HRMS: 
calculated for C28H34N3O5Si [M+H]+ 520.2268, found 520.2272. 
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(2-(1H-indol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(8-
methoxybenzo[b][1,4]dioxin-6-yl)methanone (12f). 1H NMR (400 MHz, Chloroform-d) 
δ 10.02 (d, J = 2.8 Hz, 1H), 8.36 – 8.27 (m, 1H), 7.94 (d, J = 2.8 Hz, 1H), 7.87 (s, 1H), 
7.38 – 7.31 (m, 1H), 7.30 – 7.22 (m, 2H), 7.16 (d, J = 1.9 Hz, 1H), 6.95 (d, J = 1.9 Hz, 
1H), 6.04 (d, J = 3.6 Hz, 1H), 5.98 – 5.88 (m, 3H), 3.92 (s, 3H), 3.83 – 3.67 (m, 2H), 1.03 
– 0.89 (m, 2H), 0.00 (s, 9H). HRMS: calculated for C27H30N3O5Si [M+H]+ 504.1955, 
found 504.1952. 
 
(2-(1H-indol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)(8-
methoxybenzo[b][1,4]dioxin-6-yl)methanone (18). 1H NMR (400 MHz, Chloroform-d) 
δ 8.47 (s, 1H), 7.76 (s, 1H), 7.55 (d, J = 8.2 Hz, 1H), 7.50 (d, J = 7.3 Hz, 1H), 7.34 – 7.29 
(m, 2H), 7.15 (d, J = 1.8 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H), 6.73 (s, 1H), 6.01 (d, J = 3.6 
Hz, 1H), 5.92 (d, J = 3.7 Hz, 1H), 5.78 (s, 2H), 3.91 (s, 3H), 3.43 – 3.33 (m, 2H), 0.80 – 
0.73 (m, 2H), -0.13 (s, 9H). HRMS: calculated for C27H30N3O5Si [M+H]+ 504.1955, 
found 504.1965. 
 
(8-methoxybenzo[b][1,4]dioxin-6-yl)(2-(4-methyl-1H-indol-3-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)methanone (24). 1H NMR (400 MHz, 
Chloroform-d) δ 9.17 (s, 1H), 7.36 (s, 1H), 7.21 (d, J = 8.2 Hz, 1H), 7.15 (s, 1H), 7.12 (d, 
J = 7.4 Hz, 1H), 6.94 (d, J = 7.2 Hz, 1H), 6.90 (q, J = 1.6 Hz, 1H), 6.01 (t, J = 2.4 Hz, 1H), 
5.92 (t, J = 2.8 Hz, 1H), 5.46 (s, 2H), 3.91 (s, 3H), 3.31 (t, J = 8.1 Hz, 2H), 2.34 (s, 3H), 
0.70 (t, J = 8.1 Hz, 2H), -0.14 (d, J = 1.5 Hz, 9H). HRMS: calculated for C28H32N3O5Si 
[M+H]+ 518.2111, found 518.2108. 
 
General procedure for synthesis of 13a-13f, 19 and 25. To a solution of 12a-
12f or 18 or 24 in DCM (1 ml) was added trifluoroacetic acid (1 ml). The reaction was 
stirred for 2 hr and solvent was evaporated under reduced pressure. The residue was 
partitioned between saturated NaHCO3 solution and EtOAc. The combined organic 
solvents were then evaporated under reduced pressure. The crude was purified with flash 
chromatography on silica.  Elution with hexane/ethyl acetate (4:1-1:2) gave pure 13a-13f, 
19 and 25 as yellowish solids (yields: 79-92%). 
 
(2-(1H-indol-3-yl)-1H-imidazol-5-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)methanone (13a). 1H NMR (400 MHz, DMSO-d6) δ 13.14 (s, 1H), 11.62 (s, 1H), 8.47 
– 8.36 (m, 1H), 8.30 – 8.17 (m, 1H), 7.87 (s, 1H), 7.68 (s, 2H), 7.48 (dt, J = 8.2, 0.9 Hz, 
1H), 7.25 – 7.12 (m, 2H), 7.04 (d, J = 8.8 Hz, 1H), 4.52 – 4.27 (m, 4H). HRMS: 
calculated for C20H16N3O3 [M+H]+ 346.1192, found 346.1190. 
 
(2-(1H-indol-3-yl)-1H-imidazol-5-yl)(benzo[d][1,3]dioxol-5-yl)methanone 
(13b). 1H NMR (400 MHz, DMSO-d6) δ 13.36 (s, 1H), 11.67 (s, 1H), 8.42 – 8.32 (m, 
1H), 8.23 (d, J = 2.7 Hz, 1H), 7.92 (s, 1H), 7.81 (d, J = 7.1 Hz, 1H), 7.71 – 7.56 (m, 1H), 
7.49 (dt, J = 8.2, 0.9 Hz, 1H), 7.19 (dtd, J = 17.2, 7.1, 1.3 Hz, 2H), 7.11 (d, J = 8.1 Hz, 
1H), 6.18 (s, 2H). HRMS: calculated for C19H14N3O3 [M+H]+ 332.1035, found 332.1036. 
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(2-(1H-indol-3-yl)-1H-imidazol-5-yl)(8-methoxy-2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)methanone (13c). 1H NMR (400 MHz, Chloroform-d) 
δ 8.02 (s, 1H), 7.92 (s, 1H), 7.81 (s, 1H), 7.40 (dd, J = 10.9, 7.7 Hz, 1H), 7.16 (dd, J = 7.0, 
3.0 Hz, 3H), 7.07 (s, 1H), 4.41 – 4.32 (m, 2H), 4.32 – 4.22 (m, 2H), 3.91 (s, 3H). HRMS: 
calculated for C21H18N3O4 [M+H]+ 376.1297, found 376.1294. 
 
(2-(1H-indol-3-yl)-1H-imidazol-5-yl)(7-methoxybenzo[d][1,3]dioxol-5-
yl)methanone (13d). 1H NMR (400 MHz, Chloroform-d) δ 8.16 – 8.07 (m, 1H), 7.90 (s, 
1H), 7.74 (s, 1H), 7.46 – 7.37 (m, 1H), 7.25 – 7.20 (m, 3H), 7.14 (d, J = 1.5 Hz, 1H), 6.06 
(s, 2H), 3.93 (s, 3H). HRMS: calculated for C20H16N3O4 [M+H]+ 362.1141, found 
362.1136. 
 
(2-(1H-indol-3-yl)-1H-imidazol-5-yl)(9-methoxy-3,4-dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)methanone (13e).  1H NMR (400 MHz, Chloroform-d) δ 
8.16 (dd, J = 6.5, 2.9 Hz, 1H), 7.87 (d, J = 3.0 Hz, 1H), 7.74 (d, J = 3.4 Hz, 1H), 7.62 – 
7.48 (m, 1H), 7.42 (dt, J = 6.0, 3.0 Hz, 1H), 7.25 – 7.20 (m, 2H), 7.20 – 7.13 (m, 1H), 
4.38 (t, J = 5.8 Hz, 2H), 4.34 – 4.23 (m, 2H), 3.89 (s, 3H), 2.24 (dd, J = 7.0, 4.5 Hz, 2H). 
HRMS: calculated for C22H20N3O4 [M+H]+ 390.1454, found 390.1457. 
 
(2-(1H-indol-3-yl)-1H-imidazol-5-yl)(8-methoxybenzo[b][1,4]dioxin-6-
yl)methanone (13f). 1H NMR (400 MHz, DMSO-d6) δ 13.02 (s, 1H), 11.55 (s, 1H), 8.40 
(d, J = 7.8 Hz, 1H), 7.94 (s, 2H), 7.47 (d, J = 7.9 Hz, 1H), 7.16 (dtd, J = 16.1, 8.1, 7.6, 6.4 
Hz, 2H), 6.30 (d, J = 9.2 Hz, 2H), 3.88 (s, 3H). HRMS: calculated for C21H16N3O4 
[M+H]+ 374.1141, found 374.1142. 
 
(2-(1H-indol-4-yl)-1H-imidazol-5-yl)(8-methoxybenzo[b][1,4]dioxin-6-
yl)methanone (19). 1H NMR (400 MHz, Chloroform-d) δ 10.59 (s, 1H), 8.51 (s, 1H), 
7.90 (s, 1H), 7.68 (d, J = 7.2 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 2.9 Hz, 1H), 
7.29 (d, J = 7.8 Hz, 1H), 7.25 (s, 1H), 7.19 (s, 1H), 7.01 (s, 1H), 6.01 (d, J = 3.6 Hz, 1H), 
5.93 (d, J = 3.6 Hz, 1H), 3.90 (s, 3H). HRMS: calculated for C21H16N3O4 [M+H]+ 
374.1141, found 374.1144. 
 
(8-methoxybenzo[b][1,4]dioxin-6-yl)(2-(4-methyl-1H-indol-3-yl)-1H-
imidazol-5-yl)methanone (25). 1H NMR (400 MHz, Methylene Chloride-d2) δ 9.11 (s, 
1H), 7.74 (d, J = 2.0 Hz, 1H), 7.30 (s, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.19 (s, 1H), 7.10 (t, 
J = 7.8 Hz, 1H), 6.98 (s, 1H), 6.90 (d, J = 7.1 Hz, 1H), 6.00 (d, J = 2.7 Hz, 1H), 5.95 (t, J 
= 2.8 Hz, 1H), 3.83 (s, 3H), 2.47 (s, 3H). HRMS: calculated for C22H18N3O4 [M+H]+ 
388.1297, found 388.1303. 
 
Synthesis of 4-bromo-1-(phenylsulfonyl)-1H-indole (14). To a solution of 4-
bromoindole (1.0 g, 5.1 mmol) in THF (10 ml) was added sodium hydride (314 mg, 7.6 
mmol) in portions under ice temperature. After 1 hr, benzenesulfonyl chloride (0.81 ml, 
6.1 mmol) was added dropwise. The reaction was stirred at room temperature for 2 hr.  
Water was then added and the reaction mixture was extracted with ethyl acetate, washed 
with brine and dried with anhydrous Na2SO4. The combined extracts were evaporated 
under vacuum to give crude product which was purified with flash chromatography on 
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silica. Elution with hexane/ethyl acetate (20:1-6:1) gave 14 as colorless solid (1.6 g, 
93%). 1H NMR (400 MHz, Chloroform-d) δ 7.96 (dd, J = 8.4, 0.8 Hz, 1H), 7.91 – 7.84 
(m, 2H), 7.64 (d, J = 3.7 Hz, 1H), 7.57 – 7.50 (m, 1H), 7.44 (dd, J = 8.5, 7.1 Hz, 2H), 
7.39 (d, J = 7.8 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 6.74 (d, J = 3.7 Hz, 1H). HRMS: 
calculated for C14H11BrNO2S [M+H]+ 335.9694, found 335.9691. 
 
Synthesis of 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)-1H-indole (15). To a solution of 14 (0.86 g, 2.5 mmol) in dioxane (10 ml) was added 
bis(pinacolato)diboron (1.9 g, 7.5 mmol), potassium acetate (0.75 g, 7.5 mmol) and [1,1′-
Bis(diphenylphosphino)ferrocene]dichloropalladium complex with dichloromethane (220 
mg, 0.125 mmol). The mixture was heated to reflux for overnight.  Dioxane was removed 
under reduced pressure and then water was partitioned between water and EtOAc. The 
combined extracts were evaporated under vacuum to give crude product which was 
purified with flash chromatography on silica. Elution with hexane/ethyl acetate (20:1) 
gave 15 as colorless solid (2.47 g, 86%). 1H NMR (400 MHz, Chloroform-d) δ 8.11 (dt, J 
= 8.4, 0.9 Hz, 1H), 7.88 – 7.82 (m, 2H), 7.71 (dd, J = 7.2, 1.0 Hz, 1H), 7.60 (d, J = 3.7 
Hz, 1H), 7.53 – 7.47 (m, 1H), 7.40 (dd, J = 8.5, 7.0 Hz, 2H), 7.32 (dd, J = 8.3, 7.3 Hz, 
1H), 7.21 (d, J = 3.6 Hz, 1H), 1.35 (s, 12H). HRMS: calculated for C20H23BNO4S 
[M+H]+ 384.1441, found 384.1438. 
 
Synthesis of 21. Compound 21 was synthesized following our previously 
reported procedures [169].  
 
Synthesis of 22. To a solution of 21 (1.0 g, 3.3 mmol) in THF (10 ml) was added 
N-bromosuccinimide (1.07 g, 6.0 mmol) in portions.  The reaction was stirred for 1.5 hr, 
quenched with saturated Na2S2O3 solution, and extracted with EtOAc. The combined 
extracts were evaporated under reduced pressure and dried under vacuum to give crude 
product. The crude was dissolved in anhydrous THF (10 mL) at ice temperature; sodium 
hydride (122 mg, 3.3 mmol) was added in portions under argon. The mixture was stirred 
for another 1 hr at this temperature and was added 2-(trimethylsilyl)ethoxymethyl 
chloride (0.62 ml, 3.3 mmol) dropwise. Reaction was then warmed to room temperature 
and stirred for 1.5 hr. Water was then added and the reaction mixture was extracted with 
ethyl acetate, washed with brine and dried with Na2SO4. The combined extracts were 
evaporated under vacuum to give the oily residue which was purified with flash 
chromatography on silica. Elution with hexane/ethyl acetate (10:0-10:1) gave 22 as pale-
yellow solid (1.4 g, 70%).  
 
 
Cell culture and reagents 
 
Human melanoma carcinoma cell lines A375, M14, and RPMI7951 (American 
Type Culture Collection or ATCC, Manassas, VA, USA) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Corning, Manasas, VA) supplemented with 10% 
(v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawernceville, GA) and 1% 
antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Murine melanoma 
B16F10 cells (ATCC, Manassas, VA, USA) were cultured in Minimum essential medium 
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(Invitrogen, Carlsbad, CA), supplemented with 5% heat-inactivated Hyclone FBS 
(Thermo Scientific, Rockford, IL), 1 % antibiotic-antimycotic mixture (Sigma-Aldrich, 
St. Louis MO), 1% Mem-sodium pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin 
(Invitrogen, Carlsbad, CA), L-Glutamine (2mM final concentration) (Invitrogen, 
Carlsbad, CA), and 1% Mem NEAA (Invitrogen, Carlsbad, CA). All cell lines were 
authenticated by ATCC by short tandem repeat profiling.  Cultures were maintained to 
80-90% confluency at 37°C in a humidified atmosphere containing 5% CO2. Compounds 
were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to make a 
stock solution of 20 mM. Compound solutions were freshly prepared by diluting stocks 
with cell culture medium before use.  
 
 
Cytotoxicity assay  
 
A375, M14, and RPMI7951were seeded in 96-well plates at a concentration of 
1,000–5,000 cells per well, depending on growth rate of the cell line. After overnight 
incubation, the media was replaced and cells were treated with the test compounds at 10 
concentrations ranging from 0.03 nM to 1μM plus a vehicle control for 72 h in four 
replicates. Following treatment, the MTS reagent (Promega, Madison, WI) was added to 
the cells and incubated in dark at 37°C for at least 1 hour. Absorbance at 490 nm was 
measured using a plate reader (DYNEX Technologies, Chantilly VA). Percentages of cell 
survival versus drug concentrations were plotted, and the IC50 (concentration that 
inhibited cell growth by 50% of untreated control) values were obtained by nonlinear 
regression analysis using GraphPad Prism (GraphPad Software, San Diego, CA).   
 
 
Chemistry 
 
Scheme 3-1 showed the synthetic method we followed to access the 
commercially expensive or unavailable benzoyl chlorides. Commercially available 
methyl 3-methoxy-4,5-dihydroxybenzoate was treated with dibromomethane or 1,3-
dibromopropane to form 1a and 1b in the presence of potassium carbonate. The cyclized 
benzoates were then hydrolyzed under basic condition to provide carboxylic acids 2a and 
2b. 2a and 2b subsequently refluxed with thionyl chloride in DCM to generate benzoyl 
chlorides 3a and 3b, which were used directly for next step without purification. 
 
Another commercially unavailable benzoyl chloride 8 was prepared following 
Scheme 3-2. Methyl 3-methoxy-4,5-dihydroxybenzoate refluxed together with allyl 
bromide in the presence of potassium carbonate to generate alkylated methyl benzoate 4. 
An isomerization/ring closing metathesis strategy as reported in the literature [195] was 
followed to furnish the dioxene moiety in 6. In brief, 4 was treated with a catalytic 
equivalent of (Ph3P)3Ru(CO)(Cl)H in toluene to provide 5, which was subjected to 
Grubbs` reaction to afford 6. Hydrolysis of the methyl ester under basic condition 
provided 7, which was converted to benzoyl chloride 8 by refluxing with thionyl 
chloride. 8 was used directly for next step without purification. 
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Scheme 3-1. Synthesis of the benzoyl chlorides 3a-3b 
Reagents and conditions: (a): dibromomethane or 1,3-dibromopropane, K2CO3, 
acetonitrile, reflux; (b): LiOH, dioxane-H2O (2:1), 50oC; (c): SO2Cl, DCM, reflux. 
 
 
 
 
 
 
Scheme 3-2. Synthesis of the benzoyl chloride 8 
Reagents and conditions: (a): allyl bromide, K2CO3, acetonitrile, reflux; (b): 
(Ph3P)3Ru(CO)(Cl)H, toluene, reflux; (c): Grubbs` catalyst 2nd generation, toluene, 
reflux; (d): LiOH, dioxane-H2O(2:1), 50oC; (e): SO2Cl, DCM, reflux. 
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ABI structure was constructed through a Suzuki coupling/Grignard reaction 
strategy as depicted in Scheme 3-3. In short, SEM-protected compound 9 was obtained 
from the treatment of 2,4,5-tribromoimidazole with SEMCl in the presence of sodium 
hydride. 9 coupled with 1-(Phenylsulfonyl)-3-indolylboronic acid pinacol ester in the 
presence of Pd2(dba)3 and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl to 
provide 10 in 34% yield. It is worthy mentioning that Suzuki coupling reaction of this 
tribromo substrate under current condition was not regioselective. Coupling reactions 
happening on the 4- or 5-bromo were also observed. 10 was treated with i-PrMgCl(LiCl) 
and benzoyl chlorides to furnish compounds 11a-11f in 31-48% yields. Bromo on the 
imidazole moiety and benzenesulfonyl were simultaneously removed in the presence of 
Pd(OAc)2, PPh3 and K2CO3 in n-BuOH under reflux condition, giving 12a-12f in 76-89% 
yields. Deprotection of SEM using TFA in DCM finally provided ABI-231 analogues 
13a-13f in 79-92% yields. 
 
Analogue 19 was synthesized according to Scheme 3-4. In brief, 4-bromoindole 
was treated with benzenesulfonyl chloride in the presence of sodium hydride to provide 
14 in 93% yield. 14 was then subjected Miyaura borylation catalyzed by 
Pd(pddf)2Cl2.CH2Cl2 to generate 15 in 86% yield. The boronic ester 15 was then 
subjected to Suzuki coupling, Grignard reaction and deprotections to eventually yield 
analog 19. 
 
To synthesize analog 25, we followed the synthetic method as shown in Scheme 
3-5. 20 was prepared by following a reported procedure [169]. Bromination of imidazole 
20 using N-bromosuccinimide in THF was followed by protection in the presence of 
SEMCl and sodium hydride to afford intermediate 22 in 70% yield over two steps. 22 
was then subject to Grignard reaction and deprotections to provide analogue 25. 
 
 
Results 
 
All analogues of ABI-231 were evaluated for their cytotoxicities in human 
melanoma cell lines including A375, WM1641 and M14. Colchicine was used as a 
positive control. The antiproliferative effects of the compounds were evaluated by MTT 
assay. IC50s were reported in nM and calculated from at least three independent 
experiments, each performed in duplicates. In vitro growth inhibitory effects of the new 
analogues were shown in Table 3-1. 
 
13a structurally replaced the 3,4,5-TMP in ABI-231 with a benzo[4,5]-dioxane 
moiety. It exhibited remarkable loss of cytotoxicity in several cell lines and had an 
average IC50 of more than 150 nM. Shrinkage of the benzo[4,5]-dioxane to benzo[4,5]-
dioxole resulted in analogue 13b, which showed comparable antiproliferative activity to 
that of 13a. In contrast to 13a, 3-methoxy counterpart 3-methoxybenzo[4,5]-dioxane 
analogue 13c showed dramatically increased inhibitory effect with an average IC50 of 21 
nM, suggesting the importance of the 3-methoxy in this scaffold. The same phenomenon 
was observed for 13d. When 3-methoxy was introduced to benzo[4,5]-dioxole analogue 
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Scheme 3-3. Synthesis of the ABI-231 analogues 13a-13f 
Reagents and conditions: (a): SEMCl, NaH, THF, 0oC to rt; (b):Pd2(dba)3, 2-
dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, Na2CO3, toluene-MeOH-H2O 
(20:4:1), reflux; (c): benzoyl chlorides, i-PrMgCl(LiCl), THF, rt to reflux; (d):Pd(OAc)2, 
K2CO3, PPh3, n-BuOH, reflux; (e): TFA, DCM, rt. 
 
 
 
 
 
 
Scheme 3-4. Synthesis of 19 
Reagents and conditions: (a): PhSO2Cl, NaH, THF, 0oC to rt; (b): bis(pinacolato)diboron, 
Pd(dppf)2.CH2Cl2, KOAc, dioxane, 80oC; (c): Pd2(dba)3, 2-dicyclohexylphosphino-
2′,4′,6′-triisopropylbiphenyl, Na2CO3, toluene-MeOH-H2O (20:4:1), reflux; (d): 8, i-
PrMgCl(LiCl), THF, rt to reflux; (e): Pd(OAc)2, K2CO3, PPh3, n-BuOH, reflux; (f): TFA, 
DCM, rt. 
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Scheme 3-5. Synthesis of 25 
Reagents and conditions: (a): PhSO2Cl, NaH, THF, 0oC to rt; (b):NH4OH, glyoxal, 
ethanol, reflux; (c): NBS, THF, 0oC to rt; (d): 8, i-PrMgCl(LiCl), THF, rt to reflux; (e): 
Pd(OAc)2, K2CO3, PPh3, n-BuOH, reflux; (f): TFA, DCM, rt. 
 
 
 
 
Table 3-1. In vitro growth inhibitory effects (nM) of ABI-231 analogues 
modifying the 3,4,5-TMP moiety (n=3) 
 
Compound A375 M14 RPMI7951 
13a 158.7 ± 16.4 118.8 ± 14.3 213.7 ± 17.1 
13b 190.6 ± 16.8 154.6 ± 10.4 235.6 ± 19.3 
13c 21.0 ± 1.6 11.3 ± 0.8 29.2 ± 1.7 
13d 3.5 ± 0.4 5.6 ± 0.6 5.6 ± 0.5 
13e 32.2 ± 3.4 38.2 ± 3.5 47.7 ± 3.9 
13f 1.1 ± 0.1 1.2 ± 0.2 3.3 ± 0.3 
19 17.1 ± 1.1 13.8 ± 0.9 34.8 ± 2.2 
25 6.1 ± 0.2 6.1 ± 0.2 8.8 ± 0.5 
Colchicine 3.6 ± 0.2 4.8 ± 0.4 4.3 ± 0.6 
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13b, 3-methoxybenzo[4,5]-dioxole analogue 13d was resulted in. 13d had an average 
IC50 value of 5.0 nM and was comparable to that of ABI-231. It showed more than 30-
fold enhancement of activity compared to 13b. 13d was ~2-fold more potent than 13c. 
While 3-methoxy was crucial for the activities of ABI-231 analogues, the size of the 
cyclic rings on the phenyl moiety also mattered (13c vs 13d). Increasing the five or six-
membered rings to seven-membered ring resulted in 3-methoxybenzo[4,5]dioxepin 
analogue 13e, which had an average IC50 value of 39.4 nM. Taken 13c, 13d and 13e 
together, five-membered dioxole ring was preferred to both six-membered dioxane ring 
and seven-membered dioxepin ring. The likely explanation for this phenomenon is that 
the pocket in tubulin where the 3,4,5-TMP fit was so shallow that only small moieties 
(five or six-membered rings) instead of large moieties (seven-membered ring) can be 
accommodated. Among all the analogues modifying the 3,4,5-TMPs, 13f, a unique 3-
methoxybenzo[4,5]-dioxene analogue, exhibited the most potent antiproliferative activity 
and had an average IC50 of 1.9 nM against a panel of melanoma cell lines. This 
significant improvement of activity might result from an extra hydrophobic interaction 
between the double bond of the dioxene and the methionine residue nearby. The current 
effort is on obtaining the co-crystal structure of 13f in complex with tubulin to clarify the 
additional interaction between dioxene moiety and tubulin. 
 
Our previous SAR study of ABI-231 has demonstrated that ABI-231 analogues 
with a 4-indoly or a 4-methyl-3-indolyl moiety showed the most potent antiproliferative 
activities. After optimization of the 3,4,5-TMP moiety, we, therefore, have produced 
analogues 19 and 25. The purpose of synthesis of 19 and 25 is to investigate the 
combinational effect of the unique 3-methoxybenzo[4,5]-dioxene moiety with 4-indolyl 
moiety or 4-methyl-3-indolyl moiety. Surprisingly, the 4-indolyl analogue 19 exhibited ~ 
11 folds reduced antiproliferative activity compared to 13f. This might due to the 
disappearance of the H-bond interaction between the NH of 4-indolyl in 19 and α-
THR179 or the absence of hydrophobic interaction between the dioxene moiety and 
methionine residue. Compared to 19, the 4-methyl-3-indolyl analogue 25 showed much 
stronger antiproliferative activity and had an average IC50 of 7.0 nM. 
 
To summarize the SAR, 3-methoxy is indispensable in the related scaffolds. 
Cyclizing 4,5-dimethoxy of the 3,4,5-TMP in ABI-231 to large heterocycle (e.g. 
dioxepin) is detrimental to inhibitory activity. 13f with a unique 3-methoxybenzo[4,5]-
dioxene moiety shows the most potent activity, indicating a possible hydrophobic 
interaction between the dioxene and nearby residue in tubulin. 
 
 
Discussion 
 
Reported CBSIs such as colchicine, CA-4, podophyllotoxin share a common 
character, the 3,4,5-TMP moiety. While most structural modifications of CA-4 focus on 
either the double bond linkage or the 3-hydroxy-4-methoxy benzene moiety, a rare 
modification has been conducted on the 3,4,5-TMP moiety.  
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ABI-231 showed potent antiproliferative activity and ability to surmount major 
drug-resistance mechanisms (e.g. overexpression of P-gp or tubulin β-III isotype). Thus, 
ABI-231 represents a promising scaffold for the development of anticancer agents. ABI-
231 consists of 3,4,5-TMP, carbonyl, imidazole and indole moieties. In Chapter 2, we 
have shown our effort on investigating the SAR of ABI-231 by modifying the indole 
moiety. The co-crystal structure of the most potent 4-methyl-3-indole analogue reported 
in the last chapter indicates the existence of a methionine residue nearby the 3,4,5-TMP 
in tubulin. We assume that this methionine residue can serve as an opportunity to 
introduce a hydrophobic interaction to ABI-231 scaffold. With this hypothesis in mind, 
we have carried out the SAR investigation of ABI-231 by modifying the 3,4,5-TMP 
moiety. 
 
We herein have established a concise alternative that can efficiently generate 
ABI-231 analogues in gram-scale. This method circumvents the involvement of a 
potentially explosive azide intermediate that is reported in Chapter 2. The novel strategy 
involves Suzuki coupling and Grignard reactions to yield eight new ABI-231 analogues. 
Among the eight analogues, analogue 13f exhibits the strongest antiproliferative activity 
against a panel of melanoma cell lines. It has a unique 3-methoxybenzo[4,5]-dioxene 
moiety and an average IC50 of 1.9 nM. To the best of our knowledge, this analogue 
represents the most successful instance of isosterically modifying the 3,4,5-TMP moiety 
in CA-4 derivatives. To validate the significant potency of 13f, obtaining the co-crystal 
structure of 13f in complex with tubulin is currently undergoing. 
 
In conclusion, we have established a concise synthetic method for ABI-231 
analogues modifying the 3,4,5-TMP moiety. Eight new ABI-231 analogues are 
synthesized. The most potent analogue 13f has an average IC50 of 1.9 nM and was 3.7-
fold more potent than ABI-231. 
  
 62 
CHAPTER 4.    DESIGN AND SYNTHESIS OF NOVEL RABI ANALOGUES AS 
POTENT ANTITUBULINS  
 
 
Introduction 
 
Immunotherapy includes the adoptive cellular therapy and the monoclonal 
antibody. Immunotherapy has brought unprecedented improved survival rate for cancer 
patients in advanced stages and is advancing at an inspiring pace [45, 196]. However, 
cancer cells are able to develop multiple resistant mechanisms to circumvent the 
surveillance of normal host immune systems. The resistant mechanisms include but are 
not limited to tumor heterogeneity and metastasis, production of immune suppressive 
mediators, and down-modulating antigens [197, 198]. Current cancer treatments, 
therefore, still rely on targeted therapy and chemotherapy. Microtubules, the hollow 
cylinders, are composed of α and β-tubulin heterodimers. Microtubules are of great 
importance for a variety of cellular functions in all eukaryotes [199]. During mitosis, 
microtubules are responsible for the formation of mitotic spindles, which segregate sister 
chromatids into daughter cells [200]. Disruption of the microtubule dynamics can lead to 
the mitotic arrest and eventually apoptosis. Thus, microtubule dynamics are targetable for 
developing cancer therapy [91]. 
 
Most of the MTAs are summarized well in several reviews published recently 
[101, 102, 201, 202]. Due to their significant off-target effects, MTAs are infertile to 
produce an FDA-approved drug in the last years. Different from toxin alone, ADC 
utilizes its monoclonal antibody part to specifically expose the anticancer agent to 
cancerous cells rather than healthy cells; this results in limited undesirable off-target 
toxicity [203]. In February 2013, the FDA approved trastuzumab emtansine, a tubulin 
inhibitor based ADC, for the treatment of HER2 positive breast cancer. 
 
In order to develop a successful ADC, it is of great cruciality for the payload to 
possess extremely potent cytotoxicity (typically IC50 in sub-nanomolar range) because 
minimal of the payloads (approximately 1-2%) can penetrate tumor cells [204]. In our 
previous search for potent anti-tubulins, a variety of scaffolds (Figure 4-1) including 
SMARTs, ABI-Is, ABI-IIs and RABIs were designed, synthesized and biologically 
evaluated. The SAR has shown that replacement of the phenyl moieties in ABI-I/IIs with 
indole moiety can improve the IC50 from double-digit nanomolar range to single-digit 
nanomolar range [169]. In view of the structural similarity between ABI-I/IIs and RABIs, 
we hypothesize that replacing the benzene moiety in RABIs with indole moiety can 
significantly boost the cytotoxicity (Figure 4-2). With this hypothesis in mind, we herein 
report the establishment of a novel and concise synthetic route for RABI scaffold. Twelve 
new RABI analogues with modifications of the benzene moiety are synthesized and 
tested for biological activities. 
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Figure 4-1. Examples of microtubule inhibitors binding to the colchicine binding 
sites in tubulin 
 
 
 
 
 
 
Figure 4-2. Hypothesis: modifying the benzene in RABI to indole can increase 
activity 
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Experimental Section 
 
 
General chemistry 
 
Tetrahydrofuran was distilled from sodium-benzophenone. All other solvents and 
chemical reagents were obtained from commercial sources and directly used without 
further purification. Glassware was oven-dried before use. All reactions were performed 
under an argon atmosphere. TLC was performed on silica gel 60 GF254 and monitored 
under UV light or visualized using phosphomolybdic acid reagent. Flash chromatography 
was performed on 230-400 mesh silica gel (Fisher Scientific). Melting points were 
recorded on a MPA100 Automated Melting Point Apparatus. NMR spectra were obtained 
on a Bruker Ascend 400 (Billerica, MA) spectrometer or a Varian Inova-500 
spectrometer (Agilent Technologies, Santa Clara, CA). HR-MS were obtained on Waters 
Acquity UPLC linked to Waters Acquity Photodiode Array Detector and Waters Acquity 
Single Quadrupole Mass Detector. Chemical shifts are given in ppm with 
tetramethylsilane (TMS) as an internal reference. All coupling constants (J) are given in 
Hertz (Hz). 
 
 
Chemical synthesis 
 
General procedure for Boc protection. To a solution of indole or indazole or 
imidazole or pyrrolo[2,3-b]pyridine (1.34 mmol) and 4-dimethylaminopyridine (65 mg, 
0.54 mol) in anhydrous dichloromethane (5 mL) under argon was added di-tert-butyl 
dicarbonate (351 mg, 1.61 mmol) while stirring. After 1 hour, water was added and the 
reaction mixture was extracted with dichloromethane, washed with brine and dried with 
Na2SO4. Evaporation under vacuum gave the crude solid residue which was purified with 
flash chromatography on silica. Elution with hexane/ethyl acetate (10:1-3:1) gave pure 
boc-protected compounds as white to yellowish solids (55-94% yield). 
 
Tert-butyl 4-bromo-1H-indazole-1-carboxylate (1b). 1H NMR (400 MHz, 
Chloroform-d) δ 8.12 (d, J = 2.0 Hz, 1H), 8.08 (dd, J = 8.1, 2.0 Hz, 1H), 7.38 (dd, J = 7.7, 
2.0 Hz, 1H), 7.35 – 7.28 (m, 1H), 1.69 (s, 9H). HRMS: calculated for C12H14BrN2O2 
[M+H]+ 297.0239, found 297.0241. 
 
Tert-butyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (1d). 1H NMR 
(400 MHz, Chloroform-d) δ 8.30 – 8.20 (m, 1H), 7.64 (t, J = 2.9 Hz, 1H), 7.35 – 7.29 (m, 
1H), 6.51 (t, J = 2.9 Hz, 1H), 1.62 (s, 9H). HRMS: calculated for C12H14BrN2O2 [M+H]+ 
297.0239, found 297.0237. 
 
4-bromo-1-(phenylsulfonyl)indoline (2). 1H NMR (400 MHz, Chloroform-d) δ 
7.85 – 7.77 (m, 2H), 7.62 – 7.53 (m, 2H), 7.46 (dd, J = 8.4, 7.1 Hz, 2H), 7.14 – 7.03 (m, 
2H), 3.95 (t, J = 8.5 Hz, 2H), 2.91 (t, J = 8.5 Hz, 2H). HRMS: calculated for 
C14H13BrNO2S [M+H]+ 337.9850, found 337.9855. 
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5-bromoquinoline (5). 1H NMR (400 MHz, Chloroform-d) δ 8.85 (dd, J = 4.2, 
1.7 Hz, 1H), 8.40 (dt, J = 8.5, 1.2 Hz, 1H), 8.00 (dt, J = 8.5, 1.0 Hz, 1H), 7.71 (dd, J = 7.5, 
1.1 Hz, 1H), 7.46 (dd, J = 8.5, 7.5 Hz, 1H), 7.37 (dd, J = 8.5, 4.2 Hz, 1H). HRMS: 
calculated for C9H7BrN [M+H]+ 207.9762, found 207.9763. 
 
General procedure for synthesis of boronic ester 6a-6d, 7, 8, 9, 10a-10b, 11. 
To a solution of bromide (1.0 mmol) in dioxane (10 mL) under argon was added 
bis(pinacolato)diboron (3.0 mmol), Pd(dppf)2.CH2Cl2 (0.05 mmol), KOAc (3.0 
mmol).The reaction was kept stirring at 90 oC overnight. Dioxane was removed uder 
reduced pressure. Water was added and the reaction mixture was extracted with 
dichloromethane, washed with brine and dried with Na2SO4. Evaporation under vacuum 
gave the crude solid residue which was purified with flash chromatography on silica. 
Elution with hexane/ethyl acetate (30:1-10:1) gave pure boronic esters as white to 
yellowish oil (31-87% yield). 
 
Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-
carboxylate (6a). 1H NMR (400 MHz, Chloroform-d) δ 8.26 (d, J = 8.3 Hz, 1H), 7.72 
(dd, J = 7.2, 1.1 Hz, 1H), 7.63 (d, J = 3.7 Hz, 1H), 7.32 (dd, J = 8.3, 7.2 Hz, 1H), 7.15 – 
7.06 (m, 1H), 1.68 (s, 9H), 1.39 (s, 12H). HRMS: calculated for C19H27BNO4 [M+H]+ 
344.2033, found 344.2034. 
 
Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-
carboxylate (6b). 1H NMR (400 MHz, Chloroform-d) δ 8.49 (d, J = 2.0 Hz, 1H), 8.19 (d, 
J = 8.4 Hz, 1H), 7.70 (dd, J = 7.0, 1.9 Hz, 1H), 7.48 – 7.40 (m, 1H), 1.65 (s, 9H), 1.31 (s, 
12H). HRMS: calculated for C18H26BN2O4 [M+H]+ 345.1986, found 345.1988. 
 
Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
benzo[d]imidazole-1-carboxylate (6c). 1H NMR (400 MHz, Chloroform-d) δ 8.55 (s, 
1H), 8.08 (dd, J = 8.2, 1.3 Hz, 1H), 7.83 (dd, J = 7.3, 1.2 Hz, 1H), 7.37 (dd, J = 8.1, 7.3 
Hz, 1H), 1.68 (s, 9H), 1.41 (s, 12H). HRMS: calculated for C18H26BN2O4 [M+H]+ 
345.1986, found 345.1987. 
 
Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-
b]pyridine-1-carboxylate (6d). 1H NMR (400 MHz, Chloroform-d) δ 8.48 (t, J = 3.5 Hz, 
1H), 7.62 (t, J = 3.3 Hz, 1H), 7.51 (t, J = 3.6 Hz, 1H), 6.90 (t, J = 3.2 Hz, 1H), 1.63 (d, J = 
2.8 Hz, 9H), 1.34 (d, J = 2.5 Hz, 12H). HRMS: calculated for C18H26BN2O4 [M+H]+ 
345.1986, found 345.1988. 
 
1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline (7). 
1H NMR (400 MHz, Chloroform-d) δ 7.77 (ddd, J = 17.2, 8.2, 1.1 Hz, 3H), 7.56 – 7.49 
(m, 1H), 7.46 – 7.38 (m, 3H), 7.22 – 7.16 (m, 1H), 3.90 (t, J = 8.5 Hz, 2H), 3.11 (t, J = 
8.5 Hz, 2H), 1.27 (s, 12H). HRMS: calculated for C20H25BNO4S [M+H]+ 386.1597, 
found 386.1597. 
 
Tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-
carboxylate (9). 1H NMR (400 MHz, Chloroform-d) δ 8.66 (s, 1H), 7.65 (dd, J = 7.8, 0.9 
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Hz, 1H), 7.62 (d, J = 3.7 Hz, 1H), 7.55 (dd, J = 7.8, 0.8 Hz, 1H), 6.59 – 6.51 (m, 1H), 
1.68 (s, 9H), 1.26 (s, 12H). HRMS: calculated for C19H27BNO4 [M+H]+ 344.2033, found 
344.2029. 
 
Tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-
carboxylate (10a). HRMS: calculated for C19H27BNO4 [M+H]+ 344.2033, found 
344.2035. 
 
Tert-butyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
indole-1-carboxylate (10b). 1H NMR (400 MHz, Chloroform-d) δ 8.05 (d, J = 8.5 Hz, 
1H), 8.01 (d, J = 2.3 Hz, 1H), 7.23 – 7.16 (m, 1H), 7.04 (dd, J = 7.3, 2.1 Hz, 1H), 2.71 (d, 
J = 2.4 Hz, 3H), 1.67 (d, J = 2.3 Hz, 9H), 1.40 – 1.34 (m, 12H). HRMS: calculated for 
C20H29BNO4 [M+H]+ 358.2190, found 358.2192. 
 
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolone (11). 1H NMR (400 
MHz, Chloroform-d) δ 9.10 (ddd, J = 8.5, 1.8, 0.9 Hz, 1H), 8.89 (dd, J = 4.1, 1.7 Hz, 1H), 
8.18 (dt, J = 8.4, 1.0 Hz, 1H), 8.13 (dd, J = 6.9, 1.3 Hz, 1H), 7.69 (dd, J = 8.4, 6.9 Hz, 
1H), 7.41 (dd, J = 8.6, 4.2 Hz, 1H), 1.39 (s, 12H). HRMS: calculated for C15H19BNO2 
[M+H]+ 256.1509, found 256.1510. 
 
Synthesis of 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole (12). 
To a stirred solution of 4-bromoimidazole (25.0 g, 0.17 mol) in anhydrous THF (300 mL) 
at ice temperature was added sodium hydride (7.5 g, 0.187 mol) in portions under argon. 
The mixture was stirred for 1 hr at this temperature and was added 2-
(trimethylsilyl)ethoxymethyl chloride (33.0 ml, 0.187 mol) dropwise. Reaction was then 
warmed to room temperature and stirred for another 2 hr. Water was then added at ice 
temperature carefully and the reaction mixture was extracted with ethyl acetate, washed 
with brine and dried with Na2SO4. The combined extracts were evaporated under vacuum 
to give the oily residue which was purified with flash chromatography on silica.  Elution 
with hexane/ethyl acetate (10:1) gave 12 as slightly yellowish oil (40.5 g, 86% yield). 1H 
NMR (400 MHz, Chloroform-d) δ 7.46 (s, 1H), 7.01 (s, 1H), 5.22 (s, 2H), 3.53 – 3.40 (m, 
2H), 0.95 – 0.85 (m, 2H), -0.01 (s, 9H). HRMS: calculated for C9H18BrN2OSi [M+H]+ 
277.0372, found 277.0370. 
 
Synthesis of (4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-
yl)(3,4,5-trimethoxyphenyl)methanone (13). To a stirring solution of compound 12 
(2.77 g, 10.0 mmol) in anhydrous THF (15.0 mL) under argon was added 
isopropylmagnesium chloride lithium chloride complex solution (1.3 M in THF, 9.3 ml, 
12.0 mmol) at room temperature. The mixture was stirred for 1 hr and was added freshly 
made 3,4,5-trimethoxybenzoyl chloride (2.76 g, 12.0 mmol) in anhydrous THF ( 15.0 
mL). Reaction was kept stirring at room temperature for another 4 hr and then saturated 
NH4Cl solution was added to quench the reaction. Reaction mixture was extracted with 
ethyl acetate, washed with brine and dried with Na2SO4. The combined extracts were 
evaporated under vacuum to give the crude product which was purified with flash 
chromatography on silica. Elution with hexane/ethyl acetate (20:1-5:1) gave 13 as pale-
yellow oil (1.1 g, 24% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.72 (s, 2H), 7.40 (s, 
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1H), 5.81 (s, 2H), 3.97 (d, J = 2.8 Hz, 9H), 3.70 – 3.63 (m, 2H), 1.03 – 0.95 (m, 2H), 0.02 
(s, 9H). HRMS: calculated for C19H28BrN2O5Si [M+H]+ 471.0951, found 471.0955. 
 
General procedure for the synthesis of 14a-14k. To the mixture of 13 (1.0 
mmol), boronate (1.1 mmol), sodium carbonate (2.0 mmol) 
tris(dibenzylideneacetone)dipalladium (0.05 mmol) and 2-dicyclohexylphosphino-
2′,4′,6′-triisopropyl-1,1′-biphenyl (0.15 mmol) was added 6.25 mL mixed solvent PhCH3-
MeOH-H2O (20:4:1). After refluxed for 4 hr, water was added and the reaction mixture 
was extracted with ethyl acetate (3*10 mL), washed with brine and dried with Na2SO4. 
Evaporation under vacuum gave the crude product which was purified with flash 
chromatography on silica. Elution with hexane/ethyl acetate (10:1-3:1) gave 14a-14k 
pale-yellow to yellowish solids or oil (yield: 27-74%). 
 
Tert-butyl 3-(2-(3,4,5-trimethoxybenzoyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-1H-indole-1-carboxylate (14a). 1H 
NMR (400 MHz, Chloroform-d) δ 8.15 (d, J = 7.9 Hz, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.97 
(d, J = 1.8 Hz, 1H), 7.94 – 7.85 (m, 4H), 7.71 (d, J = 1.9 Hz, 1H), 7.55 – 7.47 (m, 1H), 
7.46 – 7.34 (m, 3H), 7.29 (t, J = 7.4 Hz, 1H), 5.88 (d, J = 1.9 Hz, 2H), 3.96 (s, 9H), 3.74 – 
3.62 (m, 2H), 1.04 – 0.95 (m, 2H), -0.02 (s, 9H). HRMS: calculated for C32H42N3O7Si 
[M+H]+ 608.2792, found 608.2799. 
 
Tert-butyl 4-(2-(3,4,5-trimethoxybenzoyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-1H-indole-1-carboxylate (14b). 1H 
NMR (400 MHz, Chloroform-d) δ 8.16 (d, J = 8.2 Hz, 1H), 7.95 (s, 2H), 7.80 (s, 1H), 
7.72 – 7.58 (m, 2H), 7.41 (d, J = 3.7 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 5.91 (s, 2H), 3.97 
(d, J = 8.7 Hz, 9H), 3.70 (dd, J = 8.9, 7.5 Hz, 2H), 1.69 (s, 9H), 0.99 (dd, J = 8.9, 7.7 Hz, 
2H), -0.01 (s, 9H). HRMS: calculated for C32H42N3O7Si [M+H]+ 608.2792, found 
608.2783. 
 
Tert-butyl 4-methyl-3-(2-(3,4,5-trimethoxybenzoyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-1H-indole-1-carboxylate (14d). 1H 
NMR (400 MHz, Chloroform-d) δ 8.12 (d, J = 8.3 Hz, 1H), 7.92 – 7.83 (m, 2H), 7.69 (t, J 
= 1.7 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.25 (td, J = 8.2, 1.9 Hz, 1H), 7.02 (d, J = 7.4 Hz, 1H), 
5.95 – 5.83 (m, 2H), 3.93 (s, 3H), 3.91 (s, 6H), 3.69 (td, J = 8.9, 2.1 Hz, 2H), 2.49 (s, 3H), 
1.67 (s, 9H), 1.04 – 0.94 (m, 2H), -0.00 (s, 9H). HRMS: calculated for C33H44N3O7Si 
[M+H]+ 622.2949, found 622.2955. 
 
(4-(quinolin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-
yl)(3,4,5-trimethoxyphenyl)methanone (14e). 1H NMR (400 MHz, Chloroform-d) δ 
9.20 (ddd, J = 8.6, 1.7, 0.8 Hz, 1H), 8.95 (dd, J = 4.1, 1.8 Hz, 1H), 8.13 (dt, J = 8.1, 1.2 
Hz, 1H), 7.96 (s, 2H), 7.82 – 7.73 (m, 2H), 7.72 (s, 1H), 7.39 (dd, J = 8.6, 4.2 Hz, 1H), 
5.94 (s, 2H), 3.95 (s, 3H), 3.93 (s, 6H), 3.80 – 3.65 (m, 2H), 1.05 – 0.96 (m, 2H), -0.00 (s, 
9H). HRMS: calculated for C28H34N3O5Si [M+H]+ 520.2268, found 520.2277. 
 
(4-(1-(phenylsulfonyl)indolin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (14f). 1H NMR (400 MHz, 
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Chloroform-d) δ 7.88 – 7.82 (m, 5H), 7.67 (dd, J = 8.0, 0.9 Hz, 1H), 7.59 – 7.53 (m, 3H), 
7.46 (dd, J = 8.4, 7.1 Hz, 2H), 7.31 (t, J = 7.9 Hz, 1H), 5.86 (s, 2H), 4.03 (d, J = 8.4 Hz, 
2H), 3.99 (s, 3H), 3.94 (s, 6H), 3.70 – 3.65 (m, 2H), 3.27 (t, J = 8.4 Hz, 2H), 1.01 – 0.96 
(m, 2H), 0.00 (s, 9H). HRMS: calculated for C33H40N3O7SSi [M+H]+ 650.2356, found 
650.2351. 
 
4-(2-(3,4,5-trimethoxybenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
imidazol-4-yl)indolin-2-one (14h). 1H NMR (400 MHz, Chloroform-d) δ 9.06 (s, 1H), 
7.87 (d, J = 2.1 Hz, 2H), 7.67 (d, J = 2.1 Hz, 1H), 7.56 (dd, J = 8.1, 2.0 Hz, 1H), 7.36 – 
7.24 (m, 1H), 6.93 – 6.83 (m, 1H), 5.88 (d, J = 2.1 Hz, 2H), 3.99 (dd, J = 4.8, 2.2 Hz, 9H), 
3.87 (s, 2H), 3.74 – 3.64 (m, 2H), 1.08 – 0.93 (m, 2H), 0.00 (s, 9H). HRMS: calculated 
for C27H34N3O6Si [M+H]+ 524.2217, found 524.2210. 
 
Tert-butyl 4-(2-(3,4,5-trimethoxybenzoyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-1H-benzo[d]imidazole-1-
carboxylate (14j). 1H NMR (400 MHz, Chloroform-d) δ 8.63 (s, 1H), 8.48 (s, 1H), 8.15 
(dd, J = 7.8, 1.1 Hz, 1H), 7.96 (s, 2H), 7.92 (dd, J = 8.2, 1.1 Hz, 1H), 7.45 (t, J = 7.9 Hz, 
1H), 5.92 (s, 2H), 3.98 (s, 6H), 3.97 (s, 3H), 3.73 – 3.66 (m, 2H), 1.72 (s, 9H), 1.01 – 
0.95 (m, 2H), -0.04 (s, 9H). HRMS: calculated for C31H41N4O7Si [M+H]+ 609.2745, 
found 609.2751. 
 
Tert-butyl 4-(2-(3,4,5-trimethoxybenzoyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-1-
carboxylate (14k). 1H NMR (400 MHz, Chloroform-d) δ 8.54 (dd, J = 5.4, 2.2 Hz, 1H), 
7.95 (t, J = 1.5 Hz, 1H), 7.91 (t, J = 1.6 Hz, 2H), 7.68 (t, J = 3.2 Hz, 1H), 7.57 (dd, J = 5.6, 
2.2 Hz, 1H), 7.29 (q, J = 2.2, 1.4 Hz, 1H), 5.91 (s, 2H), 4.00 (s, 3H), 3.96 (s, 6H), 3.75 – 
3.68 (m, 2H), 1.70 (s, 9H), 1.05 – 0.98 (m, 2H), 0.00 (s, 9H). HRMS: calculated for 
C31H41N4O7Si [M+H]+ 609.2745, found 609.2740. 
 
General procedure for synthesis of 15a-15k. For deprotection of protecting 
group PhSO2 and SEM: To a solution of 14a-14k (0.3 mmol) in MeOH (3 mL) was 
added 40% NaOH (1.0 mL). The mixture was refluxed for 2 hr, solvent was removed 
under reduced pressure. Water was added and the reaction mixture was extracted with 
ethyl acetate (3*10 mL). Combined solvent was evaporated under reduced pressure to 
provide crude product. To the crude was then added trifluoroacetic acid in 
dichloromethane (1:1, 2mL). After 2 hour, solvent was removed under reduced pressure. 
Saturated NaHCO3 solution and ethyl acetate was then added and the organic phase was 
separated, washed with brine and dried with Na2SO4. Evaporation under vacuum gave the 
solid residue which was purified with flash chromatography on silica. Elution with 
hexane/ethyl acetate (3:1-1:3) gave 15a-15k as pale-yellow to yellowish solids (yield: 39-
76% over two steps). For deprotection of Boc and SEM: To a solution of 14a-14k (0.2 
mmol) in dichloromethane (1.5 mL) was added trifluoroacetic acid (1.5 mL). The mixture 
was stirred for 2 hr. Solvent was removed under reduced pressure. Saturated NaHCO3 
solution and ethyl acetate was then added and the organic phase was separated, washed 
with brine and dried with Na2SO4. Evaporation under vacuum gave the solid residue 
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which was purified with flash chromatography on silica. Elution with hexane/ethyl 
acetate (3:1-1:3) gave 15a-15k as pale-yellow to yellowish solids (yield: 33-81%).  
 
(4-(1H-indol-3-yl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
(15a). 1H NMR (400 MHz, Methylene Chloride-d2) δ 8.58 (s, 1H), 8.16 (s, 2H), 8.06 (s, 
1H), 7.67 (s, 1H), 7.60 (d, J = 2.0 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.25 (dt, J = 22.6, 7.4 
Hz, 2H), 3.97 (s, 6H), 3.90 (s, 3H). HRMS: calculated for C21H20N3O4 [M+H]+ 378.1454, 
found 378.1453. 
 
(4-(1H-indol-4-yl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
(15b). 1H NMR (400 MHz, Chloroform-d) δ 11.09 (d, J = 64.7 Hz, 1H), 8.56 (d, J = 64.0 
Hz, 1H), 8.32 (s, 1H), 8.07 (s, 1H), 7.76 (dd, J = 27.3, 1.9 Hz, 1H), 7.65 (d, J = 7.3 Hz, 
1H), 7.47 – 7.36 (m, 2H), 7.36 – 7.22 (m, 3H), 6.85 (t, J = 2.6 Hz, 1H), 4.00 (d, J = 10.8 
Hz, 9H). HRMS: calculated for C21H20N3O4 [M+H]+ 378.1454, found 378.1451. 
 
(4-(1H-indol-6-yl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
(15c), HRMS: calculated for C21H20N3O4 [M+H]+ 378.1454, found 378.1455. 
 
(4-(4-methyl-1H-indol-3-yl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone (15d). 1H NMR (400 MHz, Methylene Chloride-d2) δ 
7.98 (d, J = 2.1 Hz, 2H), 7.34 (d, J = 2.0 Hz, 1H), 7.30 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 
8.2 Hz, 1H), 7.15 – 7.04 (m, 1H), 6.89 (d, J = 7.1 Hz, 1H), 3.90 (s, 6H), 3.88 (s, 3H), 2.46 
(s, 3H). HRMS: calculated for C20H22N3O4 [M+H]+ 392.1610, found 392.1606. 
 
(4-(quinolin-5-yl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (15e). 
1H NMR (400 MHz, Chloroform-d) δ 11.95 (s, 1H), 9.31 (ddd, J = 8.6, 1.7, 0.9 Hz, 1H), 
8.98 (dd, J = 4.2, 1.7 Hz, 1H), 8.25 (s, 2H), 8.14 (dt, J = 8.0, 1.2 Hz, 1H), 7.81 – 7.67 (m, 
2H), 7.62 (d, J = 2.4 Hz, 1H), 7.40 (dd, J = 8.7, 4.2 Hz, 1H), 3.94 (d, J = 15.7 Hz, 9H). 
HRMS: calculated for C22H20N3O4 [M+H]+ 390.1454, found 390.1455. 
 
(4-(1-(phenylsulfonyl)indolin-4-yl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone (15f). 1H NMR (400 MHz, Chloroform-d) δ 7.96 (s, 2H), 
7.79 – 7.71 (m, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.38 (dd, J = 8.4, 7.1 
Hz, 3H), 7.34 (s, 1H), 7.22 (t, J = 7.9 Hz, 1H), 3.93 (t, J = 8.4 Hz, 2H), 3.88 (s, 3H), 3.87 
(s, 6H), 3.16 (dd, J = 16.8, 8.6 Hz, 2H). HRMS: calculated for C27H26N3O6S [M+H]+ 
520.1542, found 520.1554. 
 
(4-(indolin-4-yl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (15g). 
1H NMR (400 MHz, Chloroform-d) δ 10.90 (d, J = 15.6 Hz, 1H), 8.23 (s, 1H), 8.05 (s, 
1H), 7.55 – 7.41 (m, 1H), 7.27 (d, J = 7.8 Hz, 1H), 7.16 – 7.03 (m, 1H), 6.64 (dd, J = 7.9, 
4.3 Hz, 1H), 3.98 (d, J = 5.3 Hz, 9H), 3.65 (dt, J = 11.5, 8.3 Hz, 2H), 3.40 (t, J = 8.3 Hz, 
1H), 3.25 (t, J = 8.4 Hz, 1H). HRMS: calculated for C21H22N3O4 [M+H]+ 380.1610, 
found 380.1605. 
 
4-(2-(3,4,5-trimethoxybenzoyl)-1H-imidazol-4-yl)indolin-2-one (15h). 1H 
NMR (400 MHz, DMSO-d6) δ 13.68 (s, 1H), 10.47 (s, 1H), 8.02 (d, J = 21.6 Hz, 3H), 
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7.54 (d, J = 8.0 Hz, 1H), 7.24 (t, J = 7.9 Hz, 1H), 6.76 (d, J = 7.6 Hz, 1H), 3.92 (s, 6H), 
3.84 (s, 2H), 3.80 (s, 3H). HRMS: calculated for C21H20N3O5 [M+H]+ 378.1454, found 
378.1452. 
 
(4-(1H-indazol-4-yl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
(15i). 1H NMR (400 MHz, DMSO-d6) δ 13.80 (s, 1H), 13.18 (s, 1H), 8.82 (s, 1H), 8.29 (s, 
1H), 8.13 (s, 2H), 7.72 (d, J = 6.6 Hz, 1H), 7.48 (dd, J = 28.9, 7.4 Hz, 2H), 3.97 (s, 6H), 
3.87 (s, 3H). HRMS: calculated for C20H19N4O4 [M+H]+ 379.1406, found 379.1409. 
 
(4-(1H-benzo[d]imidazol-4-yl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone (15j). 1H NMR (400 MHz, Chloroform-d) δ 8.00 (s, 1H), 
7.74 (d, J = 24.9 Hz, 3H), 7.63 – 7.24 (m, 2H), 7.23 – 7.13 (m, 1H), 3.83 (d, J = 4.3 Hz, 
9H). HRMS: calculated for C20H19N4O4 [M+H]+ 379.1406, found 379.1407. 
 
(4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone (15k). 1H NMR (400 MHz, DMSO-d6) δ 14.05 – 13.58 
(m, 1H), 11.68 (s, 1H), 8.39 – 8.19 (m, 2H), 8.11 (s, 2H), 7.57 (dd, J = 29.4, 3.7 Hz, 2H), 
7.20 (s, 1H), 3.93 (s, 6H), 3.82 (s, 3H). HRMS: calculated for C20H19N4O4 [M+H]+ 
379.1406, found 379.1403. 
 
Synthesis of (4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-
yl)(8-methoxybenzo[b][1,4]dioxin-6-yl)methanone (16). To a stirring solution of 
compound 12 (1.38 g, 5.0 mmol) in anhydrous THF (10.0 mL) under argon was added 
isopropylmagnesium chloride lithium chloride complex solution (1.3 M in THF, 4.6 ml, 
6.0 mmol) at room temperature. The mixture was stirred for 1 hr and was added 3-
methoxy[4,5]dioxene benzoyl chloride (1.5 g, 6.5 mmol) in anhydrous THF ( 7.0 mL). 
Reaction was kept stirring at room temperature for another 4 hr and then saturated NH4Cl 
solution was added to quench the reaction. Reaction mixture was extracted with ethyl 
acetate, washed with brine and dried with Na2SO4. The combined extracts were 
evaporated under vacuum to give the crude product which was purified with flash 
chromatography on silica. Elution with hexane/ethyl acetate (20:1-5:1) gave 16 as pale-
yellow oil (0.74 g, 32% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.59 (s, 1H), 7.44 
(s, 1H), 7.36 – 7.30 (m, 1H), 5.98 (dd, J = 3.7, 1.6 Hz, 1H), 5.90 (dd, J = 3.8, 1.5 Hz, 
1H), 5.79 – 5.70 (m, 2H), 3.96 – 3.82 (m, 3H), 3.61 (td, J = 8.4, 1.4 Hz, 2H), 1.00 – 0.90 
(m, 2H), -0.01 (s, 9H). HRMS: calculated for C19H24BrN2O5Si [M+H]+ 467.0638, found 
467.0644. 
 
Synthesis of tert-butyl 4-(2-(8-methoxybenzo[b][1,4]dioxine-6-carbonyl)-1-
((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-3-methyl-1H-indole-1-
carboxylate (17). To the mixture of 16 (467 mg, 1.0 mmol), 10b (392 mg, 1.1 mmol), 
sodium carbonate (2.0 mmol) tris(dibenzylideneacetone)dipalladium (0.05 mmol) and 2-
dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl (0.15 mmol) was added 6.25 
mL mixed solvent PhCH3-MeOH-H2O (20:4:1). After refluxed for 4 hr, water was added 
and the reaction mixture was extracted with ethyl acetate (3*10 mL), washed with brine 
and dried with Na2SO4. Evaporation under vacuum gave the crude product which was 
purified with flash chromatography on silica. Elution with hexane/ethyl acetate (10:1-3:1) 
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gave 17 as yellowish solid (376 mg, 61%). 1H NMR (400 MHz, Chloroform-d) δ 8.25 (d, 
J = 8.3 Hz, 1H), 7.82 (d, J = 1.9 Hz, 1H), 7.62 (d, J = 1.9 Hz, 1H), 7.45 (s, 1H), 7.39 (d, J 
= 2.1 Hz, 1H), 7.33 (dd, J = 8.3, 7.4 Hz, 1H), 7.29 – 7.24 (m, 1H), 5.97 (d, J = 3.6 Hz, 
1H), 5.92 – 5.86 (m, 3H), 3.88 (s, 3H), 3.71 – 3.64 (m, 2H), 2.06 (d, J = 1.3 Hz, 3H), 1.68 
(s, 9H), 1.02 – 0.96 (m, 2H), 0.00 (s, 9H). HRMS: calculated for C33H40N3O7Si [M+H]+ 
618.2636, found 618.2628. 
 
Synthesis of (8-methoxybenzo[b][1,4]dioxin-6-yl)(4-(3-methyl-1H-indol-4-yl)-
1H-imidazol-2-yl)methanone (18). To a solution of 17 (0.1 mmol) in dichloromethane 
(1.5 mL) was added trifluoroacetic acid (1.5 mL). The mixture was stirred for 2 hr. 
Solvent was removed under reduced pressure. Saturated NaHCO3 solution and ethyl 
acetate was then added and the organic phase was separated, washed with brine and dried 
with Na2SO4. Evaporation under vacuum gave the solid residue which was purified with 
flash chromatography on silica. Elution with hexane/ethyl acetate (3:1-1:3) gave 18 as 
yellowish solid (28 mg, 74%). 1H NMR (400 MHz, Chloroform-d) δ 11.36 (s, 1H), 8.30 
(s, 1H), 7.85 (s, 1H), 7.63 (s, 1H), 7.40 (d, J = 22.8 Hz, 2H), 7.15 (dd, J = 24.1, 7.4 Hz, 
2H), 6.98 (s, 1H), 5.95 (dd, J = 29.6, 3.5 Hz, 2H), 3.87 (s, 3H), 2.05 (s, 3H). HRMS: 
calculated for C22H18N3O4 [M+H]+ 388.1297, found 388.1301. 
 
 
Cell culture and reagents 
 
Human melanoma carcinoma cell lines A375, M14, and RPMI7951 (American 
Type Culture Collection or ATCC, Manassas, VA, USA) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Corning, Manasas, VA) supplemented with 10% 
(v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawernceville, GA) and 1% 
antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Murine melanoma 
B16F10 cells (ATCC, Manassas, VA, USA) were cultured in Minimum essential medium 
(Invitrogen, Carlsbad, CA), supplemented with 5% heat-inactivated Hyclone FBS 
(Thermo Scientific, Rockford, IL), 1 % antibiotic-antimycotic mixture (Sigma-Aldrich, 
St. Louis MO), 1% Mem-sodium pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin 
(Invitrogen, Carlsbad, CA), L-Glutamine (2mM final concentration) (Invitrogen, 
Carlsbad, CA), and 1% Mem NEAA (Invitrogen, Carlsbad, CA). All cell lines were 
authenticated by ATCC by short tandem repeat profiling.  Cultures were maintained to 
80-90% confluency at 37°C in a humidified atmosphere containing 5% CO2. Compounds 
were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to make a 
stock solution of 20 mM. Compound solutions were freshly prepared by diluting stocks 
with cell culture medium before use.  
 
 
Cytotoxicity assay  
 
A375, M14, and RPMI7951were seeded in 96-well plates at a concentration of 
1,000–5,000 cells per well, depending on growth rate of the cell line. After overnight 
incubation, the media was replaced and cells were treated with the test compounds at 10 
concentrations ranging from 0.03 nM to 1μM plus a vehicle control for 72 h in four 
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replicates. Following treatment, the MTS reagent (Promega, Madison, WI) was added to 
the cells and incubated in dark at 37°C for at least 1 hour. Absorbance at 490 nm was 
measured using a plate reader (DYNEX Technologies, Chantilly VA). Percentages of cell 
survival versus drug concentrations were plotted, and the IC50 (concentration that 
inhibited cell growth by 50% of untreated control) values were obtained by nonlinear 
regression analysis using GraphPad Prism (GraphPad Software, San Diego, CA).   
 
 
Chemistry 
 
Our proposed synthetic strategy for RABI analogues is illustrated in Scheme 4-1. 
To construct the RABI scaffold, we resort to Suzuki coupling reaction using boronic 
esters and bromides. The bromides are afforded by Grignard reactions, in which 4-
bromoimidazole is treated with benzoyl chlorides. 
 
Preparation of the boronic esters was carried out according to reported procedures 
[205-207] as outlined in Scheme 4-2. In brief, bromides were protected with Boc or 
benzenesulfonyl, followed by Miyaura borylation in the presence of Pd(dppf)2 in 
complex with CH2Cl2 and potassium acetate to provide boronates 6a-6d and 7-11. 
 
RABI analogues 15a-15k were accomplished by following the synthetic approach 
as depicted in Scheme 4-3. Commercially available 4-bromoimidazole reacted with 
SEMCl in the presence of sodium hydride to provide SEM protected product 12 in 86% 
yield. Treatment of 12 with Grignard reagent i-PrMgCl(LiCl) and 3,4,5-
trimethoxybenzoyl chloride provided 13 in 24% yield. Suzuki cross-coupling of 13 with 
pinacol boronic esters in the presence of Pd2(dba)3 and 2-dicyclohexylphosphino-2′,4′,6′-
triisopropylbiphenyl afforded compounds 14a-14k. 14a-14k were subjected to the 
deprotection of benzensulfonyl, Boc and 2-(Trimethylsilyl)ethoxymethyl to furnish target 
RABI analogues 15a-15k. Cleavage of the protecting groups of 2-
(Trimethylsilyl)ethoxymethyl and boc in 15a-15k can be simultaneously achieved using 
trifluoroacetic acid while benzenesulfonyl group can be removed by refluxing in sodium 
hydroxide solution. 
 
Analogue 18 was obtained in a similar manner to that of 15a-15k. Its synthesis 
was outlined in Scheme 4-4. The synthesis of the starting material 3-
methoxy[4,5]dioxene benzoyl chloride was described in Chapter 3. 
 
 
Results 
 
All new RABI analogues were evaluated for their cytotoxicity in human 
melanoma cell lines including A375, M14 and RMPI7951. Colchicine was used as a 
positive control. The antiproliferative effects of all the compounds were evaluated using 
MTT assay. IC50s were reported in nM and calculated from at least three independent 
experiments, each of which were performed in duplicates. The in vitro assay result was  
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Scheme 4-1. Retrosynthetic analysis of RABI analogues 
 
 
 
 
 
 
Scheme 4-2. Synthesis of boronic esters 
Reagents and conditions: (a): Boc2O, DMAP, DCM, rt; (b): bis(pinacolato)diboron, 
Pd(dppf)2.CH2Cl2, KOAc, dioxane, 80oC; (c):PhSO2Cl, NaH, THF, 0oC to rt. 
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Scheme 4-3. Synthesis of RABI analogues 15a-15k 
Reagents and conditions: (a): SEMCl, NaH, THF, 0oC to rt; (b): 3,4,5-trimethoxybenzoyl 
chloride, i-PrMgCl(LiCl), THF, rt; (c):Pd2(dba)3, 2-dicyclohexylphosphino-2′,4′,6′-
triisopropylbiphenyl, Na2CO3, toluene-MeOH-H2O (20:4:1), reflux; (d): NaOH(40% in 
H2O), MeOH, reflux; (e): TFA, DCM, rt. 
 
 
 
 
 
 
Scheme 4-4. Synthesis of RABI analog 18 
Reagents and conditions: (a): 3-methoxy[4,5]dioxene benzoyl chloride, i-PrMgCl(LiCl), 
THF, rt; (b):Pd2(dba)3, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, Na2CO3, 
toluene-MeOH-H2O (20:4:1), reflux; (c): TFA, DCM, rt. 
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shown in Table 4-1.  
 
In our previously disclosed RABI series, the most potent analogue MX-RABI had 
an average IC50 of 14nM against a panel of melanoma and prostate cancer cell lines. 
When the benzene moiety in MX-RABI was replaced with a 3-indolyl group, compound 
15a was resulted in. 15a was 2.5-fold less active than the MX-RABI. Our previous SAR 
study of ABI-231 in Chapter 2 showed that rotation of the indole ring or introduction of 
small substituents to the indole ring in ABI-231 can significantly improve antitubulin 
activity. To further develop SAR, we synthesized 4-indolyl, 6-indolyl and 4-methyl-3-
indolyl RABI analogues 15b, 15c and 15d. It turned out that neither altering the 3-indolyl 
to 6-indolyl (15c) nor adding a 4-methyl group to 3-indolyl (15d) was beneficial to the 
antiproliferative activity. 15b, an analogue resulted from alteration of the 3-indolyl to 4-
indolyl, exhibited greatly enhanced antiproliferative activity and had an average IC50 of 
3.5 nM. 15b was 4-fold and ~2-fold more cytotoxic than MX-RABI and ABI-231, 
respectively. Having shown that a 4-indolyl moiety significantly improved the 
antiproliferative activity, we shifted our effort to investigate SAR by replacing 4-indole 
with structurally similar bicyclic heterocycles. With this aim in mind, we have 
synthesized analogues 15e-15k. When the 4-indolyl was enlarged to 5-quinolyl (15e), 
antiproliferative activity was markedly lost, suggesting the crucial role of the NH in4-
indolyl. Replacement of the N-PhSO2 in 15f with N-H (15g) restored the activity from 
micromolar range to 21 nM, which supported the significance of the free NH in 4-
indoline. Analogue 15h with a 4-oxindolyl substructure showed equipotent activity to 
MX-RABI and had an average IC50 of 13.7 nM. Adding extra nitrogen to the 4-indolyl 
analogue (15b) formed a 4-indazoyl analogue 15i. 15i had an average IC50 of 0.8 nM. It 
was >4-fold more cytotoxic than 15b; its antiproliferative activity increased by 
approximately 18-fold compared to that of MX-RABI; its activity enhanced by nearly an 
order of magnitude when compared to that of ABI-231. Encouraged by this observation, 
we have synthesized another two analogues 15j and 15k. 15j shifted the nitrogen on the 
2-position of indazole to the 3-position while 15k relocated that to the 7-position. 15j and 
15k both were significantly less active than 15i although showed potent activities with 
IC50s in double-digit nanomolar range. 
 
 
Discussion 
 
RABI compounds structurally resulted from the rotation of imidazole in ABI 
scaffold. RABIs are potent tubulin inhibitors with antiproliferative activities in double-
digit nanomolar range. In our continuing effort on improving the biological activities of 
RABIs, we hypothesize that replacing the benzene moiety in MX-RABI with indoles can 
improve its inhibitory activity. 
 
In our initial attempt to establish the RABI scaffold, we followed the synthetic 
method reported previously [185] and have tried the Debus-Radziszewski imidazole 
synthesis as shown in Figure 4-3. The tested reaction involved indolyl 3-glyoxal and 
3,4,5-trimethoxyphenyl glyoxal as reactants. Disappointingly, only the product with two  
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Table 4-1. In vitro growth inhibitory effects (nM) of RABI analogues (n=3) 
 
Compound A375 M14 RMPI7951 
15a 26.8 ± 1.0 29.1 ± 1.2 49.9 ± 3.2 
15b 3.2 ± 0.2 2.3 ± 0.2 5.1 ± 0.3 
15c 37.9 ± 2.0 38.5 ± 3.8 85.2 ± 7.0 
15d 101.4  ± 2.4 99.7 ± 3.4 134.4 ± 5.9 
15e >1000.0 >1000.0 >1000.0 
15f >1000.0 >1000.0 >1000.0 
15g 16.3 ± 0.7 21.0 ± 1.7 25.7 ± 1.6 
15h 12.7 ± 0.8 13.4 ± 0.6 15.0 ± 0.7 
15i 0.7 ± 0.1 0.7 ± 0.1 1.1 ± 0.1 
15j 34.6 ± 2.1 38.5 ± 2.4 43.1 ± 2.9 
15k 18.7 ± 1.1 18.4 ± 0.8 32.0 ± 1.4 
18 281.8 ± 23.7 249.1 ± 19.9 376.2 ± 65.7 
  
 77 
 
 
Figure 4-3. Synthesis of RABI scaffolds and proposed mechanism toward the 
observed major product 
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3,4,5-TMP moieties was observed while the other three products were absent. This might 
because that (1) 3,4,5-trimethoxyphenyl glyoxal is more active than indolyl 3-glyoxal to 
form diimine intermediate (2) 3,4,5-trimethoxyphenyl glyoxal is more active than indolyl 
3-glyoxal to react with the formed diimine intermediate. The possible mechanism is 
illustrated in Figure 4-3. 
 
During our exploration of a synthetic method to establish ABI-231 analogues 
modifying the 3,4,5-TMP moiety, a reaction as depicted in Figure 4-4 was conducted. In 
this reaction, we expected the occurrence of magnesium-halogen exchange to form the 
target product. However, the targeted product was not obtained. Instead, a moiety of the 
RABI scaffold was generated. The possible explanation is that the proton on the 2-
position of imidazole was more susceptible (too acidic ?) than the bromo to i-
PrMgCl(LiCl). Despite this, this unexpected reaction provided us an opportunity to 
investigate the SAR of MX-RABI by modifying the 3,4,5-TMP and the benzene 
moieties. 
 
Among the twelve RABI analogues, 15a, an ABI-231 based RABI analogue, 
showed less potent antiproliferative activity than ABI-231. According to the co-crystal 
structure of the 4-methyl-3-indole ABI-231 analogue reported in Chapter 2, NH on the 
imidazole formed an H-bond interaction with the α-Thr179 residue. The observed 
decreased activity in 15a might due to the absence of an H-bond interaction between NH 
on the imidazole of 15a and the α-Thr179 residue (Figure 4-5). Analogues 15b with a 4-
indole moiety and 15i with a 4-indazole moiety exhibited markedly improved anticancer 
activities; they had average IC50s of 3.5 and 0.8 nM, respectively. Compared to MX-
RABI, 15b and 15i displayed 4-fold and 17.5- fold improvements of antiproliferative 
activities, respectively. The difference in the activity of 15b and 15i may suggest an extra 
H-bond interaction is formed between nitrogen on the 2-position of indazole with nearby 
residue (Figure 4-5). We are currently exerting effort on obtaining a co-crystal structure 
of 15i in complex with tubulin protein to rationalize its strong activity. 
 
In conclusion, we have established a concise synthetic method for RABI scaffold 
and have synthesized twelve new RABI analogues. The most potent analogue 15i has an 
average IC50 of 0.8 nM. 15i represents the first CBSI with sub-nM activity in the related 
scaffold. 
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Figure 4-4. Synthesis of an intermediate for ABI-231 analogue 
 
 
 
 
 
 
Figure 4-5. Structure and IC50 comparisons between ABI-231 and 15a, 15b and 
15i  
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CHAPTER 5.    DESIGN, SYNTHESIS AND STRUCTURE-ACTIVITY 
RELATIONSHIP STUDY OF NOVEL UC-112 ANALOGUES 
 
 
Introduction 
 
Survivin is the smallest member in the family of the Inhibitor of Apoptosis 
Protein (IAP). It is almost absent in healthy tissues while is highly overexpressed in 
tumors [105]. Survivin is therefore considered as a cancer specific biomarker [106]. 
Regardless of the apparent role of survivin in anti-apoptosis, the biological mechanism 
how survivin promotes anti-apoptosis remains debatable. On one hand, it is demonstrated 
that survivin can directly bind to the caspases and subsequently block their apoptotic 
activities [107, 108]. On the other hand, survivin is reported to exert its anti-apoptotic 
function by indirectly binding to caspases. Evidence has shown that survivin interacts 
with XIAP and HBXIP, another two members of the IAP family [109]; these interactions 
can protect XIAP or HBXIP from ubiquitination and thereafter block activation of 
caspase-9. Alternatively, survivin may bind to the mitochondrial protein SMAC to 
antagonized its pro-apoptotic ability [110]. Besides its role in anti-apoptosis, survivin is 
also responsible for multidrug resistance and radiation resistance [111, 112]. The tumor 
cells with high expression of survivin are shown to develop resistance more easily to 
cisplatin and vincristine than the tumor cells with low expression of survivin [113]. Due 
to its specific expression in tumor cells and important role in regulating cellular 
functions, survivin is regarded as a promising therapeutic target for the development of 
anticancer therapy [104]. 
 
Selective expression of survivin in tumor cells has been validated thus down-
regulating survivin expression to treat cancer may be effective. Many strategies have 
been applied to block the anti-apoptotic ability of survivin. These strategies include but 
are not limited to introducing recombinant cell-permeable dominant-negative survivin 
protein [114, 115], obstructing protein translation using antisense oligonucleotides [116], 
and small-molecule based survivin antagonists [117, 118]. The crystal structure of human 
survivin was revealed in the early of this century, indicating this protein is an unusual 
bow tie-shape dimer [130]. Targeting survivin by employing small-molecule survivin 
inhibitors is challenging because no binding pocket in survivin has been identified. The 
challenge in developing survivin specific small-molecule inhibitor also lies in that 
survivin interacts with many other molecules such as P53, STAT3, caspases and notch 
signaling pathway to mediate apoptosis and mitosis [208-211]; it is therefore difficult to 
specify the drug target and evaluate the drug efficacy. A number of survivin inhibitors 
have been released so far, including YM155, FL118, shepherdin, 5-deazaflavin 
analogues, panepoxydone, terameprocol and MK2206; only YM155, LY2181308 and 
SPC3042 have successfully reached clinical trials [212], however, none of them has been 
granted an approval by the FDA. YM155 was discovered by Astellas Pharma in 2007, it 
has an IC50 in sub-nanomolar range against several types of cancer cell lines [125]. In 
clinical trials, YM155 was evaluated as monotherapy or combinational forms for many 
cancer types including blood cancer and solid tumors [213]. YM155 was withdrawn in 
phase II clinical trial due to its systemic toxicity. 
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In our previous exploration, we have disclosed the identification of [5-
((benzyloxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol] (UC-112, the structure is 
shown in Figure 5-1) through virtual screening [126]. UC-112 is a potent and selective 
survivin inhibitor. UC-112 promoted apoptosis by mechanistically lowering the level of 
survivin protein and activating caspases 3/7 and 9. UC-112 is demonstrated to be 
effective for the P-gp overexpressed multidrug-resistant cancer cell lines. Subsequent 
SAR study of UC-112 results in MX-106 (Figure 5-1), which shows a significant effect 
in suppressing survivin expression. The in vivo efficacy of MX-106 to inhibit tumor 
growth is also demonstrated by using an A375 human melanoma xenograft model [214]. 
The SAR result indicates that both the 8-hydroxyquinoline and the pyrrolidine in UC-112 
are essential for maximum activity; hydrophobic substituent on the benzene is beneficial 
to activity. Based on this SAR result, we hypothesize that (1): the benzyloxy moiety in 
UC-112 is amicable to modify; (2) the benzyloxy moiety is too flexible in this molecule; 
reducing the flexibility of the benzyloxy moiety can improve the activity (Figure 1-8). 
With these hypotheses in mind, we herein show our extensive effort on modifying the 
benzyloxy moiety in UC-112. Thirty-six UC-112 analogues are synthesized and 
evaluated for activities. 
 
 
Experimental Section 
 
 
General chemistry 
 
Tetrahydrofuran was distilled from sodium-benzophenone. All other solvents and 
chemical reagents were obtained from commercial sources and directly used without 
further purification. Glassware was oven-dried before use. All reactions were performed 
under an argon atmosphere. TLC was performed on silica gel 60 GF254 and monitored 
under UV light or visualized using phosphomolybdic acid reagent. Flash chromatography 
was performed on 230-400 mesh silica gel (Fisher Scientific). Melting points were 
recorded on a MPA100 Automated Melting Point Apparatus. NMR spectra were obtained 
on a Bruker Ascend 400 (Billerica, MA) spectrometer or a Varian Inova-500 
spectrometer (Agilent Technologies, Santa Clara, CA). HR-MS were obtained on Waters 
Acquity UPLC linked to Waters Acquity Photodiode Array Detector and Waters Acquity 
Single Quadrupole Mass Detector. Chemical shifts are given in ppm with 
tetramethylsilane (TMS) as an internal reference. All coupling constants (J) are given in 
Hertz (Hz). 
 
 
Chemical synthesis 
 
General procedure for synthesis of 1a-1g, 9a-9y. To a stirred suspension of 5-
chloromethyl-8-quinolinol hydrochloride (1.0 mmol, 230 mg), sodium carbonate (6.0 
mmol, 636 mg) and amine or indole (1.1 mmol) in acetonitrile (10 mL) was added 
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Figure 5-1. Example of reported survivin inhibitors 
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potassium iodide (0.3 mmol, 50 mg). The mixture was refluxed for 6 hr and then filtered; 
the residue was washed with acetonitrile. The combined solution was evaporated under 
vacuum to give the crude which was purified with flash chromatography on silica. 
Elution with hexane/ethyl acetate (10:1-1:1) gave desired compounds 1a-1g, 9a-9g 
(yield: 21-72%). 
 
5-((5-fluoro-1H-indazol-1-yl)methyl)quinolin-8-ol (1a). 1H NMR (400 MHz, 
DMSO-d6) δ 10.08 (s, 1H), 8.87 (dd, J = 4.2, 1.5 Hz, 1H), 8.67 (dd, J = 8.6, 1.6 Hz, 1H), 
8.39 (d, J = 0.9 Hz, 1H), 7.67 (ddt, J = 9.3, 4.7, 0.9 Hz, 1H), 7.64 – 7.51 (m, 2H), 7.40 
(ddd, J = 9.6, 2.5, 0.7 Hz, 1H), 7.22 – 7.05 (m, 2H), 6.05 (s, 2H). 
 
5-((1H-benzo[d][1,2,3]triazol-1-yl)methyl)quinolin-8-ol (1b). 1H NMR (400 
MHz, DMSO-d6) δ 10.09 (s, 1H), 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.72 (dd, J = 8.6, 1.6 Hz, 
1H), 8.01 (dt, J = 8.3, 1.0 Hz, 1H), 7.80 (dt, J = 8.4, 1.0 Hz, 1H), 7.64 (d, J = 7.9 Hz, 1H), 
7.59 (dd, J = 8.6, 4.2 Hz, 1H), 7.45 (ddd, J = 8.2, 6.9, 1.0 Hz, 1H), 7.32 (ddd, J = 8.1, 6.9, 
1.0 Hz, 1H), 7.11 (d, J = 7.8 Hz, 1H), 6.37 (s, 2H). 
 
1-((8-hydroxyquinolin-5-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (1d). 1H 
NMR (400 MHz, DMSO-d6) δ 9.83 (s, 1H), 8.92 (dd, J = 4.2, 1.5 Hz, 1H), 8.50 (dd, J = 
8.6, 1.6 Hz, 1H), 7.76 (dd, J = 7.9, 1.7 Hz, 1H), 7.63 (dd, J = 8.6, 4.1 Hz, 1H), 7.51 – 7.28 
(m, 2H), 7.04 (d, J = 7.8 Hz, 1H), 6.86 (d, J = 8.6 Hz, 1H), 6.72 (t, J = 7.4 Hz, 1H), 4.95 
(s, 2H), 3.54 (dd, J = 7.7, 6.2 Hz, 2H), 2.62 (dd, J = 7.8, 6.2 Hz, 2H). 
 
5-(((1-phenyl-1H-benzo[d]imidazol-2-yl)amino)methyl)quinolin-8-ol (1e). 1H 
NMR (400 MHz, Acetone-d6) δ 8.79 (dd, J = 4.2, 1.6 Hz, 1H), 8.75 – 8.64 (m, 1H), 8.61 
(dd, J = 8.6, 1.6 Hz, 1H), 7.53 – 7.41 (m, 2H), 7.34 (d, J = 7.8 Hz, 1H), 7.19 (td, J = 6.7, 
5.8, 3.1 Hz, 3H), 7.12 – 7.04 (m, 3H), 7.00 (dd, J = 7.7, 2.3 Hz, 2H), 6.91 (td, J = 7.6, 1.2 
Hz, 1H), 6.41 (t, J = 5.5 Hz, 1H), 5.27 (s, 2H), 5.07 (d, J = 5.1 Hz, 2H). 
 
Tert-butyl (R)-(1-(((8-hydroxyquinolin-5-yl)methyl)amino)-1-oxo-3-
(phenylthio)propan-2-yl)carbamate (1f). 1H NMR (400 MHz, Chloroform-d) δ 8.79 
(dd, J = 4.2, 1.5 Hz, 1H), 8.33 (dd, J = 8.6, 1.5 Hz, 1H), 7.46 (dd, J = 8.6, 4.2 Hz, 1H), 
7.38 (d, J = 7.8 Hz, 1H), 7.26 – 7.15 (m, 5H), 7.09 (d, J = 7.8 Hz, 1H), 6.43 (s, 1H), 5.22 
(s, 1H), 4.77 (d, J = 5.5 Hz, 2H), 4.19 (d, J = 6.1 Hz, 1H), 3.75 – 3.59 (m, 2H), 2.88 (dd, J 
= 13.9, 5.8 Hz, 1H), 2.74 (dd, J = 13.8, 6.8 Hz, 1H), 1.35 (s, 9H). 
 
5-((1H-indol-1-yl)methyl)quinolin-8-ol (9a). 1H NMR (400 MHz, Methanol-d4) 
δ 8.68 (dd, J = 4.2, 1.6 Hz, 1H), 8.34 (dd, J = 8.6, 1.6 Hz, 1H), 7.46 (dt, J = 8.0, 1.0 Hz, 
1H), 7.32 (dt, J = 8.1, 1.0 Hz, 1H), 7.30 – 7.24 (m, 2H), 7.08 (ddd, J = 8.2, 6.9, 1.1 Hz, 
1H), 7.00 (d, J = 7.8 Hz, 1H), 6.96 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.70 (d, J = 1.1 Hz, 
1H), 4.34 (s, 2H). 
 
5-((2-methyl-1H-indol-1-yl)methyl)quinolin-8-ol (9b). 1H NMR (400 MHz, 
DMSO-d6) δ 10.84 (s, 1H), 9.55 (s, 1H), 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.58 (dd, J = 8.6, 
1.6 Hz, 1H), 7.54 (dd, J = 8.6, 4.1 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 7.8 Hz, 
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1H), 7.11 (d, J = 7.9 Hz, 1H), 7.01 – 6.90 (m, 2H), 6.82 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 
4.35 (s, 2H), 2.33 (s, 3H). 
 
5-((2-ethyl-1H-indol-1-yl)methyl)quinolin-8-ol (9c). 1H NMR (400 MHz, 
Chloroform-d) δ 8.84 (s, 1H), 8.57 (d, J = 8.6 Hz, 1H), 8.30 (s, 1H), 7.96 (s, 1H), 7.59 – 
7.33 (m, 3H), 7.24 – 7.00 (m, 4H), 4.46 (s, 2H), 2.75 (t, J = 7.5 Hz, 2H), 1.25 (d, J = 7.9 
Hz, 3H). 
 
5-((4-fluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9d). 1H NMR (400 MHz, 
DMSO-d6) δ 11.14 (s, 1H), 9.61 (s, 1H), 8.85 (dd, J = 4.1, 1.6 Hz, 1H), 8.55 (dd, J = 8.6, 
1.6 Hz, 1H), 7.55 (dd, J = 8.6, 4.1 Hz, 1H), 7.23 (dd, J = 19.3, 8.0 Hz, 2H), 7.15 – 6.95 
(m, 2H), 6.88 (d, J = 2.4 Hz, 1H), 6.72 (dd, J = 11.5, 7.7 Hz, 1H), 4.50 (s, 2H). 
 
5-((4-nitro-1H-indol-1-yl)methyl)quinolin-8-ol (9e). 1H NMR (400 MHz, 
Acetone-d6) δ 10.91 (s, 1H), 8.86 – 8.81 (m, 1H), 8.52 (dd, J = 8.5, 1.6 Hz, 1H), 7.85 (d, J 
= 8.1 Hz, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.54 (dd, J = 8.5, 4.1 Hz, 1H), 7.29 (t, J = 8.0 Hz, 
1H), 7.15 (d, J = 7.8 Hz, 1H), 7.07 (d, J = 2.3 Hz, 1H), 7.01 (t, J = 7.3 Hz, 1H), 4.58 (s, 
2H). 
 
5-((5-fluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9f). 1H NMR (400 MHz, 
Chloroform-d) δ 8.76 (dd, J = 4.2, 1.5 Hz, 1H), 8.32 (dd, J = 8.5, 1.6 Hz, 1H), 7.95 (s, 
1H), 7.41 – 7.33 (m, 2H), 7.30 – 7.20 (m, 2H), 7.11 (d, J = 7.7 Hz, 1H), 6.96 (td, J = 9.0, 
2.5 Hz, 1H), 6.70 (dt, J = 2.4, 1.1 Hz, 1H), 4.38 (s, 2H). 
 
5-((5-chloro-1H-indol-1-yl)methyl)quinolin-8-ol (9g). 1H NMR (400 MHz, 
Chloroform-d) δ 8.79 (dd, J = 4.2, 1.5 Hz, 1H), 8.38 (s, 1H), 8.09 (dd, J = 8.6, 1.5 Hz, 
1H), 7.61 (d, J = 2.0 Hz, 1H), 7.41 (dd, J = 8.5, 4.2 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 
7.21 – 7.13 (m, 2H), 7.09 (d, J = 7.9 Hz, 1H), 6.95 (d, J = 3.2 Hz, 1H), 6.43 (dd, J = 3.2, 
0.8 Hz, 1H), 5.58 (s, 2H). 
 
1-((8-hydroxyquinolin-5-yl)methyl)-1H-indole-5-carbonitrile (9h). 1H NMR 
(400 MHz, Chloroform-d) δ 8.82 (dd, J = 4.2, 1.5 Hz, 1H), 8.40 (s, 1H), 8.09 (dd, J = 8.5, 
1.5 Hz, 1H), 7.99 (t, J = 1.1 Hz, 1H), 7.48 – 7.39 (m, 3H), 7.21 – 7.14 (m, 1H), 7.11 (d, J 
= 7.9 Hz, 1H), 7.06 (d, J = 3.3 Hz, 1H), 6.57 (d, J = 3.2 Hz, 1H), 5.65 (s, 2H). 
 
5-((5-nitro-1H-indol-1-yl)methyl)quinolin-8-ol (9i). 1H NMR (400 MHz, 
DMSO-d6) δ 9.91 (s, 1H), 8.90 (dd, J = 4.2, 1.5 Hz, 1H), 8.61 (d, J = 2.3 Hz, 1H), 8.52 
(dd, J = 8.6, 1.6 Hz, 1H), 8.03 (dd, J = 9.1, 2.4 Hz, 1H), 7.76 (d, J = 9.1 Hz, 1H), 7.70 – 
7.54 (m, 2H), 7.15 – 6.93 (m, 2H), 6.80 (d, J = 3.2 Hz, 1H), 5.93 (s, 2H). 
 
Ethyl 1-((8-hydroxyquinolin-5-yl)methyl)-1H-indole-5-carboxylate (9j). 1H 
NMR (400 MHz, Acetone-d6) δ 10.43 (s, 1H), 8.82 (dt, J = 4.2, 1.1 Hz, 1H), 8.58 (dt, J = 
8.6, 1.1 Hz, 1H), 8.35 (d, J = 1.5 Hz, 1H), 7.84 (dd, J = 8.8, 1.6 Hz, 1H), 7.53 (dd, J = 8.6, 
4.3 Hz, 1H), 7.48 (d, J = 8.6 Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 7.8 Hz, 1H), 
7.04 (d, J = 1.3 Hz, 1H), 4.63 – 4.41 (m, 2H), 4.33 (dd, J = 7.1, 0.8 Hz, 2H), 1.36 (td, J = 
7.1, 0.8 Hz, 3H). 
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5-((6-fluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9k). 1H NMR (400 MHz, 
Chloroform-d) δ 8.80 (dd, J = 4.2, 1.5 Hz, 1H), 8.44 (s, 1H), 8.12 (dd, J = 8.5, 1.5 Hz, 
1H), 7.57 (dd, J = 8.7, 5.4 Hz, 1H), 7.42 (dd, J = 8.6, 4.2 Hz, 1H), 7.21 – 7.15 (m, 1H), 
7.11 (d, J = 7.8 Hz, 1H), 7.07 (dd, J = 9.8, 2.3 Hz, 1H), 6.96 – 6.89 (m, 2H), 6.48 (dd, J = 
3.2, 0.9 Hz, 1H), 5.54 (s, 2H). 
 
5-((6-chloro-1H-indol-1-yl)methyl)quinolin-8-ol (9l). 1H NMR (400 MHz, 
Methanol-d4) δ 8.77 (dd, J = 4.2, 1.6 Hz, 1H), 8.46 (dd, J = 8.6, 1.6 Hz, 1H), 7.46 – 7.40 
(m, 2H), 7.36 – 7.30 (m, 2H), 7.04 (d, J = 7.8 Hz, 1H), 6.95 (dd, J = 8.5, 1.9 Hz, 1H), 
6.80 (d, J = 1.1 Hz, 1H), 4.43 (s, 2H). 
 
5-((6-bromo-1H-indol-1-yl)methyl)quinolin-8-ol (9m). 1H NMR (400 MHz, 
Chloroform-d) δ 8.80 (dd, J = 4.2, 1.5 Hz, 1H), 8.38 (dd, J = 8.4, 1.8 Hz, 1H), 8.09 (dd, J 
= 8.5, 1.5 Hz, 1H), 7.56 (dt, J = 1.5, 0.6 Hz, 1H), 7.53 – 7.48 (m, 1H), 7.41 (dd, J = 8.6, 
4.2 Hz, 1H), 7.25 – 7.22 (m, 1H), 7.17 – 7.12 (m, 1H), 7.09 (d, J = 7.8 Hz, 1H), 6.88 (d, J 
= 3.3 Hz, 1H), 6.45 (dd, J = 3.2, 0.9 Hz, 1H), 5.54 (s, 2H). 
 
5-((6-nitro-1H-indol-1-yl)methyl)quinolin-8-ol (9n). 1H NMR (400 MHz, 
Chloroform-d) δ 8.74 (ddt, J = 7.8, 3.6, 1.8 Hz, 1H), 8.47 – 8.14 (m, 1H), 7.46 – 7.20 (m, 
3H), 7.09 (ddd, J = 9.8, 7.7, 3.0 Hz, 1H), 6.97 (dddd, J = 9.5, 7.8, 4.7, 2.3 Hz, 1H), 6.92 – 
6.82 (m, 1H), 6.71 – 6.64 (m, 1H), 4.49 – 4.33 (m, 2H). 
 
5-((6-methoxy-1H-indol-1-yl)methyl)quinolin-8-ol (9o). 1H NMR (400 MHz, 
Chloroform-d) δ 8.75 (dd, J = 4.2, 1.5 Hz, 1H), 8.35 (dd, J = 8.5, 1.5 Hz, 1H), 7.78 (s, 
1H), 7.46 (d, J = 8.7 Hz, 1H), 7.40 – 7.34 (m, 2H), 7.10 (d, J = 7.8 Hz, 1H), 6.86 (d, J = 
2.1 Hz, 1H), 6.79 (dd, J = 8.6, 2.3 Hz, 1H), 6.54 (dt, J = 2.3, 1.2 Hz, 1H), 4.40 (s, 2H), 
3.85 (s, 3H). 
 
5-((7-fluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9p). 1H NMR (400 MHz, 
Chloroform-d) δ 8.83 (dd, J = 4.2, 1.5 Hz, 1H), 8.45 (dd, J = 1.8, 1.0 Hz, 1H), 8.08 (ddd, 
J = 15.1, 8.7, 1.8 Hz, 2H), 7.70 (dd, J = 8.8, 0.5 Hz, 1H), 7.46 (dd, J = 8.6, 4.2 Hz, 1H), 
7.25 – 7.21 (m, 1H), 7.19 (d, J = 3.2 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 6.59 (dd, J = 3.2, 
0.9 Hz, 1H), 5.71 (d, J = 0.9 Hz, 2H). 
 
5-((7-methyl-1H-indol-1-yl)methyl)quinolin-8-ol (9q). 1H NMR (400 MHz, 
Acetone-d6) δ 9.97 (s, 1H), 8.80 (dd, J = 4.2, 1.6 Hz, 1H), 8.65 (s, 1H), 8.55 (dd, J = 8.5, 
1.6 Hz, 1H), 7.49 (dd, J = 8.6, 4.2 Hz, 1H), 7.42 (d, J = 7.7 Hz, 2H), 7.09 (d, J = 7.9 Hz, 
1H), 7.05 – 6.78 (m, 3H), 4.47 (s, 2H), 2.49 (s, 3H). 
 
5-((2,3-dimethyl-1H-indol-1-yl)methyl)quinolin-8-ol (9r). 1H NMR (400 MHz, 
Chloroform-d) δ 8.86 (dd, J = 4.2, 1.5 Hz, 1H), 8.40 (dd, J = 8.5, 1.5 Hz, 1H), 7.66 – 7.51 
(m, 2H), 7.22 – 7.06 (m, 3H), 6.95 (d, J = 7.9 Hz, 1H), 6.55 – 6.38 (m, 1H), 5.62 (d, J = 
1.2 Hz, 2H), 2.35 (s, 3H), 2.27 (s, 3H). 
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5-((5-methoxy-2-methyl-1H-indol-1-yl)methyl)quinolin-8-ol (9s). 1H NMR 
(400 MHz, DMSO-d6) δ 10.70 (s, 1H), 9.60 (s, 1H), 8.86 (dd, J = 4.1, 1.6 Hz, 1H), 8.60 
(dd, J = 8.6, 1.6 Hz, 1H), 7.56 (dd, J = 8.6, 4.2 Hz, 1H), 7.17 (dd, J = 15.5, 8.3 Hz, 2H), 
7.01 (d, J = 7.8 Hz, 1H), 6.71 (d, J = 2.4 Hz, 1H), 6.64 (dd, J = 8.7, 2.4 Hz, 1H), 4.34 (s, 
2H), 3.61 (s, 3H), 2.31 (s, 3H). 
 
5-((2-ethyl-5-fluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9t). 1H NMR (400 
MHz, Acetone-d6) δ 10.97 (s, 1H), 8.84 (dd, J = 4.2, 1.5 Hz, 1H), 8.76 (dd, J = 8.6, 1.5 
Hz, 1H), 8.61 (s, 1H), 7.60 (dd, J = 8.6, 4.2 Hz, 1H), 7.55 (ddd, J = 8.9, 4.5, 0.7 Hz, 1H), 
7.19 (dt, J = 7.9, 1.1 Hz, 1H), 7.15 – 7.10 (m, 1H), 7.10 – 7.05 (m, 1H), 7.03 (d, J = 7.9 
Hz, 1H), 4.92 (d, J = 1.0 Hz, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 
 
1-((8-hydroxyquinolin-5-yl)methyl)-6-methoxy-1H-indole-3-carbonitrile (9u). 
1H NMR (400 MHz, DMSO-d6) δ 10.72 (s, 1H), 9.74 (s, 1H), 8.86 (dd, J = 4.1, 1.5 Hz, 
1H), 8.53 (dd, J = 8.5, 1.5 Hz, 1H), 7.57 (dd, J = 8.6, 4.1 Hz, 1H), 7.44 (d, J = 8.6 Hz, 
1H), 7.19 (d, J = 7.9 Hz, 1H), 7.05 (d, J = 7.8 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.71 (dd, 
J = 8.6, 2.3 Hz, 1H), 4.48 (s, 2H), 3.73 (s, 3H). 
 
5-((4,5-difluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9v). 1H NMR (400 MHz, 
DMSO-d6) δ 10.97 (s, 1H), 9.58 (s, 1H), 8.83 (dd, J = 4.0, 1.6 Hz, 1H), 8.53 (dd, J = 8.6, 
1.6 Hz, 1H), 7.52 (dd, J = 8.6, 4.1 Hz, 1H), 7.43 (dd, J = 11.5, 8.0 Hz, 1H), 7.38 (d, J = 
7.8 Hz, 1H), 7.32 (dd, J = 11.3, 7.0 Hz, 1H), 7.06 (d, J = 2.4 Hz, 1H), 7.02 (d, J = 7.8 Hz, 
1H), 4.37 (s, 2H). 
 
5-((5,6-difluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9w). 1H NMR (400 MHz, 
Acetone-d6) δ 10.24 (s, 1H), 8.79 (dd, J = 4.2, 1.6 Hz, 1H), 8.52 (dd, J = 8.6, 1.6 Hz, 1H), 
7.48 (dd, J = 8.6, 4.2 Hz, 1H), 7.44 – 7.35 (m, 2H), 7.31 (dd, J = 11.2, 7.0 Hz, 1H), 7.08 
(d, J = 7.8 Hz, 1H), 7.05 – 6.99 (m, 1H), 4.43 (d, J = 1.0 Hz, 2H). 
 
5-((6-chloro-5-fluoro-1H-indol-1-yl)methyl)quinolin-8-ol (9x). 1H NMR (400 
MHz, Acetone-d6) δ 10.28 (s, 1H), 8.80 (dd, J = 4.2, 1.6 Hz, 1H), 8.53 (dd, J = 8.6, 1.6 
Hz, 1H), 7.54 – 7.47 (m, 2H), 7.41 (t, J = 8.6 Hz, 2H), 7.12 – 7.05 (m, 2H), 4.45 (s, 2H). 
 
5-((5,6-dichloro-1H-indol-1-yl)methyl)quinolin-8-ol (9y). 1H NMR (400 MHz, 
DMSO-d6) δ 11.30 – 10.99 (m, 1H), 9.63 (s, 1H), 8.84 (dd, J = 4.1, 1.4 Hz, 1H), 8.52 (dd, 
J = 8.5, 1.6 Hz, 1H), 7.72 (s, 1H), 7.60 (s, 1H), 7.53 (dd, J = 8.5, 4.1 Hz, 1H), 7.37 (d, J = 
7.8 Hz, 1H), 7.13 (d, J = 2.3 Hz, 1H), 7.04 (d, J = 7.7 Hz, 1H), 4.40 (s, 2H). 
 
General procedure for synthesis of 2a-2f, 6a-6f, 8 and 10a-10y. To a stirred 
suspension of 1a-1g or 5a-5g or 7 or 9a-9y (0.5 mmol) and paraformaldehyde (0.5 mmol, 
15 mg) in ethanol (6 mL) was added pyrrolidine (0.45 mmol, 32 mg). The mixture was 
refluxed for 1-5 hr and solvent was evaporated under reduced pressure to give the crude 
which was purified with flash chromatography on silica. Elution with dichloromethane-
methanol (10:0-10:1) gave desired compounds 2a-2f, 6a-6f, 8 and 10a-10y (34-81% 
yield). 
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5-((5-fluoro-1H-indazol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(2a). 1H NMR (400 MHz, Chloroform-d) δ 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.74 (dd, J = 
4.2, 1.7 Hz, 1H), 8.19 (dd, J = 8.6, 1.6 Hz, 1H), 7.68 (ddt, J = 9.2, 4.6, 1.0 Hz, 1H), 7.64 
(d, J = 0.9 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.10 – 6.99 (m, 2H), 5.87 (s, 2H), 4.02 (s, 2H), 
2.84 – 2.62 (m, 4H), 1.88 (p, J = 3.3 Hz, 4H). 
 
5-((1H-benzo[d][1,2,3]triazol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-
8-ol (2b). 1H NMR (400 MHz, Chloroform-d) δ 10.42 (s, 1H), 8.78 (dd, J = 4.2, 1.6 Hz, 
1H), 8.44 (dd, J = 8.6, 1.6 Hz, 1H), 7.96 (dt, J = 7.9, 1.2 Hz, 1H), 7.44 – 7.17 (m, 5H), 
6.11 (s, 2H), 3.95 (s, 2H), 2.64 (td, J = 5.6, 4.5, 2.3 Hz, 4H), 1.81 (p, J = 3.4 Hz, 4H). 
 
5-((6-chloro-9H-purin-9-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(2c). 1H NMR (400 MHz, Chloroform-d) δ 8.83 (s, 1H), 8.79 (dd, J = 4.2, 1.5 Hz, 1H), 
8.69 (s, 1H), 8.60 (dd, J = 8.6, 1.5 Hz, 1H), 8.46 (s, 1H), 7.49 (dd, J = 8.6, 4.2 Hz, 1H), 
5.80 (s, 2H), 4.45 (s, 2H), 3.30 (s, 4H), 2.16 – 2.11 (m, 4H). 
 
1-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methyl)-2,3-
dihydroquinolin-4(1H)-one (2d). 1H NMR (400 MHz, Chloroform-d) δ 8.95 (d, J = 4.1 
Hz, 1H), 8.31 (dd, J = 8.5, 2.2 Hz, 1H), 8.05 – 7.96 (m, 1H), 7.50 – 7.37 (m, 2H), 7.23 (s, 
1H), 6.93 – 6.78 (m, 2H), 4.82 (s, 2H), 4.01 (d, J = 1.9 Hz, 2H), 3.46 (t, J = 6.7 Hz, 2H), 
2.73 (d, J = 6.1 Hz, 4H), 2.65 (t, J = 6.9 Hz, 2H), 1.90 (p, J = 3.3, 2.6 Hz, 4H). 
 
5-(((1-phenyl-1H-benzo[d]imidazol-2-yl)amino)methyl)-7-(pyrrolidin-1-
ylmethyl)quinolin-8-ol (2e). 1H NMR (400 MHz, Chloroform-d) δ 8.84 (dd, J = 4.2, 1.6 
Hz, 1H), 8.21 (dd, J = 8.5, 1.6 Hz, 1H), 7.60 (dt, J = 7.8, 0.9 Hz, 1H), 7.29 (dd, J = 8.5, 
4.1 Hz, 1H), 7.19 (ddd, J = 9.9, 5.3, 2.3 Hz, 5H), 7.12 – 7.07 (m, 2H), 7.06 – 7.01 (m, 
2H), 5.05 (s, 2H), 5.01 – 4.92 (m, 2H), 4.21 (s, 1H), 3.96 (s, 2H), 2.81 – 2.58 (m, 4H), 
1.88 (p, J = 3.3 Hz, 4H). 
 
Tert-butyl (R)-(1-(((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-
yl)methyl)amino)-1-oxo-3-(phenylthio)propan-2-yl)carbamate (2f). 1H NMR (400 
MHz, Chloroform-d) δ 8.81 (s, 1H), 8.41 (d, J = 8.6 Hz, 1H), 7.88 (s, 1H), 7.52 (s, 1H), 
7.32 – 7.07 (m, 5H), 5.96 (s, 1H), 4.97 (s, 1H), 4.68 (d, J = 15.4 Hz, 1H), 4.47 (s, 1H), 
4.39 – 4.16 (m, 2H), 3.75 (d, J = 2.0 Hz, 2H), 3.21 (s, 4H), 3.03 – 2.88 (m, 2H), 2.10 (s, 
4H), 1.41 (s, 9H). 
 
N-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methyl)-2-(3,4,5-
trimethoxyphenyl)acetamide (6a). 1H NMR (400 MHz, Methanol-d4) δ 8.78 (d, J = 4.1 
Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 7.40 (dd, J = 8.5, 4.2 Hz, 1H), 7.31 (s, 1H), 6.55 (s, 
2H), 4.74 (s, 1H), 3.97 (s, 2H), 3.75 (s, 3H), 3.70 (s, 6H), 3.45 (s, 2H), 3.37 (d, J = 1.7 Hz, 
2H), 2.72 (s, 4H), 1.89 (s, 4H). 
 
N-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methyl)-2-(4-
nitrophenyl)acetamide (6b). 1H NMR (400 MHz, DMSO-d6) δ 8.85 (dd, J = 4.1, 1.5 Hz, 
1H), 8.66 (t, J = 5.6 Hz, 1H), 8.37 (dd, J = 8.5, 1.6 Hz, 1H), 8.23 – 8.12 (m, 2H), 7.60 – 
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7.47 (m, 3H), 7.39 (s, 1H), 4.64 (d, J = 5.5 Hz, 2H), 3.78 (s, 2H), 3.64 (s, 2H), 2.51 (dt, J 
= 3.7, 1.8 Hz, 4H), 1.73 (p, J = 3.0 Hz, 4H). 
 
2-(4-fluorophenyl)-N-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-
yl)methyl)acetamide (6c). 1H NMR (400 MHz, DMSO-d6) δ 8.92 (dd, J = 4.1, 1.5 Hz, 
1H), 8.60 (t, J = 5.5 Hz, 1H), 8.43 (dd, J = 8.6, 1.6 Hz, 1H), 7.70 – 7.49 (m, 2H), 7.36 – 
7.23 (m, 2H), 7.18 – 7.04 (m, 2H), 4.63 (d, J = 5.5 Hz, 2H), 4.25 (s, 2H), 3.47 (s, 2H), 
3.04 (s, 4H), 1.89 (p, J = 3.4 Hz, 4H). 
 
N-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methyl)-2-(4-
(trifluoromethyl)phenyl)acetamide (6d). 1H NMR (400 MHz, Chloroform-d) δ 8.86 (dd, 
J = 4.1, 1.6 Hz, 1H), 8.20 (dd, J = 8.6, 1.6 Hz, 1H), 7.61 – 7.51 (m, 2H), 7.44 – 7.30 (m, 
3H), 7.15 (s, 1H), 5.76 (s, 1H), 4.75 (d, J = 5.4 Hz, 2H), 3.95 (s, 2H), 3.61 (s, 2H), 2.71 
(td, J = 5.4, 4.4, 2.3 Hz, 4H), 1.88 (p, J = 3.3 Hz, 4H). 
 
N-(8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)-2-(4-
nitrophenyl)acetamide (6e). 1H NMR (400 MHz, Methanol-d4) δ 8.93 (dd, J = 4.2, 1.6 
Hz, 1H), 8.34 (dd, J = 8.6, 1.6 Hz, 1H), 8.32 – 8.22 (m, 2H), 7.80 – 7.67 (m, 5H), 7.64 
(dd, J = 8.6, 4.2 Hz, 1H), 7.60 (s, 1H), 7.40 – 7.29 (m, 3H), 4.58 (s, 2H), 4.02 (s, 2H), 
3.49 – 3.40 (m, 4H), 3.37 (s, 1H), 2.11 (p, J = 4.0 Hz, 4H). 
 
N-(8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)-2-(4-
(trifluoromethyl)phenyl)acetamide (6f). 1H NMR (400 MHz, Methanol-d4) δ 8.88 (dd, 
J = 4.2, 1.6 Hz, 1H), 8.27 (dd, J = 8.5, 1.6 Hz, 1H), 7.68 (q, J = 8.4 Hz, 4H), 7.62 – 7.52 
(m, 2H), 7.49 (d, J = 3.3 Hz, 2H), 4.33 (s, 2H), 3.95 (s, 2H), 3.57 (s, 1H), 3.19 – 3.05 (m, 
4H), 2.07 – 1.94 (m, 4H). 
 
1-(4-bromobenzyl)-3-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-
yl)methyl)urea (8). 1H NMR (400 MHz, Methanol-d4) δ 8.83 (dd, J = 4.2, 1.6 Hz, 1H), 
8.50 (dd, J = 8.6, 1.6 Hz, 1H), 7.53 (dd, J = 8.6, 4.2 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.35 (s, 
1H), 7.29 – 7.14 (m, 2H), 4.71 (s, 2H), 4.32 (s, 2H), 4.06 (s, 2H), 3.00 – 2.64 (m, 4H), 
1.92 (p, J = 3.3 Hz, 4H). 
 
5-((1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol (10a). 1H 
NMR (400 MHz, Acetone-d6) δ 9.88 (s, 1H), 8.63 (dd, J = 4.1, 1.5 Hz, 1H), 8.37 (dd, J = 
8.6, 1.6 Hz, 1H), 7.43 (dt, J = 7.9, 1.0 Hz, 1H), 7.39 (s, 1H), 7.30 (dd, J = 8.5, 4.1 Hz, 
1H), 7.23 (dt, J = 8.1, 0.9 Hz, 1H), 6.94 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 6.84 (ddd, J = 8.0, 
7.0, 1.0 Hz, 1H), 6.79 (p, J = 1.1 Hz, 1H), 4.33 (s, 2H), 3.73 (s, 2H), 2.48 – 2.35 (m, 4H), 
1.61 (p, J = 3.2 Hz, 4H). 
 
5-((2-methyl-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10b). 1H NMR (400 MHz, Chloroform-d) δ 10.51 (s, 1H), 9.06 – 8.84 (m, 1H), 8.70 – 
8.31 (m, 2H), 7.55 – 7.25 (m, 3H), 7.21 – 7.08 (m, 1H), 7.01 (t, J = 7.5 Hz, 1H), 6.96 (s, 
1H), 4.39 (s, 2H), 3.86 (s, 2H), 2.63 (d, J = 6.1 Hz, 4H), 1.99 – 1.64 (m, 4H). 
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5-((2-ethyl-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10c). 1H NMR (400 MHz, Chloroform-d) δ 8.90 (dd, J = 4.2, 1.5 Hz, 1H), 8.46 (dd, J = 
8.6, 1.5 Hz, 1H), 8.15 (s, 1H), 7.39 (dd, J = 8.5, 4.1 Hz, 1H), 7.34 (dt, J = 8.0, 1.3 Hz, 
2H), 7.17 – 7.10 (m, 1H), 7.05 – 6.99 (m, 1H), 6.95 (s, 1H), 4.42 (s, 2H), 3.88 (s, 2H), 
2.73 – 2.61 (m, 6H), 1.84 (h, J = 3.2 Hz, 4H), 1.19 (t, J = 7.6 Hz, 3H). 
 
5-((4-fluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10d). 1H NMR (400 MHz, Chloroform-d) δ 8.75 (dd, J = 4.1, 1.6 Hz, 1H), 8.35 – 8.24 
(m, 1H), 8.22 (d, J = 16.3 Hz, 1H), 7.26 (dd, J = 8.5, 4.1 Hz, 1H), 7.19 (d, J = 4.0 Hz, 2H), 
7.14 – 6.96 (m, 2H), 6.69 (ddd, J = 11.2, 7.4, 1.3 Hz, 1H), 6.43 (s, 1H), 4.48 (s, 2H), 3.98 
(s, 2H), 2.75 (t, J = 5.3 Hz, 4H), 1.83 (p, J = 3.3 Hz, 4H). 
 
5-((4-nitro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10e). 1H NMR (400 MHz, Chloroform-d) δ 9.42 (s, 1H), 8.71 (dd, J = 4.1, 1.6 Hz, 1H), 
8.15 (dd, J = 8.5, 1.6 Hz, 1H), 7.76 (dd, J = 7.9, 0.9 Hz, 1H), 7.56 (dd, J = 8.1, 0.9 Hz, 
1H), 7.23 – 7.16 (m, 2H), 7.13 (t, J = 8.0 Hz, 1H), 6.98 (s, 1H), 6.50 (s, 1H), 4.43 (s, 2H), 
3.86 (s, 2H), 2.60 (q, J = 5.0, 4.0 Hz, 4H), 1.75 (p, J = 3.2 Hz, 4H). 
 
5-((5-fluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10f). 1H NMR (400 MHz, Methanol-d4) δ 8.76 (dd, J = 4.2, 1.6 Hz, 1H), 8.47 (dd, J = 
8.6, 1.6 Hz, 1H), 7.43 (dd, J = 8.6, 4.2 Hz, 1H), 7.33 – 7.24 (m, 2H), 7.09 (dd, J = 9.9, 2.5 
Hz, 1H), 6.88 (s, 1H), 6.83 (td, J = 9.1, 2.5 Hz, 1H), 4.41 (s, 2H), 3.98 (s, 2H), 2.79 – 
2.62 (m, 4H), 1.86 (p, J = 3.3 Hz, 4H). 
 
5-((5-chloro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10g). 1H NMR (400 MHz, Chloroform-d) δ 8.89 (dd, J = 4.1, 1.6 Hz, 1H), 8.05 (dd, J = 
8.5, 1.6 Hz, 1H), 7.62 (dd, J = 2.1, 0.5 Hz, 1H), 7.35 (dd, J = 8.6, 4.1 Hz, 1H), 7.31 (dt, J 
= 8.7, 0.7 Hz, 1H), 7.17 (dd, J = 8.7, 2.0 Hz, 1H), 6.97 – 6.91 (m, 2H), 6.43 (dd, J = 3.2, 
0.8 Hz, 1H), 5.58 (d, J = 0.8 Hz, 2H), 3.93 (s, 2H), 2.67 (d, J = 6.3 Hz, 4H), 1.87 (p, J = 
3.3 Hz, 4H). 
 
1-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methyl)-1H-indole-5-
carbonitrile (10h). 1H NMR (400 MHz, Chloroform-d) δ 8.90 (dd, J = 4.2, 1.6 Hz, 1H), 
8.05 – 7.98 (m, 2H), 7.46 (d, J = 1.1 Hz, 2H), 7.37 (dd, J = 8.6, 4.1 Hz, 1H), 7.05 (d, J = 
3.3 Hz, 1H), 6.97 (s, 1H), 6.57 (d, J = 3.3 Hz, 1H), 5.63 (d, J = 0.8 Hz, 2H), 3.95 (s, 2H), 
2.78 – 2.59 (m, 4H), 1.88 (p, J = 3.3 Hz, 4H). 
 
5-((5-nitro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol (10i). 
1H NMR (400 MHz, Chloroform-d) δ 10.95 (s, 1H), 8.90 (dd, J = 4.1, 1.6 Hz, 1H), 8.59 
(d, J = 2.2 Hz, 1H), 8.11 (dd, J = 9.1, 2.2 Hz, 1H), 8.03 (dd, J = 8.6, 1.6 Hz, 1H), 7.43 (d, 
J = 9.1 Hz, 1H), 7.36 (dd, J = 8.6, 4.1 Hz, 1H), 7.08 (d, J = 3.3 Hz, 1H), 6.97 (s, 1H), 6.66 
(dd, J = 3.3, 0.8 Hz, 1H), 5.71 – 5.52 (m, 2H), 3.94 (s, 2H), 2.68 (td, J = 5.8, 4.9, 2.5 Hz, 
4H), 1.94 – 1.77 (m, 4H). 
 
Ethyl 1-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methyl)-1H-
indole-5-carboxylate (10j). 1H NMR (400 MHz, Chloroform-d) δ 10.22 (s, 1H), 9.53 (s, 
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1H), 8.82 (dd, J = 4.1, 1.5 Hz, 1H), 8.43 (d, J = 1.5 Hz, 1H), 8.25 (dd, J = 8.6, 1.6 Hz, 
1H), 7.91 (dd, J = 8.6, 1.6 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.33 – 7.25 (m, 1H), 7.15 (s, 
1H), 6.64 (s, 1H), 4.86 – 4.35 (m, 4H), 3.94 (s, 2H), 2.68 (d, J = 6.1 Hz, 4H), 2.15 – 1.72 
(m, 4H), 1.42 (t, J = 7.1 Hz, 3H). 
 
5-((6-fluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10k). 1H NMR (400 MHz, Chloroform-d) δ 8.89 (dd, J = 4.1, 1.6 Hz, 1H), 8.06 (dd, J = 
8.6, 1.6 Hz, 1H), 7.55 (dd, J = 8.7, 5.4 Hz, 1H), 7.35 (dd, J = 8.6, 4.1 Hz, 1H), 7.07 (dd, J 
= 10.0, 2.3 Hz, 1H), 6.98 (s, 1H), 6.94 – 6.84 (m, 2H), 6.46 (dd, J = 3.3, 0.9 Hz, 1H), 5.52 
(s, 2H), 3.94 (s, 2H), 2.84 – 2.54 (m, 4H), 1.87 (p, J = 3.3 Hz, 4H). 
 
5-((6-chloro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10l). 1H NMR (400 MHz, Chloroform-d) δ 8.89 (dd, J = 4.2, 1.6 Hz, 1H), 8.06 (dd, J = 
8.6, 1.6 Hz, 1H), 7.55 (dd, J = 8.5, 0.6 Hz, 1H), 7.44 – 7.33 (m, 2H), 7.19 – 7.03 (m, 2H), 
6.93 (d, J = 3.2 Hz, 1H), 6.46 (dd, J = 3.3, 0.9 Hz, 1H), 5.56 (d, J = 0.8 Hz, 2H), 4.03 (s, 
2H), 2.79 (s, 4H), 1.91 (s, 4H). 
 
5-((6-bromo-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10m). 1H NMR (400 MHz, Chloroform-d) δ 10.37 (s, 1H), 8.88 (dd, J = 4.1, 1.6 Hz, 1H), 
8.02 (dd, J = 8.5, 1.6 Hz, 1H), 7.60 – 7.53 (m, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.34 (dd, J = 
8.5, 4.1 Hz, 1H), 7.23 (dd, J = 8.4, 1.7 Hz, 1H), 6.95 (s, 1H), 6.87 (d, J = 3.2 Hz, 1H), 
6.44 (dd, J = 3.3, 0.9 Hz, 1H), 5.51 (s, 2H), 3.93 (s, 2H), 2.68 (p, J = 3.9, 3.5 Hz, 4H), 
1.86 (p, J = 3.3 Hz, 4H). 
 
5-((6-nitro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10n). 1H NMR (400 MHz, Chloroform-d) δ 9.54 (s, 1H), 8.91 (dd, J = 4.1, 1.6 Hz, 1H), 
8.44 (d, J = 1.9 Hz, 1H), 8.03 (ddd, J = 10.6, 8.7, 1.8 Hz, 2H), 7.68 (d, J = 8.8 Hz, 1H), 
7.36 (dd, J = 8.5, 4.1 Hz, 1H), 7.18 (d, J = 3.1 Hz, 1H), 7.07 (s, 1H), 6.57 (dd, J = 3.2, 0.9 
Hz, 1H), 5.68 (s, 2H), 3.97 (s, 2H), 2.80 – 2.58 (m, 4H), 1.88 (p, J = 3.3 Hz, 4H). 
 
5-((6-methoxy-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10o). 1H NMR (400 MHz, Chloroform-d) δ 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.27 (dd, J = 
8.5, 1.6 Hz, 1H), 7.90 (s, 1H), 7.46 (d, J = 8.7 Hz, 1H), 7.28 (dd, J = 8.6, 4.1 Hz, 1H), 
7.15 (s, 1H), 6.84 (d, J = 2.2 Hz, 1H), 6.78 (dd, J = 8.6, 2.3 Hz, 1H), 6.48 (dt, J = 2.4, 1.2 
Hz, 1H), 4.37 (s, 2H), 3.94 (s, 2H), 3.84 (s, 3H), 2.78 – 2.57 (m, 4H), 1.85 (p, J = 3.2 Hz, 
4H). 
 
5-((7-fluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10p). 1H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.81 (dd, J = 4.2, 1.5 Hz, 1H), 
8.53 (dd, J = 8.6, 1.6 Hz, 1H), 7.65 – 7.40 (m, 2H), 7.40 – 7.24 (m, 1H), 7.12 (s, 1H), 
7.02 – 6.68 (m, 2H), 4.41 (s, 2H), 3.80 (s, 2H), 2.50 (d, J = 6.3 Hz, 4H), 1.68 (h, J = 3.2 
Hz, 4H). 
 
5-((7-methyl-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10q). 1H NMR (400 MHz, Chloroform-d) δ 9.74 (s, 1H), 8.84 (dd, J = 4.2, 1.6 Hz, 1H), 
8.28 (dd, J = 8.6, 1.6 Hz, 1H), 8.18 (s, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.30 – 7.24 (m, 1H), 
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7.19 (s, 1H), 7.11 – 6.99 (m, 2H), 6.57 (d, J = 2.0 Hz, 1H), 4.41 (s, 2H), 3.95 (s, 2H), 
2.82 – 2.62 (m, 4H), 2.47 (s, 3H), 1.97 – 1.78 (m, 4H). 
 
5-((2,3-dimethyl-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-
ol (10r). 1H NMR (400 MHz, Chloroform-d) δ 10.57 (s, 1H), 8.94 (dd, J = 4.2, 1.6 Hz, 
1H), 8.28 (dd, J = 8.6, 1.6 Hz, 1H), 7.57 (dd, J = 8.2, 1.7 Hz, 1H), 7.45 (dd, J = 8.5, 4.2 
Hz, 1H), 7.20 – 6.97 (m, 3H), 6.27 (s, 1H), 5.54 (d, J = 1.2 Hz, 2H), 3.75 (s, 2H), 2.72 – 
2.46 (m, 4H), 2.33 (s, 3H), 2.24 (s, 3H), 1.79 (p, J = 3.2 Hz, 4H). 
 
5-((5-methoxy-2-methyl-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-
ylmethyl)quinolin-8-ol (10s). 1H NMR (400 MHz, Chloroform-d) δ 10.18 (s, 1H), 8.87 
(dd, J = 4.2, 1.5 Hz, 1H), 8.41 (dd, J = 8.5, 1.6 Hz, 1H), 8.20 (s, 1H), 7.36 (dd, J = 8.5, 
4.1 Hz, 1H), 7.23 – 7.07 (m, 1H), 6.93 (s, 1H), 6.74 (dt, J = 3.9, 1.9 Hz, 2H), 4.32 (s, 2H), 
3.85 (s, 2H), 3.69 (s, 3H), 2.84 – 2.41 (m, 4H), 2.22 (s, 3H), 1.93 – 1.70 (m, 4H). 
 
5-((2-ethyl-5-fluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-
8-ol  (10t). 1H NMR (400 MHz, Chloroform-d) δ 9.11 (s, 1H), 8.89 (dd, J = 4.1, 1.6 Hz, 
1H), 8.50 (dd, J = 8.6, 1.7 Hz, 1H), 7.50 – 7.40 (m, 1H), 7.39 – 7.31 (m, 1H), 7.10 – 6.92 
(m, 3H), 4.83 (s, 2H), 4.39 (q, J = 7.1 Hz, 2H), 3.92 (s, 2H), 2.81 – 2.57 (m, 4H), 1.85 (p, 
J = 3.2 Hz, 4H), 1.28 (t, J = 7.1 Hz, 3H). 
 
1-((8-hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methyl)-6-methoxy-1H-
indole-3-carbonitrile (10u). 1H NMR (400 MHz, DMSO-d6) δ 10.73 (s, 1H), 8.83 (dd, J 
= 4.1, 1.5 Hz, 1H), 8.46 (dd, J = 8.5, 1.6 Hz, 1H), 7.51 (dd, J = 8.5, 4.1 Hz, 1H), 7.45 (d, 
J = 8.5 Hz, 1H), 7.27 (s, 1H), 6.82 (d, J = 2.3 Hz, 1H), 6.71 (dd, J = 8.6, 2.3 Hz, 1H), 4.48 
(s, 2H), 4.01 (s, 2H), 3.79 (s, 2H), 3.73 (s, 3H), 2.65 – 2.36 (m, 4H), 1.66 (h, J = 3.1 Hz, 
4H). 
 
5-((4,5-difluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10v). 1H NMR (400 MHz, Chloroform-d) δ 8.86 (dd, J = 4.1, 1.5 Hz, 1H), 8.50 (s, 1H), 
8.27 (dd, J = 8.6, 1.6 Hz, 1H), 7.37 – 7.31 (m, 1H), 7.29 (d, J = 2.2 Hz, 1H), 7.19 (s, 1H), 
7.15 (dd, J = 10.6, 6.5 Hz, 1H), 6.69 (s, 1H), 4.35 (s, 2H), 4.01 (s, 2H), 2.75 (q, J = 5.3, 
4.6 Hz, 4H), 2.13 – 1.81 (m, 4H). 
 
5-((5,6-difluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol  
(10w). 1H NMR (400 MHz, Chloroform-d) δ 8.91 – 8.63 (m, 1H), 8.42 – 8.15 (m, 1H), 
7.46 – 6.98 (m, 4H), 6.66 (d, J = 21.3 Hz, 1H), 4.45 – 4.21 (m, 2H), 3.98 – 3.78 (m, 2H), 
2.81 – 2.51 (m, 4H), 1.99 – 1.69 (m, 4H). 
 
5-((6-chloro-5-fluoro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-
ylmethyl)quinolin-8-ol (10x). 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.80 (dd, 
J = 4.2, 1.5 Hz, 1H), 8.50 (dd, J = 8.6, 1.6 Hz, 1H), 7.64 – 7.44 (m, 3H), 7.40 (d, J = 10.3 
Hz, 1H), 7.18 (d, J = 1.7 Hz, 1H), 4.38 (s, 2H), 3.80 (s, 2H), 2.60 – 2.40 (m, 4H), 1.69 (q, 
J = 3.7, 3.3 Hz, 4H). 
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5-((5,6-dichloro-1H-indol-1-yl)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol 
(10y). 1H NMR (400 MHz, DMSO-d6) δ 11.15 (s, 1H), 8.82 (d, J = 4.2 Hz, 1H), 8.52 (d, 
J = 8.5 Hz, 1H), 7.67 (s, 1H), 7.59 (s, 1H), 7.55 – 7.38 (m, 2H), 7.22 (s, 1H), 4.41 (s, 2H), 
3.82 (s, 2H), 2.51 (d, J = 6.7 Hz, 4H), 1.76 – 1.45 (m, 4H). 
 
General procedure for synthesis of 5a-5f. To a stirred solution of compound 4 
(1.0 mmol, 140 mg) or 5-amino-8-hydroxyquinoline dihydrochloride and carboxylic acid 
(1.2 mmol) in DMF-H2O (1:5) were added oxyma (2.0 mmol, 284 mg), EDCI (2.0 mmol, 
310 mg), and NaHCO3 (6.0 mmol, 636 mg). After stirring at room temperature for 12 hr, 
the solution was extracted with EtOAc. The combined organic layers were washed with 
brine (3 ml), and then dried over Na2SO4. Concentration of organic phase gave crude 
product which was purified with flash chromatography on silica.  Elution with 
dichloromethane/methanol (10:0-10:1) gave desired compounds 5a-5f (yield: 27-59%).  
 
N-((8-hydroxyquinolin-5-yl)methyl)-2-(3,4,5-trimethoxyphenyl)acetamide 
(5a). 1H NMR (400 MHz, Chloroform-d) δ 8.79 (dd, J = 4.2, 1.5 Hz, 1H), 8.34 (dd, J = 
8.5, 1.5 Hz, 1H), 7.46 (dd, J = 8.6, 4.2 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.06 (d, J = 7.8 
Hz, 1H), 6.37 (s, 2H), 5.71 (s, 1H), 4.78 (d, J = 5.6 Hz, 2H), 3.80 (s, 3H), 3.72 (s, 6H), 
3.52 (s, 2H). 
 
N-((8-hydroxyquinolin-5-yl)methyl)-2-(4-nitrophenyl)acetamide (5b). 1H 
NMR (400 MHz, DMSO-d6) δ 9.78 (s, 1H), 8.87 (dd, J = 4.1, 1.6 Hz, 1H), 8.64 (t, J = 5.5 
Hz, 1H), 8.39 (dd, J = 8.6, 1.6 Hz, 1H), 8.23 – 8.12 (m, 2H), 7.60 – 7.49 (m, 3H), 7.41 (d, 
J = 7.8 Hz, 1H), 7.04 (d, J = 7.8 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 3.64 (s, 2H). 
2-(4-fluorophenyl)-N-((8-hydroxyquinolin-5-yl)methyl)acetamide (5c). 1H 
NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 8.87 (dd, J = 4.1, 1.6 Hz, 1H), 8.52 (t, J = 5.6 
Hz, 1H), 8.40 (dd, J = 8.6, 1.6 Hz, 1H), 7.55 (dd, J = 8.6, 4.1 Hz, 1H), 7.39 (d, J = 7.8 Hz, 
1H), 7.32 – 7.23 (m, 2H), 7.16 – 7.06 (m, 2H), 7.03 (d, J = 7.8 Hz, 1H), 4.62 (d, J = 5.5 
Hz, 2H), 3.44 (s, 2H). 
N-((8-hydroxyquinolin-5-yl)methyl)-2-(4-(trifluoromethyl)phenyl)acetamide 
(5d). 1H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 8.87 (dd, J = 4.1, 1.5 Hz, 1H), 8.61 
(t, J = 5.6 Hz, 1H), 8.39 (dd, J = 8.6, 1.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.55 (dd, J = 
8.6, 4.1 Hz, 1H), 7.48 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 7.8 Hz, 1H), 7.03 (d, J = 7.8 Hz, 
1H), 4.64 (d, J = 5.5 Hz, 2H), 3.57 (s, 2H). 
N-(8-hydroxyquinolin-5-yl)-2-(4-nitrophenyl)acetamide (5e). 1H NMR (400 
MHz, DMSO-d6) δ 10.12 (s, 1H), 9.83 (s, 1H), 8.88 (dd, J = 4.1, 1.6 Hz, 1H), 8.32 (d, J = 
1.6 Hz, 1H), 8.30 – 8.16 (m, 2H), 7.87 – 7.67 (m, 2H), 7.60 (dd, J = 8.6, 4.1 Hz, 1H), 
7.46 (d, J = 8.2 Hz, 1H), 7.06 (d, J = 8.2 Hz, 1H), 3.97 (s, 2H). 
 
N-(8-hydroxyquinolin-5-yl)-2-(4-(trifluoromethyl)phenyl)acetamide (5f). 1H 
NMR (400 MHz, DMSO-d6) δ 10.10 (s, 1H), 9.83 (s, 1H), 8.88 (dd, J = 4.1, 1.6 Hz, 1H), 
8.30 (dd, J = 8.5, 1.6 Hz, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.60 (dd, 
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J = 8.6, 4.1 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 7.56-7.40 (m, 1H), 7.06 (d, J = 8.2 Hz, 1H), 
3.90 (s, 2H). 
 
Synthesis of 5-(azidomethyl)quinolin-8-ol (3). To a stirred solution of 5-
chloromethyl-8-quinolinol hydrochloride (10 mmol, 2.3 g) in acetone (20 ml) were added 
sodium azide (30 mmol, 1.95 g) at room temperature. After refluxed for 20 hr, the 
mixture was filtered and the residue was washed with acetone. Combined organic solvent 
was removed under reduced pressure to give crude product which was purified with flash 
chromatography on silica.  Elution with hexanes/ethylacetate (10:1-1:1) gave desired 
compound 3 (1.54 g, 77%). 1H NMR (400 MHz, DMSO-d6) δ 10.04 (s, 1H), 8.92 (dd, J = 
4.1, 1.6 Hz, 1H), 8.50 (dd, J = 8.6, 1.6 Hz, 1H), 7.67 (dd, J = 8.6, 4.1 Hz, 1H), 7.55 (d, J 
= 7.8 Hz, 1H), 7.08 (d, J = 7.8 Hz, 1H), 4.83 (s, 2H). 
 
Synthesis of 5-(aminomethyl)quinolin-8-ol (4). A suspension of azide 3 (2.00 g, 
10 mol) and 10% Pd/C (0.15 g) in ethylacetate (15 ml) was hydrogenated overnight, the 
reaction mixture was filtered off and washed with dichloromethane-methanol (1:1). The 
combined filtration was evaporated under vacuum to give the oily crude which was 
purified with flash chromatography on silica. Compound 4 was eluted out with 
dichloromethane/methanol (15:0-10:1) (1.18 g, 68%). 1H NMR (400 MHz, DMSO-d6) δ 
8.86 (dd, J = 4.1, 1.6 Hz, 1H), 8.57 (dd, J = 8.6, 1.6 Hz, 1H), 7.58 (dd, J = 8.5, 4.1 Hz, 
1H), 7.44 (dd, J = 7.8, 0.9 Hz, 1H), 7.02 (d, J = 7.8 Hz, 1H), 4.10 (d, J = 0.8 Hz, 2H),. 
 
Synthesis of 1-(4-bromobenzyl)-3-((8-hydroxyquinolin-5-yl)methyl)urea (7). 
To a stirred solution of compound 4 (1.0 mmol, 140 mg) and 4-bromobenzyl isocyanate 
(1.0 mmol, 212 mg) in anhydrous dichloromethane (5ml) were added catalytic amount of 
trimethylamine (0.1 mmol, 10.1 mg). After stirring at room temperature for 5 hr, solvent 
was removed under reduced pressure to give crude product which was purified with flash 
chromatography on silica.  Elution with hexanes/ethylacetate (10:1-1:1) gave desired 
compounds 7 (220 mg, 57%).  1H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 1H), 8.88 (dd, J 
= 4.1, 1.5 Hz, 1H), 8.52 (dd, J = 8.6, 1.6 Hz, 1H), 7.60 (dd, J = 8.6, 4.2 Hz, 1H), 7.56 – 
7.46 (m, 2H), 7.38 (d, J = 7.8 Hz, 1H), 7.30 – 7.14 (m, 2H), 7.03 (d, J = 7.8 Hz, 1H), 6.44 
(t, J = 5.8 Hz, 1H), 6.39 (t, J = 6.1 Hz, 1H), 4.60 (d, J = 5.7 Hz, 2H), 4.21 (d, J = 6.1 Hz, 
2H), 3.18 (d, J = 5.1 Hz, 1H). 
 
 
Cell culture and reagents 
 
Human melanoma A375, M14, WM164, RPMI7951, M14/MDR1 and B16F101 
cell lines were purchased from ATCC (American Type Culture Collection, Manassas, 
VA, USA), and cultured in DMEM media (Mediatech, Inc., Manassas, VA) at 37qC in a 
humidified atmosphere containing 5% CO2. The culture media were supplemented with 
10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic-
antimycotic mixture (Sigma-Aldrich, St. Louis, MO). Compounds were dissolved in 
dimethylsulfoxide (DMSO; Sigma-Aldrich) to make a stock solution of 10 mM. 
Compound solutions were freshly prepared by diluting stocks with cell culture medium 
before use (final solution contained less than 0.5% DMSO). 5000 cells in logarithm 
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growing phase were seeded overnight into each well of a 96-well plate. Then the cells 
were continuously incubated for 48 h with sequential diluted compound solution (100 μM 
to 3 nM, 100 μl per well) in cell culture medium. The cell viability was determined in 
MTS assay and IC50 was calculated (n = 4), following similar procedures as described 
previously [215-218]. Dulbecco’s modified Eagle’s Medium (DMEM), fetal bovine 
serum (FBS), penicillin/streptomycin and trypsin 0.25% were purchased from Hyclone 
(GE Healthcare Life Science, Pittsburgh, PA). Phosphate buffered saline (PBS) was 
purchased from Invitrogen GIBCO (Grand Island, NY). Dimethyl sulfoxide (DMSO) and 
3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) were purchased 
from Sigma Chemical Co (St. Louis, MO). The P-glycoprotein (P-gp) overexpressing 
KB-C2 cell line was established from a parental human epidermoid carcinoma cell line 
KB-3-1, by a step-wise selection of KB-3-1 in increasing concentrations of colchicine up 
to 2 μg/ml[219]. SW620/Ad300, which is also a P-gp overexpressing drug resistant cell 
line, was established by stepwise exposure of the parental human colon cancer cell line 
SW620 to increasing concentrations of doxorubicin up to 300 ng/ml[220]. The SW620 
and SW620/Ad300 cell lines were kindly provided by Dr. Susan E. Bates and Dr. Robert 
W. Robey (NCI, NIH, Bethesda, MD, USA). All the cell lines were grown in DMEM 
supplemented with 10% FBS and 100 unit/ml penicillin/streptomycin in a humidified 
incubator containing 5% CO2 at 37 °C. 
 
 
Cytotoxicity assay  
 
A375, M14, WM164, RPMI7951, M14/MDR1 and B16F101were seeded in 96-
well plates at a concentration of 1,000–5,000 cells per well, depending on growth rate of 
the cell line. After overnight incubation, the media was replaced and cells were treated 
with the test compounds at 10 concentrations ranging from 0.03 nM to 1μM plus a 
vehicle control for 72 h in four replicates. Following treatment, the MTS reagent 
(Promega, Madison, WI) was added to the cells and incubated in dark at 37°C for at least 
1 hour. Absorbance at 490 nm was measured using a plate reader (DYNEX 
Technologies, Chantilly VA). Percentages of cell survival versus drug concentrations 
were plotted, and the IC50 (concentration that inhibited cell growth by 50% of untreated 
control) values were obtained by nonlinear regression analysis using GraphPad Prism 
(GraphPad Software, San Diego, CA). 
 
 
Cytotoxicity against P-gp overexpressed cell lines by MTT assay 
 
The MTT colorimetric assay was used to measure the sensitivity of the cells 
against the synthesized compounds. The assay detects the formazan product formed from 
the reduction of MTT in active cells thus assesses the cell viability[221]. Cells were 
seeded in 96-well plates at 5000 cells/well (KB-3-1 or KB-C2 cells) or at 7000 cells/well 
(SW620 or SW620/Ad300 cells) in 180 μl completed medium and cultured overnight. 
Then various concentrations of the compounds (20 μl) were added to the designated 
wells. After 72 h continuous drug incubation, 20 μl of MTT reagent (5 mg/ml) was added 
to each well and the plates were incubated at 37 °C for 4 h. Subsequently, the medium 
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was removed and 100 μl of DMSO were added to dissolve the formazan crystals in each 
well. The absorbance was determined at 570 nm by the accuSkan™ GO UV/Vis 
Microplate Spectrophotometer (Fisher Sci., Fair Lawn, NJ). The IC50 values of each 
compound on each cell line were calculated from the survival curves to represent the 
cytotoxicity of the compounds. The fold of drug resistance was calculated by dividing the 
IC50 of the P-gp overexpressing cells by that of the parental cells. Two known P-gp 
substrates, YM155 and paclitaxel, were used as positive controls for P-gp overexpressing 
cell lines. On the other hand, cisplatin, which is not a substrate of P-gp, was used as 
negative control.  
 
 
Liver microsomes stability assay 
 
Liver microsomes stability assay was conducted following literature reports [222, 
223]. The NADPH regenerating agent solutions A (catalog#: 451220) and B (catalog#: 
451200) and mouse liver microsomes (CD-1, mixture of male, catalog#:452701, and 
female, catalog#: 452702) were obtained from BD Gentest (Woburn, MA). For each test 
compound, the mouse liver microsomal solution was prepared by adding 0.058 mL of 
concentrated mouse liver microsomes (20 mg/mL protein concentration) to 1.756 mL of 
0.1 M potassium phosphate buffer (pH 7.4) containing 5 μL of 0.5 M EDTA to make a 
0.6381 mg/mL (protein) microsomal solution. Each test compound (2.2 μL of 10 mM 
DMSO solution) was added directly to 1.79 mL of mouse liver microsomal solution and 
90 μL was transferred to wells in 96-well plates (0, 0.25, 0.5, 1, 2, and 4 h time points 
each in triplicate). The NADPH regenerating agent was prepared by mixing 0.113 mL of 
NADPH regenerating agent Solutions A, 0.023 mL of solution B and 0.315 mL of 0.1 M 
potassium phosphate buffer (pH 7.4) for each tested compound. To each well of the 96-
well plate, 22.5 μL of the NADPH regenerating agent was added to initiate the reaction, 
and the plate was incubated at 37 °C for each time point (0, 0.25, 0.5, 1, 2, and 4 h time 
points each in triplicate). The reaction was quenched by adding 225 μL of cold 
acetonitrile containing warfarin (4 mg/ml) as internal control to each well. All of the 
plates were centrifuged at 4000 rpm for 20 min and the supernatants (100 μL) were 
transferred to another 96-well plates for analysis on UPLC–MS (Waters Acquity UPLC 
linked to Waters Acquity Photodiode Array Detector and Waters Acquity Single 
Quadrupole Mass Detector) on Acquity UPLC BEH C18 1.7 mm (2.1x50 mm) column 
by running 90–5% gradient for water (+0.1% formic acid) and acetonitrile (+0.1% formic 
acid) in 2 minutes. The area under the single ion recording (SIR) channel for the test 
compound divided by the area under the SIR for internal control at 0 time concentration 
was considered as 100% to calculate remaining concentration at each time point. The 
terminal phase rate constant (ke) was estimated by linear regression of logarithmic 
transformed concentration versus the data, where ke = slope x(-ln10). The half life t1/2 
was calculated as ln2/ke. The intrinsic clearance (CLint,app)= (0.693/in vitro t1/ 2) x 
(1ml incubation volume/0.5 mg of microsomal protein) x (45 mg microsomal 
protein/gram of liver) x (55 g of liver/kg body weight) [224, 225]. 
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Chemistry 
 
Scheme 5-1 showed the synthetic method to access UC-112 analogues 2a-2f. 
Starting material 5-chloromethyl-8-quinolinol hydrochloride was synthesized by 
following a reported procedure [214]. 5-chloromethyl-8-quinolinol hydrochloride was 
treated with commercially available amines in the presence of sodium hydride or sodium 
carbonate and potassium iodide to give 1a-1f. 1a-1f refluxed with paraformaldehyde and 
pyrrolidine in ethanol to provide analogues 2a-2f. 
 
Scheme 5-2 depicted the synthesis to obtain analogues 6a-6f and 8. To synthesize 
amide and urea analogues 6a-6d and 8, 5-chloromethyl-8-quinolinol hydrochloride was 
refluxed with sodium azide in acetone to yield azide compound 3. 3 was subsequently 
hydrogenated in the presence of a catalytic equivalent of 10% Pd/C to provide amine 4. 
With 4 in hand, treatment of it with carboxylic acids, EDCI and oxyma was able to form 
amide 5a-5d. Refluxing the mixture of 5a-5d, paraformaldehyde and pyrrolidine in 
ethanol gave the amide analogues 6a-6d. Syntheses of another two amide analogues 6e 
and 6f were carried out using commercially available 5-amino-8-hydroxyquinoline 
dihydrochloride by following the same method. Treatment of amine 4 using a catalytic 
equivalent of triethylamine generated the urea intermediate 8, which was subjected to 
Mannich reaction to give urea analogue 9. 
Indole analogues 10a-10y with either mono-substitution or di-substitution were 
prepared by following Scheme 5-3. In brief, 5-chloromethyl-8-quinolinol hydrochloride 
was refluxed together with indoles in the presence of sodium carbonate and a catalytic 
amount of potassium iodide in acetonitrile to generate intermediate 9a-9y. Treatment of 
9a-9y with paraformaldehyde and pyrrolidine under reflux condition subsequently 
furnished analogues 10a-10y. 
 
 
Results 
 
All analogues of UC-112 were evaluated for their cytotoxicity in human 
melanoma cell lines including A375, WM1641, M14, RPMI, M14/MDR1 and B16F10. 
The antiproliferative effects of the compounds were evaluated by MTT assay. IC50s were 
reported in μM and calculated from at least three independent experiments, each 
performed in duplicates.  
 
 
In vitro growth inhibitory effects of UC-112 analogues with modification of 
benzyloxy moiety 
 
As a continuation of our effort to develop selective survivin inhibitor based on 
UC-112, we initiated the SAR investigation by replacing the benzyloxy with a variety of 
different moieties. The structures and in vitro assay result for analogues 2a-2f, 6a-6f, 8 
and 10a were shown in Figure 5-2 and Table 5-1. Compared to the reference compound 
MX-106, analogues 2a with a 5-fluoroindazole moiety, 2b with a benzotriazole moiety 
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Scheme 5-1. Synthesis of 2a-2f 
Reagents and conditions: (a) NaH, DMF or KI, Na2CO3, MeCN, reflux; (b) 
parafomaldehyde, pyrrolidine, ethanol, reflux; 
 
 
 
 
 
 
Scheme 5-2. Synthesis of 6a-6f and 8 
Reagents and conditions:(a) NaN3, acetone, reflux; (b) H2, Pd/C(10%), ethyl acetate, rt; 
(c) Et3N, DCM, 0oC to rt; (d): parafomaldehyde, pyrrolidine, ethanol, reflux; (e) Oxyma, 
EDCI, NaHCO3, DMF-H2O, rt. 
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Scheme 5-3. Synthesis of 10a-10y 
Reagents and conditions: (a) NaH, DMF or KI, Na2CO3, MeCN, reflux; (b) 
parafomaldehyde, pyrrolidine, ethanol, reflux. 
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Figure 5-2. Structures of UC-112 analogues with modification of benzyloxy 
moiety 
 
 
 
 
Table 5-1. In vitro growth inhibitory effects (μM) of UC-112 analogues with 
modification of benzyloxy moiety (n=3) 
 
Compound A375 WM164 M14 RPMI M14/MDR1 B16F10 
2a 3.6±0.2 8.6±1.1 5.4±0.3 11.1±0.7 7.0±0.1 >30.0 
2b 1.9±0.1 >30.0 2.3±0.1 6.5±0.2 3.1±0.1 22.5±1.2 
2c 3.9±0.1 56.4±1.1 4.1±0.2 17.4±1.2 7.9±0.1 34.9±1.1 
2d 14.1±0.7 33.9±1.1 11.5±0.4 21.0±0.4 14.3±0.2 22.6±0.3 
2e 3.1±0.2 >30.0 15.9 ±0.6 1.3±0.2 0.9±0.1 4.7±0.1 
2f 7.6±0.1 24.5±0.4 16.7±0.1 23.8±0.6 22.0±0.3 >30.0 
6a >30.0 13.0 ±0.5 >30.0 >30.0 >30.0 >30.0 
6b 4.7 ±0.2 3.7 ±0.3 5.1±0.1 26.2±6.2 10.7±1.2 8.5±3.6 
6c 3.5 ±0.3 2.8 ±0.2 8.6±0.2 18.4±0.3 7.4±1.2 2.7±0.1 
6d 1.5 ±0.1 1.6 ±0.1 >30.0 12.9±0.2 12.2±0.2 >30.0 
6e 6.0±1.3 24.9 ± 1.0 6.7±0.3 25.3±2.4 12.2±0.5 11.6±11.6 
6f 2.9±0.15 ND 2.4±0.1 6.8±0.6 3.3±0.2 ND 
8 >30.0 20.18±0.49 >30.0 17.3±0.3 8.7±0.2 6.7±0.2 
10a 0.8 ±0.1 0.9 ±0.1 0.8 ±0.1 4.4±0.3 2.1±0.1 8.2±0.7 
 
ND: not determined 
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and 2c with a 4-chloropurine moiety exhibited 3~5-fold reduced activities. Replacement 
of the benzyloxy with other moieties as shown in compounds 2d, 2e and 2f resulted in 
significant reduction of inhibitory effects (> 3-fold). Replacing the benzyloxy with 
phenyl acetamides (analogues 6a-6d) was detrimental to the antiproliferative activities. 
Shortening the linkage by one methylene in 6b and 6d resulted in analogues 6e-6f, which 
showed similar activities to that of 6b and 6d. The introduction of a benzylurea was 
revealed to be significantly detrimental for antiproliferative activity. Among all the 
analogues in this series, analogue 10a had an indole moiety; it exhibited the most potent 
activity and had an average IC50 of 0.9 μM, which was comparable to that of MX-106. 
 
After discovered an equipotent scaffold to MX-106, we turned our effort to 
investigate the substitutional effect on the indole ring. Analogues with mono-substituent 
10b-10q and analogues with di-substituents 10r-10y were then synthesized. 
 
 
In vitro growth inhibitory effects of UC-112 analogues with mono-substitution on 
the indole moiety 
 
The in vitro assay result for analogues having mono-substituent (10a-10q) was 
shown in Table 5-2. For the 2-position substitutued analogues, 10b with a methyl group 
and 10c with an ethyl group showed slightly reduced activities compared to 10a. 
Introducing substituents to the 4-position on the indole diminished the antiproliferative 
activity, which was demonstrated by analogues 10d and 10e. For analogues that had 
substituents on the 5-position of indole, they generally displayed comparable activities to 
that of 10a; for example, compounds 10f, 10h and 10i had IC50s ranging from 0.7 to 
1.1μM; analogues 10g and 10j, which had chloro and bulky ester functional group, 
showed ~2-fold reduced activity in comparison with MX-106. In the series of analogues 
with substituents on the 6-position of the indole (10k-10o), they were generally 
equipotent to MX-106 and 10a; 10k-10o had IC50s as low as 0.7 μM. Analogues having 
substituents on the 7-position of indole were slightly less potent than corresponding 5- or 
6-position substituted counterparts. 
 
 
In vitro growth inhibitory effects of UC-112 analogues with di-substituents on the 
indole moiety 
 
Eight di-substituted indole analogues were synthesized in this series and their in 
vitro assay result was shown in Table 5-3. All the eight analogues did not show any 
improvement of activity compared to their mono-subsituted counterparts. 10t-10y were 
designed based on the most potent mono-substituted analogues 10f, 10l and 10o. 
Incorporation of a secondary substituent to 5-fluoroindole or 6-methoxyindole generally 
was not beneficial to activity; for example, 5-fluoroindole analogues 10t, 10v, 10w and 
10x had 2-ethylester, 4-fluro, 6-fluro and 6-chloro as the secondary functional group, 
respectively; they showed reduced cytotoxicities compared to 10f and had IC50s of >1.5 
μM; the 3-cyano-6-methoxy indole analogue 10u was less potent than the mono- 
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Table 5-2. In vitro growth inhibitory effects (μM) of UC-112 analogues with 
mono-substituent on the indole moiety (n=3) 
 
Compound A375 WM164 M14 RPMI7951 M14/MDR1 B16F10 
10a 0.8 ±0.1 0.9 ±0.1 0.8 ±0.1 4.4±0.3 2.1±0.1 8.2±0.7 
10b 2.2 ±0.2 7.5±1.2 1.4 ±0.2 2.2±0.2 0.7±0.1 5.7±0.8 
10c 2.0 ±0.1 8.9±1.4 1.5 ±0.2 3.2±0.4 1.1±0.1 11.5±0.9 
10d 1.6 ±0.3 6.5±0.6 1.2 ±0.2 2.2±0.2 0.8±0.1 8.9±1.7 
10e 1.8 ±0.1 7.0±0.3 2.1 ±0.1 0.6±0.1 0.6±0.1 6.8±0.2 
10f 0.7±0.2 0.7±0.2 1.9±0.4 ND ND ND 
10g 1.8 ±0.2 1.6 ±0.2 4.0 ±0.4 6.4±0.6 0.8±0.1 1.7±0.2 
10h 1.0 ±0.1 1.1 ±0.1 5.1±0.3 ND ND ND 
10i 0.7 ±0.1 0.8 ±0.1 5.6 ±0.4 3.7±0.3 2.2±0.1 1.3±0.1 
10j 1.9 ±0.2 4.7±0.6 2.4±0.2 1.5±0.1 0.8±0.1 6.0±0.1 
10k 0.9±0.1 0.7±0.1 1.3±0.1 2.7±0.5 1.3±0.1 0.6±0.1 
10l 0.9±0.4 0.9±0.4 0.8±0.4 7.7±0.5 3.8±0.1 25.5±2.4 
10m 0.9±0.1 1.4 ±0.2 3.5±0.3 5.3±0.6 0.7±0.1 1.4±0.2 
10n 0.9±0.1 0.7±0.1 2.8±0.2 4.3±0.7 2.8±0.2 1.1±0.2 
10o 0.8±0.2 0.7±0.1 0.9±0.4 6.2±0.4 2.8±0.1 >30.0 
10p 1.7±0.2 1.9±0.2 2.6±0.4 ND ND ND 
10q 2.0±0.2 11.5±0.8 1.4±0.1 2.6±0.2 0.9±0.1 9.7±0.8 
 
ND: not determined 
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Table 5-3. In vitro growth inhibitory effects (μM) of UC-112 analogues with di-
substituents on the indole moiety (n=3) 
 
Compound A375 WM164 M14 RPMI7951 M14/MDR1 B16F10 
10r 1.9 ±0.2 7.1±0.8 1.5±0.2 8.2±0.6 1.0±0.1 2.3±0.3 
10s 1.9±0.2 4.6±0.1 2.0±0.1 2.1±0.1 1.0±0.1 4.3±0.1 
10t 2.0 ±0.2 8.5±0.8 1.3 ±0.1 3.6±0.4 1.0±0.1 8.5±1.4 
10u 1.7±0.1 16.7±0.5 1.6 ±0.1 3.7±0.1 1.9±0.1 ND 
10v 1.2±0.1 2.8±0.1 2.1±0.1 0.8±0.1 0.6±0.1 2.4±0.1 
10w 1.5±0.1 3.2±0.1 2.6±0.1 1.3±0.0 0.7±0.1 3.1±0.1 
10x 2.0±0.2 4.5±0.2 2.0 ±0.2 1.7±0.1 1.0±0.1 2.1±0.1 
10y 0.7±0.1 0.9±0.1 8.5±0.2 9.3±1.1 2.2±0.1 ND 
 
ND: not determined 
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substituted counterpart 10o; 5,6-dichloroindole analogue 10y showed cytotoxicity 
comparable to that of 5-chloroindole analogue 10l. 
 
 
Inhibitory effect against P-gp overexpressed cell lines 
 
Multidrug resistance protein 1(MAP1) or P-gp belongs to the family of ATP-
binding cassette (ABC) transporters and is encoded by ABCB1 gene. P-gp is responsible 
for the decline of concentrations of extensive anticancer drugs in multidrug resistant 
cells. Therefore, the ability to overcome P-gp mediated drug-resistance is a favorable 
property for drug candidates. 
 
Other than M14 melanoma cell line, drug-resistant cell line M14/MDR1 was also 
tested to evaluate the ability of new analogue to overcome P-gp mediated drug-resistance. 
The result was shown in Table 5-4. 71% of the new indole analogues had RIs less than 1, 
indicating that most of the new indole analogues exhibited more potent inhibitory effects 
against P-gp overexpressed M14/MDR1 cell line than non-resistant M14 cell line. It is 
worthy noting that all the di-substituted indole analogues have RIs less than 1, implying 
that a secondary substituent on the indole is beneficial for the ability to overcome P-gp 
overexpression. 
 
Besides melanoma cell lines, cervical and colorectal carcinoma cell lines were 
also tested to evaluate abilities of the new analogues to surmount P-gp overexpression. 
The result was summarized in Table 5-5. The small-molecular survivin inhibitor YM-155 
showed remarkable cytotoxicity against KB-3-1 and SW620 cell lines with IC50s of 5 nM 
and 4 nM, respectively. YM155 however displayed significantly reduced activities 
against the P-gp overexpressed cell lines KB-C2 and SW620/Ad300, having IC50s of 
more than 20 μM. Similarly, paclitaxel, a notable substrate of P-gp, was not effective to 
P-gp overexpressed cell lines. In contrast, our indole analogues 10f, 10i, 10l, 10o and the 
previously reported MX-106 showed remarkably stronger inhibitory effects against P-gp 
overexpressed cell lines than non-resistant parent cell lines. In the non-resistant KB-3-1 
cell line, four compounds 10f, 10i, 10l and 10o exhibited micromolar range activities 
(from 1.3 to 1.7 μM); their IC50s were in sub-μM range (from 0.2 to 0.4 nM) aginst P-gp 
overexpressed KB-C2 cell line. 10f, 10i, 10l and 10o had IC50s ranging from 0.2 to 0.3 
μM against non-resistant SW620 cell line while their activities in P-gp overexpressed 
KB-C2 cell line were 3-6.7 folds more potent with IC50s ranging from 0.03 to 0.01 μM. 
Collectively, our new indole analogues of UC-112 can overcome drug-resistance 
mediated by P-gp overexpression. 
 
 
In vitro metabolic stability study 
 
Prior to in vivo study, the in vitro metabolic stabilities of analogues 10f, 10i, 10l 
and 10o were examined by measuring their half-life upon incubation with mouse, rat, and 
human liver microsomes in the presence of an NADPH regeneration system. The results 
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Table 5-4. In vitro growth inhibitory effects of indole analogues in P-gp 
overexpressed cell line M14/MDR1 (n=3) 
 
Compound M14 M14/MDR1 RI 
10a 0.8 ±0.1 2.1±0.1 2.6 
10b 1.4 ±0.2 0.7±0.1 0.5 
10c 1.5 ±0.2 1.1±0.1 0.7 
10d 1.2 ±0.2 0.8±0.1 0.7 
10e 2.1 ±0.1 0.6±0.1 0.3 
10f 1.9±0.4 ND ND 
10g 4.0 ±0.4 0.8±0.1 0.2 
10h 5.1±0.3 ND ND 
10i 5.6 ±0.4 2.2±0.1 ND 
10j 2.4±0.2 0.8±0.1 0.3 
10k 1.3±0.1 1.3±0.1 1.0 
10l 0.8±0.4 3.8±0.1 4.8 
10m 3.5±0.3 0.7±0.1 0.2 
10n 2.8±0.2 2.8±0.2 1.0 
10o 0.9±0.4 2.8±0.1 3.1 
10p 2.6±0.4 ND ND 
10q 1.4±0.1 0.9±0.1 0.6 
10r 1.5±0.2 1.0±0.1 0.7 
10s 2.0±0.1 1.0±0.1 0.5 
10t 1.3 ±0.1 1.0±0.1 0.7 
10u 1.6 ±0.1 1.9±0.1 1.2 
10v 2.1±0.1 0.6±0.1 0.3 
10w 2.6±0.1 0.7±0.1 0.3 
10x 2.0 ±0.2 1.0±0.1 0.5 
10y 8.5±0.2 2.2±0.1 0.3 
 
 ND: not determined; RI: resistance index, calculated by IC50(M14/MDR1)/IC50(M14). 
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Table 5-5. In vitro growth inhibitory effects of 10f, 10i, 10l and 10o in P-gp 
overexpressed cell lines (n=3) 
 
Compound 
IC50 ± SD (μM) 
RI 
IC50 ± SD (μM) 
RI 
KB-3-1 KB-C2 SW620 SW620/Ad300 
10f 1.4 ± 0.2 0.2 ± 0.0 0.14 0.2 ± 0.0 0.03 ± 0.00 0.15 
10i 1.4 ± 0.4 0.2 ± 0.0 0.14 0.2 ± 0.0 0.06 ± 0.02 0.30 
10l 1.7 ± 0.2 0.3 ± 0.0 0.18 0.23 ± 0.1 0.05 ± 0.03 0.22 
10o 1.3 ± 0.2 0.4 ± 0.1 0.31 0.3 ± 0.0 0.10 ± 0.04 0.33 
MX-106 1.3 ± 0.1 0.3 ± 0.1 0.23 0.2 ± 0.0 0.03± 0.01 0.15 
YM-155 0.005 ± 0.000 37.3 ± 4.0 7460.00 0.004 ± 0.001 23.4 ± 2.4 
585
0 
Paclitaxel 0.0005 ± 0.0001 0.3 ± 0.0 600.00 0.03 ± 0.00 2.0 ± 0.4 66.7 
Doxorubicin 0.4 ± 0.1 1.7 ± 0.4 4.25 0.21 ± 0.03 15.2 ± 2.9 72.4 
Cisplatin 1.1 ± 0.1 1.7 ± 0.1 1.55 1.8 ± 0.1 5.1 ± 0.6 2.83 
 
RI: resistance index, which is calculated by IC50(KB-C2)/IC50(KB-3-1) or 
IC50(SW620/Ad300)/IC50(SW620). 
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were summarized in Table 5-6. All compounds possessed acceptable stability profile in 
three microsome species. Four compounds were more stable in human microsome than in 
mouse and rat microsomes. Among the four analogues, 10f with a 5-fluoro was the most 
stable against mouse and rat microsomes. Therefore, 10f will be chosen for future in vivo 
animal study. 
 
 
Discussion 
 
UC-112 was previously discovered through a virtual screening program from a 
library of drug-like compounds [126]. UC-112 selectively lowered the protein level of 
survivin without affecting other members of the IAP family. In a subsequent SAR study 
of UC-112, a series of analogues were synthesized and evaluated for their 
antiproliferative activities in a panel of melanoma cell lines [214]. The result 
demonstrated that: (1) 8-hydroxyl group and the nitrogen in 8-hydroxyquinoline were 
essential for exerting maximum inhibitory effect; (2) modifications of the pyrrolidine ring 
to other heterocylcles were unsuccessful to improve activities; (3) modification of the 
benzyloxy was feasible to increase the activity. Based on this SAR result, we hypothesize 
that the benzyloxy moiety in UC-112 is too flexible; replacing the benzyloxy moiety with 
rigid moieties can improve the inhibitory activity. 
 
In this chapter, we replaced the benzyloxy in UC-112 with other substructures to 
decrease the flexibility. Within the series of analogues modifying the benzyloxy moiety 
(Figure 5-2 and Table 5-1), analogue 10a which had an indole moiety was found to exert 
the most potent antiproliferative activity against a panel of melanoma cell lines. Further 
structural optimization of 10a was focused on introducing mono-substituent and di-
substituents. The result showed that many substituted indole analogues exhibited 
comparable potencies to that of MX-106 and UC-112. Importantly, while YM155 was 
significantly less cytotoxic in resistant cell lines than in non-resistant cell lines, the new 
UC-112 analogues were more potent against several types of P-gp overexpressed cancer 
cell lines than non-resistant cell lines. 71% of the indole analogues had RIs less than 1 in 
melanoma cell lines (M14 vs M14/MDR1). 10f, 10i, 10l and 10o were >3-fold more 
cytotoxic against P-gp overexpressed cervical and colorectal carcinoma cell lines (KB-C2 
and SW620/Ad300) than non-resistant cervical and colorectal carcinoma cell lines (KB-
3-1 and SW620). 10f, 10i, 10l and 10o exhibit significant cytotoxicity against 
SW620/Ad300 cell line with IC50 as low as 30 nM. The new analogues showed favorable 
microsomal stability profile. Currently, the in vivo efficacy evaluation of the 5-F indole 
analogue (10f) in a subcutaneous mouse xenograft model with human A375 melanoma is 
undergoing. 
 
In conclusion, we herein have synthesized thirty-six new UC-112 analogues 
modifying the benzyloxy moiety. Several new analogues showed equipotency to that of 
MX-106 in melanoma cell lines. New analogues showed significant cytotoxicity against 
colorectal carcinoma cell line with IC50 as low as 0.2 μM. New UC-112 analogues also 
exhibited the ability to surmount P-gp mediated drug-resistance. 
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Table 5-6. In vitro microsomal stabilities of compounds 10f, 10i, 10l and 10o 
 
Compound 
Mouse Rat Human 
t1/2 
(hr) 
Clint 
(mL/Min/Kg) 
t1/2 
(hr) 
Clint 
(mL/Min/Kg) 
t1/2 
(hr) 
Clint 
(mL/Min/Kg) 
Verapermil 1.44±0.12 39.7  3.81±0.48 12.3  1.57±0.17 13.3 
10f 1.36±0.06 42.1  1.29±0.03 36.1  4.59±0.39 4.5 
10i 1.17±0.06 48.7  1.20±0.05 39.0  2.16±0.19 9.6 
10l 1.20±0.07 47.8  1.62±0.10 29.0  3.50±0.36 5.9 
10o 0.88±0.06 65.1  1.26±0.06 37.0  2.80±0.18 7.4 
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CHAPTER 6.    TOTAL SYNTHESIS OF BIOLOGICAL ACTIVE 20S-
HYDROXYVITAMIN D3* 
 
 
Introduction 
 
25-hydroxylase (CYP2R1 or CYP27A1) in the liver and 1α-hydroxylase 
(CYP27B1) in the kidney are the enzymes responsible for sequential metabolism of 
vitamin D3 to produce bioactive 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3, calcitriol] 
[226, 227]. 1,25(OH)2D3 activates nuclear vitamin D receptor (VDR). VDR is found in 
almost all tissues of the body and triggers numerous cellular effects including but not 
limited to stimulation of cell differentiation and/or apoptosis, inhibition of cell 
proliferation, regulation of secretory and immune factors of many cells, and cell 
protective functions, in a context dependent fashion [228-232]. Therefore, active forms of 
vitamin D can be used in therapy of cancer, hyperproliferative, autoimmune and 
metabolic disorders [233-235]. The applications are however limited by hypercalcemic 
(toxic) effect of calcitriol at pharmacological concentrations [144]. This side effect has 
led to the development of more than 3,000 synthetic vitamin D3 analogs showing low 
calcemic activity [236]. Some of these analogs such as paricalcitol, oxacalcitriol, 
falecalcitriol, tacalcitol and doxercalciferol were used to treat secondary 
hyperparathyroidism and psoriasis [233, 237]. Calcipotriol is also a promising agent for 
the treatment of pancreatic cancer and is currently undergoing human clinical trial [238] 
(Figure 6-1). 
 
Mammalian cytochrome P450 side-chain cleavage enzyme (P450scc or 
CYP11A1) not only cleaves the side chain of cholesterol to produce pregnenolone 
(precursor of all steroids) [145, 146] but also hydroxylates vitamin D3 in a sequential 
fashion [146-150] starting from C20 to form 20S-hydroxyvitamin D3 [20S-(OH)D3] (1, 
Figure 6-1). This intermediate is subsequently converted to di- and trihydroxy 
metabolites [147, 149-152]. Functional studies showed that 20S-(OH)D3 not only 
stimulated keratinocyte differentiation program but also inhibited NF-κB activity in 
human keratinocytes [153]. In addition, it has shown anti-inflammatory activities, strong 
anti-proliferative effects, anti-leukemia and tumorostatic effects [153-157], protective 
effects against ultra-violet B (UVB) induced damage [158], as well as antifibrotic activity 
in vivo [159]. These activities are mediated either through activation of the VDR [153, 
160] or inhibition of RORα and RORγ transcriptional activities [161]. More importantly, 
while having comparable anti-proliferative potency with 1,25(OH)2D3 which has strong 
hypercalcemic toxicity at a concentration of 1μg/kg, 20S-(OH)D3 is not hypercalcemic at 
concentrations as high as 60 μg/kg [154, 156, 158, 162].  
 
 
 
*Modified with permission. Qinghui Wang, Zongtao Lin, Tae-Kang Kim, Andrzej T. 
Slominski, Duane D. Miller, Wei Li. Total synthesis of biologically active 20S-
hydroxyvitamin D3. Steroids, 2015, 104: 153-162 
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Figure 6-1. Marketed vitamin D analogs and noncalcemic 20S-(OH)D3 
  
 110 
In-depth evaluation of the biological activity for 20S-(OH)D3 or its analogs was 
hampered by lack of an efficient synthetic method of its production [239] without using 
costly enzymatic approaches [150, 151, 240]. 20S-(OH)D3 was first chemically 
synthesized from pregnenolone acetate via Grignard reaction and low yielding UVB 
irradiation to afford low milligram scale of 20S-(OH)D3 stereo-specifically. However, 
this method also generated structurally similar and physicochemically active by-products 
including previtamin D3, lumisterol and tachysterol which presented a significant 
challenge in the purification of 20S-(OH)D3 even through preparative HPLC [239]. Due 
to these disadvantages, scope of synthesis through UVB irradiation of 5,7-dienal 
precursor, 20S-(OH)-7-dehydrocholesterol was confined to very few derivatives, if not to 
almost exclusive production of 20S-(OH)D3. Therefore, an approach that could easily 
generate large quantity of 20S-(OH)D3 with high quality ( > 98% purity) would facilitate 
further modifications on the side chain to determine the structure-activity relationships of 
this promising 20S-hydroxyl scaffold. Herein, we report an efficient total synthetic route 
for stereospecific 20S-(OH)D3.  
 
 
Experimental Section 
 
 
General chemistry 
 
Tetrahydrofuran was distilled from sodium-benzophenone. All other solvents and 
chemical reagents were obtained from commercial sources and directly used without 
further purification. Ergocalciferol was purchased from Chem Impex International Inc. 
Glassware was oven-dried before use. All reactions were performed under an argon 
atmosphere. TLC was performed on silica gel 60 GF254 and monitored under UV light 
or visualized using phosphomolybdic acid reagent. Flash chromatography was performed 
on 230-400 mesh silica gel (Fisher Scientific). Preparative TLC was performed on 
Analtech TLC Uniplates (250 μm). Melting points were recorded on a MPA100 
Automated Melting Point Apparatus. NMR spectra were obtained on a Bruker Ascend 
400 (Billerica, MA) spectrometer or a Varian Inova-500 spectrometer (Agilent 
Technologies, Santa Clara, CA). HR-MS were obtained on Waters Acquity UPLC linked 
to Waters Acquity Photodiode Array Detector and Waters Acquity Single Quadrupole 
Mass Detector. Chemical shifts are given in ppm with tetramethylsilane (TMS) as an 
internal reference. All coupling constants (J) are given in Hertz (Hz). 
 
 
Chemical synthesis  
 
(4R,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-4-((R,Z)-1-hydroxy-2-
((S)-5-hydroxy-2-methylenecyclohexylidene)ethyl)-7a-methyloctahydro-1H-inden-4-
ol (2). Following a reported procedure [241], to a solution of ergocalciferol (20 g, 50.5 
mmol) in ethanol (2 L) at -45 oC was added dropwise solution of potassium 
permanganate (9.0 g, 58.7 mmol) in water (300 mL), the mixture was stirred for half an 
hour and further 1 hour at -15 oC and then warmed to room temperature. After 3 hours, 
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the precipitate was filtered off and the solution was evaporated to give yellowish crude 
oil. The crude oil was purified on silica gel column chromatography eluting with 
hexane/ethyl acetate (3:1) to give pure triol compound 2 as white solid (10.5 g, 65%) and 
unreacted starting material (5.1 g). Mp: 170-172 qC (MeOH). 1H NMR (400 MHz, 
CD3OD): δ 5.52 (dd, J = 9.9, 1.7 Hz, 1H, 6-H), 5.30 – 5.09 (m, 2H, 22/23-H), 5.02 – 4.98 
(m, 2H, 7/19-H), 4.90 (d, J = 9.9 Hz, 1H, 19-H), 3.65 (m, 1H, 3-H), 2.55 (ddd, J = 12.4, 
4.5, 1.9 Hz, 1H), 2.49 – 2.38 (m, 1H), 2.17 – 1.90 (m, 5H), 1.90 – 1.68 (m, 4H), 1.62 (m, 
1H), 1.56 – 1.39 (m, 4H), 1.39 – 1.03 (m, 5H), 1.00 (d, J = 6.6 Hz, 3H, 21-H), 0.94 (d, J 
= 6.8 Hz, 3H, 28-H), 0.89 – 0.81 (t, J = 6.4 Hz, 9H, 18/26/27-H). 13C NMR (101 MHz, 
CD3OD): δ 147.35, 140.78, 137.06, 133.12, 126.72, 111.72, 76.25 (C7), 71.42 (C8 or 
C3), 71.39 (C3 or C8), 61.04, 58.79, 47.60, 45.14, 44.36, 41.70, 41.53, 39.23, 37.21, 
34.50, 34.38, 29.13, 22.87, 21.76, 21.29, 20.52, 20.12, 18.27, 13.59. ESI-HRMS: 
calculated for C28H46O3Na [M+Na]+ 453.3345, found 453.3352. 
 
(S,Z)-3-(2-hydroxyethylidene)-4-methylenecyclohexanol(3) and (4S,7aR)-1-
((2R,5R,E)-5,6 -dimethylhept-3-en-2-yl)-7a-methyloctahydro-1H-inden-4-ol (4). To a 
suspension of 2 (6.0 g, 13.9 mmol) and sodium carbonate (14.6 g, 138 mmol) in 
dichloromethane (50 mL) was added lead tetraacetate (6.7 g, 15.3 mmol) in portions at 0 
°C. After 2 hours, the reaction was quenched with ethylene glycol and the mixture was 
vigorously stirred at 0 °C for 10 minutes. Water was then added and the mixture was 
extracted with dichloromethane for five times, washed with brine and dried with Na2SO4. 
The combined extracts were evaporated to give crude oil mixture, which was used for 
next step without further purification. To a solution of the above crude oily mixture in 
benzene (100 mL) at 0 °C under argon with stirring, Red-Al (28.7 mmol, 8.6 mL) was 
added dropwise and the mixture was stirred for 2 hours. On completion reaction was 
quenched with water. The mixture was filtered off and extracted with ethyl acetate, 
washed with brine and dried with anhydrous Na2SO4. Organic phase was evaporated to 
generate crude oil mixture which was purified by flash chromatography on silica.  Elution 
with hexane/ethyl acetate (10:1) gave pure alcohol compound 4 as transparent oil (3.3 g, 
86% for two steps), further elution with hexane/ethyl acetate (1:2) gave pure allylic 
alcohol 3 as colorless oil (0.91 g, 43% for two steps). compound 3: 1H NMR (400 MHz, 
CDCl3): δ 5.45 (t, J = 6.6 Hz, 1H, 6-H), 4.97 (dd, J = 2.4, 1.3 Hz, 1H, 19-H), 4.59 (d, J = 
2.3 Hz, 1H, 19-H), 4.25 (ddd, J = 12.7, 7.0, 1.2 Hz, 1H, 7-H), 4.14 (ddd, J = 12.6, 6.2, 1.3 
Hz, 1H, 7-H), 3.94 (m, 1H, 3-H), 2.56 – 2.33 (m, 2H), 2.24 (dd, J = 13.2, 7.1 Hz, 1H), 
2.19 – 2.06 (m, 1H), 1.87 (m, 1H), 1.75 – 1.60 (m, 1H). 13C NMR (101 MHz, CDCl3): δ 
144.51 (C10), 139.11 (C5), 125.95 (C6), 112.23 (C19), 68.64 (C3), 59.34 (C7), 44.82, 
34.62, 31.45. ESI-HRMS: calculated for C9H11, [M-2H2O+H]+ 119.0861, found 
119.0861. compound 4: 1H NMR (400 MHz, CDCl3): δ 5.25 – 5.02 (m, 2H, C22/23-H), 
4.02 (d, J = 2.8 Hz, 1H, C8-H), 2.04 – 1.88 (m, 2H), 1.86 – 1.73 (m, 3H), 1.73 – 1.60 (m, 
1H), 1.56 – 1.33 (m, 5H), 1.33 – 1.02 (m, 5H), 0.96 (d, J = 6.6 Hz, 3H, 22-H), 0.92 (s, 
3H, C18-H), 0.89 (d, J = 11.2 Hz, 3H, 23-H), 0.80 (t, J = 6.6 Hz, 6H, C26/27-H). 13C 
NMR (101 MHz, CDCl3): δ 135.59, 131.70, 69.14 (C8), 56.48, 52.72, 42.78, 41.65, 
40.32, 39.75, 33.53, 33.00, 27.57, 22.46, 20.71, 19.88, 19.55, 17.57, 17.40, 13.61. ESI-
HRMS: calculated for C19H33 [M-H2O+H]+ 261.2582, found 261.2582.  
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(S,Z)-tert-butyl(2-(5-((tert-butyldimethylsilyl)oxy)-2-
methylenecyclohexylidene)ethoxy)dimethylsilane (5). Imidazole (1.4 g, 21.2 mmol) 
and tert-butyldimethylsilyl chloride (4.8 g, 31.6 mmol) was sequentially added to a 
solution of compound 3 (0.82 g, 5.3 mmol) in dichloromethane (50 mL) in a round 
bottom flask with stirring. The resulting suspension was stirred for 2 hours. Water was 
then added and the mixture was extracted with dichloromethane, washed with brine and 
dried with anhydrous Na2SO4. Evaporation under vacuum gave the oily residue which 
was subjected to flash chromatography on silica. Elution with hexane/ethyl acetate (80:1) 
gave pure compound 5 as colorless oil (1.8 g, 88%). 1H NMR (400 MHz, CDCl3): δ 5.38 
(ddt, J = 6.8, 5.3, 1.3 Hz, 1H, 6-H), 4.95 (p, J = 1.1 Hz, 1H, 19-H), 4.57 (dd, J = 2.4, 1.3 
Hz, 1H, 19-H), 4.31 (ddt, J = 13.0, 7.2, 0.9 Hz, 1H, 7-H), 4.21 (ddd, J = 12.9, 5.3, 2.1 Hz, 
1H, 7-H), 3.82 (tt, J = 8.9, 3.9 Hz, 1H, 3-H), 2.47 – 2.31 (m, 2H), 2.22 – 2.13 (m, 1H), 
2.06 (m, 1H), 1.93 – 1.80 (m, 1H), 1.56 (m, 1H), 0.89 (d, J = 4.7 Hz, 18H, TBS), 0.08 – 
0.03 (s, 12H, TBS). 13C NMR (101 MHz, CDCl3): δ 144.89 (C10), 138.24 (C5), 126.29 
(C6), 111.95 (C19), 70.11 (C3), 60.59 (C7), 45.93, 36.03, 32.15, 26.01 (TBS), 25.86 
(TBS), 18.43, 18.18, -4.65 (TBS), -4.69 (TBS), -4.99 (TBS), -5.05 (TBS). ESI-HRMS: 
calculated for C21H42O2Si2Na [M+Na]+ 405.2621, found 405.2629. 
 
(S,Z)-2-(5-((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethanol 
(6). To a solution of compound 5 (1.7 g, 4.4 mmol) in anhydrous THF (20 mL) in a round 
bottom flask at -5 °C under nitrogen, tetra-n-butylammonium fluoride (1.0 M in THF,  
4.8 mmol) was added dropwise with stirring. The resulting mixture was stirred for 3 
hours, water was then added and the brown mixture was extracted with dichloromethane, 
washed with brine and dried with anhydrous Na2SO4. The combined extracts were 
evaporated under vacuum to give the oily residue which was purified with flash 
chromatography on silica. Pure allylic alcohol 6 was eluted out with hexane/ethyl acetate 
(50:1) as colorless oil (0.93 g, 78%). 1H NMR (400 MHz, CDCl3): δ 5.44 (ddt, J = 7.3, 
5.9, 1.3 Hz, 1H, 6-H), 4.96 (d, J = 1.2 Hz, 1H, 19-H), 4.62 (t, J = 2.4 Hz, 1H, 19-H), 4.43 
– 4.01 (m, 2H, 7-H), 3.84 (m, 1H, 3-H), 2.48 – 2.33 (m, 2H), 2.26 – 2.14 (m, 1H), 2.13 – 
2.01 (m, 1H), 1.87 (m, 1H), 1.58 (m, 1H), 0.88 (s, 9H, TBS), 0.06 (d, J = 2.9 Hz, 6H, 
TBS). 13C NMR (101 MHz, CDCl3):  δ 144.83, 140.52, 124.88, 111.91, 70.11 (C3), 59.82 
(C7), 46.02, 35.98, 32.26, 25.82 (TBS), 18.15, -4.67 (TBS), -4.71 (TBS). ESI-HRMS: 
calculated for C15H28O2SiNa [M+Na]+ 291.1756, found 291.1755. 
 
(S,Z)-(2-(5-((tert-butyldimethylsilyl)oxy)-2-
methylenecyclohexylidene)ethyl)diphenylphosphine oxide (7). To a solution of the 
allylic alcohol 6 (0.81 g, 3.0 mmol) in anhydrous THF (20 mL) was added n-BuLi (2.5 M 
in hexanes, 30.0 mmol) under argon at 0 °C with stirring. After 5 minutes, a solution of 
p-tosyl chloride (598 mg, 3.15 mmol) dissolved in anhydrous THF (10 mL) was added to 
the allylic alcohol-BuLi solution. On the other side, to a solution of diphenylphosphine 
(1.02 mL, 6.0 mmol) in anhydrous THF (5 mL) under argon at 0 °C with stirring n-BuLi 
(2.5 M in hexanes, 2.2 mL, 5.7 mmol) was added dropwise to provide a red solution. 
After 10 minutes 4.1 mL of the red solution was then drawn to add to the solution of 
tosylate. The mixture was stirred for 30 minutes at 0 °C and quenched with H2O (1 mL). 
Evaporation of the solution under vacuum gave a phosphine residue. To the phosphine 
residue in dichloromethane (15 mL) at 0 °C with stirring was added 10% H2O2 (1.1 mL). 
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Reaction was quenched with water, extracted with dichloromethane, washed with cold 
saturated sodium sulfite solution and brine and dried with Na2SO4. Organic solvent was 
removed under vacuum to give crude residue which was subjected to flash 
chromatography on silica for purification. Elution with hexane/ethyl acetate (3:1) gave 
pure phosphine oxide compound 7 as white solid (800 mg, 59%). Mp: 94-96 oC (EtOAc). 
1H NMR (400 MHz, CDCl3): δ 7.71 (m, 4H, Ph), 7.56 – 7.36 (m, 6H, Ph), 5.35 (q, J = 
7.2 Hz, 1H, 6-H), 4.92 (t, J = 1.9 Hz, 1H, 19-H), 4.68 (dd, J = 2.4, 1.3 Hz, 1H, 19-H), 
3.52 (m, 1H, 3-H), 3.36 (m, 1H, 7-H), 3.20 (m, 1H, 7-H), 2.44 – 2.31 (m, 1H), 2.22 (dt, J 
= 13.3, 4.7 Hz, 1H), 2.15 – 2.05 (m, 1H), 1.81 – 1.71 (m, 1H), 1.66 (m, 1H), 1.47 (m, 
1H), 0.83 (s, 9H, TBS), -0.00 (d, J = 2.0 Hz, 6H, TBS); 13C NMR (101 MHz, CDCl3): δ 
145.03, 145.01, 142.62, 142.50, 133.49, 132.99, 132.52, 132.00, 131.75, 131.73, 131.61, 
131.58, 131.20, 131.11, 130.95, 130.86, 128.59, 128.48, 128.44, 128.32, 113.19, 113.11, 
111.60, 111.59, 70.46 (C3), 70.43, 46.68, 46.66, 36.21, 32.48, 32.46, 31.44, 30.74, 25.82 
(TBS), 18.12, -4.69 (TBS), -4.75 (TBS). ESI-HRMS: calculated for C27H37O2PSiNa 
[M+Na]+ 475.2198, found 475.2203. 
 
(4S,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-1H-
inden-4-yl acetate (8). Pyridine (1.3 mL, 16.1 mmol), 4-dimethylaminopyridine (352 
mg, 2.88 mmol) and acetyl anhydride (0.98 mL, 104 mmol) was sequentially added to a 
solution of compound 4 (3.2 g, 11.5 mmol) in anhydrous dichloromethane (30 mL) in a 
round bottom flask under argon. The resulting mixture was stirred for 3 hours. Water was 
then added and the mixture was extracted with dichloromethane, washed with saturated 
NaHCO3, 0.1 M HCl and brine and then dried with Na2SO4. Evaporation under vacuum 
gave the oily residue which was purified with flash chromatography on silica.  Elution 
with hexane/ethyl acetate (30:1) gave pure compound 8 as colorless oil (3.4 g, 92%). 1H 
NMR (400 MHz, CDCl3): δ 5.31 – 5.00 (m, 3H, 8/22/23-H), 2.12 – 1.92 (m, 5H), 1.92 – 
1.53 (m, 4H), 1.53 – 1.03 (m, 10H), 0.99 (d, J = 2.4 Hz, 3H, 22-H), 0.94 – 0.85 (m, 6H), 
0.82 (t, J = 6.8 Hz, 6H, 26/27-H). 13C NMR (101 MHz, CDCl3): δ 170.73 (acetyl), 
135.47, 131.90, 71.35 (C8), 56.31, 51.41, 42.79, 41.82, 39.90, 39.84, 33.05, 30.50, 27.47, 
22.61, 21.31, 20.77, 19.93, 19.60, 17.90, 17.60, 13.17. ESI-HRMS: calculated for 
C21H36O2Na [M+Na]+ 343.2613, found 343.2614. 
 
(4S,7aR)-1-((2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl)-7a-
methyloctahydro-1H-inden-4-yl acetate (9). To a solution of the compound 8 (3.3 g, 
10.3 mmol) in acetone (40 mL) was added N-methylmorpholine N-oxide (6.0 g, 51.5 
mmol) and 2.5% osmium tetroxide in tert-butanol (6.5 mL, 0.52 mmol) at room 
temperature with stirring. After 48 hours, water and ethyl acetate was added and the 
organic phase was separated, washed with brine and dried with Na2SO4. Evaporation 
under vacuum gave the oily residue which was purified with flash chromatography on 
silica. Elution with hexane/ethyl acetate (10:1) gave pure compound 9 as colorless oil 
(2.44 g, 67%). 1H NMR (400 MHz, CDCl3): δ 5.14 (d, J = 2.6 Hz, 1H, 8-H), 3.71 (dd, J = 
2.4, 4.4 Hz, 1H, 22-H), 3.59 (t, J = 2.8 Hz, 1H, 23-H), 2.39 (s, 1H), 2.04 (s, 4H), 1.94 – 
1.79 (m, 2H), 1.70 (m, 5H), 1.55 – 1.09 (m, 9H), 1.00 (d, J = 6.9 Hz, 3H, 21-H), 0.96 (d, 
J = 6.7 Hz, 3H, 28-H), 0.92 – 0.84 (m, 9H, 18/26/27-H). 13C NMR (101 MHz, CDCl3):  δ 
170.80 (acetyl), 73.26 (C23), 71.19 (C8), 70.26 (C22), 53.02, 51.04, 44.11, 43.93, 42.45, 
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41.65, 40.00, 30.49, 29.89, 29.75, 26.91, 22.82, 21.44, 21.34, 18.94, 17.88, 13.91, 13.52, 
12.83, 9.91. ESI-HRMS: calculated for C21H38O4Na [M+Na]+ 377.2668, found 377.2668.  
 
(4S,7aR)-7a-methyl-1-((S)-1-oxopropan-2-yl)octahydro-1H-inden-4-yl acetate 
(10). To a suspension of compound 9 (2.2 g, 6.2 mmol) in THF-H2O (4:1, 10 mL), 
sodium periodate (1.45 g, 6.82 mmol) was added at 0 °C in portions with stirring. After 1 
hour, the reaction was quenched with ethylene glycol and the mixture was stirred at 0 °C 
for 10 minutes. Water was then added and the mixture was extracted with ethyl acetate 
for three times, washed with brine and dried with Na2SO4. The combined extracts were 
evaporated to give crude oil, which was purified with flash chromatography on silica.  
Elution with hexane/ethyl acetate (5:1) gave pure compound 10 as transparent oil (1.03 g, 
66%). 1H NMR (400 MHz, CDCl3): δ 9.57 (d, J = 3.2 Hz, 1H, CHO ), 5.17 (d, J = 2.0 
Hz, 1H, 8-H), 2.36 (m, 1H, 20-H), 2.05 (s, 3H), 1.97 (dt, J = 12.3, 3.3 Hz, 1H), 1.89 – 
1.71 (m, 3H), 1.59 – 1.24 (m, 8H), 1.11 (d, J = 6.8 Hz, 3H, 21-H), 0.93 (s, 3H, 18-H). 13C 
NMR (101 MHz, CDCl3): δ 204.78 (CHO), 170.70 (acetyl), 70.89 (C8), 51.37, 50.74, 
49.17, 42.47, 39.75, 30.47, 26.00, 22.95, 21.32, 17.83, 13.42, 13.35. ESI-HRMS: 
calculated for C15H23O2 [M-H2O+H]+ 235.1698, found 235.1696. 
 
(1S,4S,7aS)-1-acetyl-7a-methyloctahydro-1H-inden-4-yl acetate (12). To a 
stirred solution of compound 10 (1.0 g, 3.9 mmol) in benzene (8 mL) was added 
morpholine (0.524 mL, 4.8 mmol) and p-toluenesulfonic acid (34mg, 0.195 mmol). The 
mixture was refluxed over a Dean-Stark water separator overnight. During the course of 
the reaction the theoretical amount of water (~70 mg) was separated. Upon completion as 
indicated by mass spectrum, the reaction mixture was cooled to room temperature and 
solvent was removed under vacuum to afford yellowish oil which was immediately used 
for next step. To a stirred solution of the above crude mixture  in acetone (20 mL) was 
added alumina (481 mg, 4.72 mmol) supported potassium permanganate (616 mg, 3.9 
mmol) in portions. The reaction mixture was filtered after 2 hours and washed with ethyl 
acetate. Solvents were removed under vacuum to afford crude oily product which was 
purified with flash chromatography on silica. Elution with hexane/ethyl acetate (6:1) gave 
pure compound 12 as colorless oil (659 mg, 70% for two steps). 1H NMR (400 MHz, 
CDCl3): δ 5.16 (d, J = 2.8 Hz, 1H, 8-H), 2.48 (dd, J = 10.0, 8.0 Hz, 1H, 17-H), 2.20 – 
1.99 (m, 8H), 1.92 – 1.82 (m, 1H), 1.70 – 1.39 (m, 8H), 0.81 (s, 3H, 18-H). 13C NMR 
(101 MHz, CDCl3): δ 208.52 (C20), 170.26 (acetyl), 70.27 (C8), 63.54, 51.15, 43.06, 
38.85, 31.26, 30.08, 22.54, 21.46, 20.98, 17.64, 14.51 (C18). ESI-HRMS: calculated for 
C14H22O3Na [M+Na]+ 261.1467, found 261.1467. 
 
(1S,4S,7aS)-1-((S)-2-hydroxy-6-methylheptan-2-yl)-7a-methyloctahydro-1H-
inden-4-ol (14). To a stirred suspension of magnesium (181 mg, 7.5 mmol) in anhydrous 
THF (10 mL) was added 1-bromo-4-methyl-pentane ( 0.733 mL, 5.0 mmol ) under argon 
at room temperature. The mixture was then refluxed for 2 hours and cooled down in ice 
bath to give Grignard reagent 13 which was used without further purification. Compound 
12 (100 mg, 0.42 mmol) in 2 mL THF was subsequently added to the reaction mixture 
which was warmed to room temperature after 30 minutes and stirred overnight. Cooled 
saturated NH4Cl solution was added to quench the reaction and the mixture was extracted 
with ethyl acetate for three times, washed with brine and dried with Na2SO4. The 
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combined extracts were evaporated to give crude oil, which was purified with flash 
chromatography on silica. Elution with hexane/ethyl acetate (3:1) afforded pure 
compound 14 as colorless oil (94 mg, 80%). 1H NMR (400 MHz, CDCl3): δ 4.09 (d, J = 
2.8 Hz, 1H, 8-H), 2.14 – 2.02 (m, 1H), 1.91 – 1.74 (m, 3H), 1.74 – 1.37 (m, 9H), 1.37 – 
1.08 (m, 14H), 0.87 (dd, J = 6.7, 0.8 Hz, 6H, 26/27-H). 13C NMR (101 MHz, CDCl3): δ 
75.14 (C20), 69.41 (C8), 57.82, 52.55, 44.10, 42.52, 40.77, 39.56, 33.42, 27.92, 26.29, 
22.71, 22.55, 22.21, 21.94, 21.30, 17.39, 15.44. ESI-HRMS: calculated for C18H31 [M-
2H2O+H]+ 247.2426, found 247.2430. 
 
(1S,7aR)-1-((S)-2-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1H-
inden-4(2H)-one (15). To a stirred solution of compound 14 (84 mg, 0.3 mmol) in 
dichloromethane (10 mL) was added pyridinium dichromate (225 mg, 0.6 mmol) at room 
temperature. The reaction mixture was stirred for 1 hour and filtered through celite.  The 
celite was washed with dichloromethane and the combined solvent was removed under 
vacuum to give crude oily product which was purified with flash chromatography on 
silica.  Elution with hexane/ethyl acetate (8:1) gave pure compound 15 as colorless oil 
(74 mg, 89%). 1H NMR (400 MHz, CDCl3):  δ 2.43 (dd, J = 10.5, 6.9 Hz, 1H, 9-H), 2.33 
– 2.13 (m, 3H, 9/12/14-H), 2.07 – 1.83 (m, 2H), 1.82 – 1.66 (m, 4H), 1.66 – 1.40 (m, 
4H), 1.35 – 1.10 (m, 9H), 0.87 (d, J = 6.6 Hz, 6H, 26/27-H), 0.80 (s, 3H, 18-H)). 13C 
NMR (101 MHz, CDCl3): δ 211.99 (C8), 74.63 (C20), 62.10, 58.04, 49.84, 44.07, 40.80, 
39.47, 39.26, 27.89, 26.53, 23.90, 22.67, 22.52, 21.95, 21.77, 18.73, 14.37. ESI-HRMS: 
calculated for C18H31O [M-H2O+H]+ 263.2375, found 263.2377. 
 
(1S,7aR)-1-((S)-2-(ethoxymethoxy)-6-methylheptan-2-yl)-7a-
methylhexahydro-1H-inden-4(2H)-one (16). To a stirred solution of compound 15 (67 
mg, 0.24 mmol), N,N-diisopropylethylamine (83 μL, 0.48 mmol) and 4-
dimethylaminopyridine (12 mg, 0.096 mmol) in anhydrous dichloromethane (3 mL) was 
added chloromethyl ethyl ether (45 μL, 0.48 mmol) dropwise at ice temperature. The 
resulting mixture was stirred for overnight at room temperature. Water was then added 
and the reaction mixture was extracted with dichloromethane, washed with brine and 
dried with Na2SO4. The combined extracts were evaporated under vacuum to give the 
oily residue which was separated with flash chromatography on silica.  Elution with 
hexane/ethyl acetate (30:1) gave pure compound 16 as colorless oil (73 mg, 90%). 1H 
NMR (400 MHz, CDCl3): δ 4.81 – 4.64 (m, 2H, EOM), 3.69 – 3.45 (m, 2H, EOM), 2.41 
(dd, J = 11.5, 7.0 Hz, 1H), 2.32 – 2.06 (m, 3H), 2.03 – 1.43 (m, 11H), 1.31 (s, 3H, 21-H), 
1.26 – 1.09 (m, 7H), 0.86 (dd, J = 6.6, 0.9 Hz, 6H, 26/27-H), 0.76 (s, 3H, 18-H). 13C 
NMR (101 MHz, CDCl3): δ 212.17 (C8), 88.76 (EOM), 79.75 (C20), 63.20 (EOM), 
62.19, 57.31, 49.72, 40.83, 40.26, 39.70, 39.40, 27.87, 23.92, 23.21, 22.70, 22.57, 22.50, 
21.70, 18.74, 15.14, 14.66. ESI-HRMS: calculated for C21H38O3Na [M+Na]+ 361.2719, 
found 361.2719. 
 
Tert-butyl(((1S,Z)-3-((E)-2-((1S,7aS)-1-((S)-2-(ethoxymethoxy)-6-
methylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-
methylenecyclohexyl)oxy)dimethylsilane (17). To a stirred solution of compound 7 (51 
mg, 0.15 mmol) in anhydrous THF (3 mL) was added phenyllithium (1.8 M in hexanes, 
0.37 mmol) under argon at -78 oC. The mixture was stirred for another 30 minutes at this 
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temperature and was added precooled compound 16 (167 mg, 0.37 mmol) in 100μL 
anhydrous THF. Reaction was kept stirring at this temperature for 3 hours and further 12 
hours at room temperature. Water was then added and the reaction mixture was extracted 
with ethyl acetate, washed with brine and dried with Na2SO4. The combined extracts 
were evaporated under vacuum to give the oily residue which was purified with flash 
chromatography on silica.  Elution with hexane/ethyl acetate (30:1) gave pure compound 
17 as colorless oil (45 mg, 52%). 1H NMR (400 MHz, CDCl3): δ 6.16 (d, J = 11.2 Hz, 
1H, 6-H), 6.01 (d, J = 11.2 Hz, 1H, 7-H), 5.02 (s, 1H, 19-H), 4.85 – 4.64 (m, 3H, 19-H 
and EOM), 3.81 (m, 1H, H-3), 3.71 – 3.50 (m, 2H, EOM), 2.82 (d, J = 12.4 Hz, 1H, 9-H), 
2.44 (dd, J = 13.0, 4.2 Hz, 1H), 2.36 (dt, J = 13.5, 4.8 Hz, 1H), 2.28 – 2.17 (m, 1H), 2.16 
– 1.93 (m, 3H), 1.93 – 1.79 (m, 2H), 1.77 – 1.44 (m, 13H), 1.39 – 1.08 (m, 12H), 0.87 (d, 
J = 7.7 Hz, 15H, 26/27-H and TBS), 0.67 (s, 3H, 18-H), 0.06 (d, J = 2.2 Hz, 6H, TBS); 
13C NMR (101 MHz, CDCl3): δ 145.34 (C10), 141.18 (C8), 136.36 (C5), 121.32 (C6), 
118.21 (C7), 112.13 (C19), 88.80 (EOM), 80.42 (C20), 70.54 (C3), 63.14 (EOM), 57.38, 
56.63, 46.84, 45.73, 40.98, 40.30, 39.79, 36.34, 32.73, 28.80, 27.94, 25.99, 25.96, 25.91, 
25.88, 23.32, 22.97, 22.77, 22.55, 21.98, 21.91, 18.18, 15.19, 14.15, -4.59 (TBS), -4.63 
(TBS). ESI-HRMS: calculated for C36H64O3SiNa [M+Na]+ 595.4522, found 595.4509. 
 
(1S,Z)-3-((E)-2-((1S,7aS)-1-((S)-2-hydroxy-6-methylheptan-2-yl)-7a-
methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexanol (1). 
To a stirred solution of compound 17 (10 mg, 0.017 mmol) in MeOH-DCM (5:1, 3 mL) 
was added camphorsulfonic acid (4.3 mg, 0.020 mmol) at room temperature. The mixture 
was stirred for 3 hours and saturated NaHCO3 was added. The mixture was extracted 
with dichloromethane, washed with brine and dried with Na2SO4. The combined extracts 
were evaporated under vacuo to give the oily residue which was purified with preparative 
TLC (hexane/ethyl acetate = 5:1) to afford pure compound 1 as colorless solid (2.6 mg, 
37%). Mp: 91-93 oC (MeOH). 1H NMR (400 MHz, CD3OD): δ 6.22 (d, J = 11.2 Hz, 1H, 
6-H), 6.02 (d, J = 11.2 Hz, 1H, 7-H), 5.08 – 5.00 (s, 1H, 19-H), 4.74 (d, J = 1.6 Hz, 1H, 
19-H), 3.76 (m, 1H, 3-H), 2.85 (dd, J = 11.9, 4.0 Hz, 1H, 9-H), 2.58 – 2.48 (dd, 13.0, 4.2, 
1H, 4-H), 2.40 (dt, J = 13.6, 4.9 Hz, 1H, 1-H), 2.25 – 1.91 (m, 5H), 1.81 – 1.62 (m, 5H), 
1.61 – 1.43 (m, 6H), 1.43 – 1.09 (m, 11H), 0.89 (d, J = 6.6 Hz, 6H, 26/27-H), 0.69 (s, 3H, 
18-H). 13C NMR (101 MHz, CD3OD): δ 147.00 (C10), 142.30 (C8), 137.34 (C5), 122.61 
(C6), 119.37 (C7), 112.65 (C19) , 75.99 (C20), 70.55 (C3), 59.89, 57.80, 47.02, 45.11, 
42.25, 40.95, 36.60, 33.59, 29.84, 29.17, 26.15, 24.44, 23.16, 23.06, 23.02, 22.97, 14.14. 
ESI-HRMS: calculated for C27H44O2Na [M+Na]+ 423.3239, found 423.3235. 
 
 
Chemistry 
 
A retrosynthetic strategy was proposed as Scheme 6-1. The vitamin D3 scaffold 
could be established by Wittig-Horner coupling reaction between phosphine oxide 7 and 
C/D-ring fragment 16. Due to steric effect of 18-methyl, stereoselective generation of 
20S-hydroxy of 16 could be achieved using Grignard reagent 13 to attack 12. In addition, 
introducing a relatively bulky protecting group on 8S-hydroxy was envisioned to assist 
the stereoselectivity of Grignard reaction. Conversion of VD2 to 7 and 12 could be  
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Scheme 6-1. Retrosynthetic analysis of 20S-(OH)D3 
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carried out through oxidative cleavages. 
 
The synthesis of phosphine oxide 7 and protected C/D-ring ketone 12 were 
performed following literature reports [241, 242]. To prepare 7 and 12 in large scale so as 
to facilitate future structure-activity relationship studies, we modified the synthesis which 
were outlined as Scheme 6-2 and Scheme 6-3. Initially, commercially available 
ergocalciferol was regioselectively dihydroxylated on the triene linkage to provide triol 2 
with a yield of 65% when treating with potassium permanganate in ethanol at low 
temperature. Due to steric effect of 18-methyl, single 7R,8R-diostereoisomer was 
exclusively isolated over chromatography [241]. It is worth mentioning that when 3-OH 
was protected with TBS, dihydroxylation of the triene did not proceed. Subsequent 
treatment of vicinol 2 with lead tetraacetate in dichloromethane in the presence of sodium 
carbonate led to formation of corresponding C/D-ring ketone and A-ring allylic aldehyde. 
Although complete consumption of 2 was indicated on TLC, after workup procedures 
and purification using flash chromatography, A-ring allylic aldehyde ended up with poor 
yield (<20%) while C/D-ring ketone was obtained in 94% yield. We found that A-ring 
allylic aldehyde was unstable when exposed to air and moisture as clearly indicated by its 
spot on TLC and it should be used immediately. Thus, after quenching the oxidation 
reaction with ethylene glycol followed by simple workup procedure the crude mixture 
was directly used without purification to the following reduction step using excess 
equivalent of sodium bisaluminumhydride (65% in toluene) in benzene at 0 oC. 
Gratifyingly, these modified procedures afforded pure A-ring allylic alcohol 3 and C/D-
ring alcohol 4 with yield of 43% and 86% for two steps after chromatography, 
respectively. It is worth noting that after TLC indicated completion of the oxidation 
reaction, quenching the reaction by adding ethylene glycol was crucial to prevent further 
oxidation of the aldehyde to carboxylic acid. In addition, compared with lithium 
aluminum hydride (LAH) and diisobutylaluminium hydride (DIBAL-H in toluene or 
tetrahydrofuran), Red-Al (>65% in toluene) was more efficient and regioselective 
toreduce only aldehyde rather than conjugated diene to form3. Compound 3 was 
subsequently protected with TBS to generate 5, which underwent selective removal of 
TBS on the allylic moiety to produce alcohol 6 in 71% yield for two steps when stirring 
with tetra-n-butylammonium fluoride (TBAF) in THF under low temperature (-5 oC to 
ice temperature). The final A-ring intermediate phosphine oxide 7 was prepared 
following literature procedures in three steps with 59% overall yield [242].  
 
Acetate 8 was produced when secondary alcohol 4 was treated with acetic 
anhydride and pyridine. Compound 8 was subjected to Upjohn reaction stirring with 
osmium tetroxide (0.5% wt in t-butanol) and N-methylmorpholine N-oxide in acetone at 
ambient temperature for 48 hr to form the major diastereoisomer 9 due to strong steric 
effect of 21- and 24-methyl groups. While TLC indicated existence of the other 
diastereomer as minor product, 9 was isolated in 67% yield. Cleavage of vicinol 9 in the 
presence of sodium periodate in H2O-THF (1:4) provided aldehyde 10 in 66% yield. 
Aldehyde 10 was then refluxed in a Dean-Stark apparatus stirring with morpholine and 
catalytic amount of p-toluenesulfonic acid in benzene to form crude enamine 11 as, after 
dried on vacuum, slightly yellowish oil. Due to its instability and sensitivity to moisture,  
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Scheme 6-2. Synthesis of intermediate 7 
Reagents and conditions: (a): KMnO4, EtOH-H2O, rt; 65%; (b): i. Pb(OAc)4, Na2CO3, 
DCM, 0oC;ii. Red-Al, benzene, 0oC to rt; 43% for 3 and 86% for 4 in two steps; (c): 
TBSCl, Imidazole, DCM, rt; 88%; (d): TBAF, THF, rt;78%; (e): i. n-BuLi, p-TsCl, THF, 
-78oC; ii. n-BuLi, Ph2PH, THF, -78oC; iii. H2O2, H2O, DCM, rt; 59% in three steps. 
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Scheme 6-3. Synthesis of intermediate 12 
Reagents and conditions: (a): Ac2O, Pyr, DMAP, DCM, rt; 92%; (b): OsO4, NMO, 
Acetone/t-BuOH, rt; 67%; (c): NaIO4, H2O-THF, 0oC; 66%; (d): Morpholine, p-TsOH, 
PhH, reflux; (e): KMnO4/Al2O3, Acetone, rt; 70% in two steps. 
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the crude enamine mixture was used for next step immediately without further 
purification. While the removal of C-22 on the chiron could be accomplished when 
treating 11 with singlet oxygen [242], this photo-oxygenation procedure was rather 
tedious. By referring to an alternative strategy [243], the yellowish oil was dissolved in 
acetone and treated with alumina supported potassium permanganate that was made prior 
to use, to provide the other key intermediate 12 in 70% for two steps after 
chromatography. 
 
As shown in Scheme 6-4, Grignard reagent 13 was readily accessible by refluxing 
commercially available 1-bromo-4-methyl-pentane with magnesium in anhydrous THF. 
After 2 hours, 13 was immediately subjected to Grignard reaction to form the diol 14 
with 80% yield. Similar to our previous studies [239], only the 20S-epimer was isolated 
over chromatography due to the steric effect of both 18-methyl and 8-acetyl. This stereo-
specificity is further supported by quantum mechanical calculations employing density 
functional theory (DFT) using Schrodinger Molecular Modeling Suite 2015. Figure 6-2 
shows the thermodynamically most stable and the preferred orientation of the acetyl 
group for the intermediate 12. This conformational preference dictated the strongly 
favored back-side attack by the Grignard reagent 13 to form 14 with 20S-OH 
configuration. The attack from the front side to form 20R-OH configuration is sterically 
prohibited, consistent with what we found previously [239, 244]. Oxidation of diol 14 
using Cornforth reagent pyridinium dichloromate (PDC) gave 20S-hydroxy Grundmann`s 
ketone 15 in 89% yield. Compound 15 was subsequently introduced protecting group 
EOM on its tertiary alcohol to form ketone 16, the other key intermediate for the final 
coupling step. With both C/D-ring fragment 16 and phosphine oxide 7 in hand, 
construction of the 20S-(OH)D3 framework was successfully accomplished by 
employing Wittig-Horner reaction in the presence of phenyllithium (0.18 M, diluted from 
commercial source) in THF to form 17 in 52% yield. Simultaneously removal of EOM 
and TBS was achieved using camphorsulfonic acid (CSA) to produce the target 
compound 20S-(OH)D3 in 37% yield.  
 
 
Results 
 
Figure 6-3 showed the comparison of 1H-NMR of 20S-(OH)D3s obtained from 
UVB irradiation and total synthesis. Clearly, smilar to the one that was generated via 
UVB irradiation, 20S-(OH)D3 obtained from total synthesis showed a desirable purity. 
 
 
Discussion 
 
20S-(OH)D3, a noncalcemic vitamin D3 analog, was enzymatically converted 
from vitamin D3 by P450scc and was first chemically synthesized via UVB irradiation 
[239]. However, this photochemical method also produces structurally similar and 
physicochemically active by-products that present a significant challenge for purification 
and further SAR studies for the promising 20S-hydroxyl scaffold. To overcome the  
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Scheme 6-4. Synthesis of 20S-(OH)D3 
Reagents and conditions: (a): Mg. THF, reflux; (b): THF, reflux; 80% (c): PDC, DCM, rt; 
89%; (d): EOMCl, DMAP, TEA, DCM, rt; 90%; (e): 7, PhLi, THF, -78oC to rt; 52%; (f): 
CSA, DCM-MeOH, rt; 37%. 
 
 
 
 
 
 
Figure 6-2. Preferred conformation of the intermediate (compound 12) calculated 
with density function theory with 6-31G** baseset 
“Front” side attack by the bulky Grignard agent 13 to form 20R isomer of 14 is prohibited 
due to the steric hindrance from the 18-methyl and other moieties in compound 12, while 
the “back” side attack to form 20S isomer is strongly favored. 
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Figure 6-3. 1H-NMR comparison of 20S-(OH)D3 obtained via UVB irradiation 
and total synthesis 
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deficiencies in current synthesis an alternative synthetic method was developed. The total 
synthetic strategy described in this report involves Wittig-Horner coupling and Grignard 
reaction and is successful in generating 20S-(OH)D3 in 0.4% overall yield in 16 steps. A 
distinct advantage of this method over our previously reported method is that after we 
generate the two key intermediates phosphine oxide 7 and C/D-ring ketone 12 on gram 
scale from a common starting material vitamin D2, we can efficiently make side chain 
derivatives for in-depth SAR studies of this 20S-hydroxyl scaffold. 
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CHAPTER 7.    SUMMARY AND FUTURE DIRECTION 
 
 
Cancer poses a tremendous challenge for public health in the 21st century. 
According to the statistics from the American Cancer Society, 1,688,780 new cases and 
600,920 deaths are estimated to result from cancers in 2017. Melanoma is the least 
common but is the most lethal form of all skin cancers. About 80% deaths of patients 
with skin cancers are attributed to melanoma. Melanoma can spread to nearby lymph 
nodes and distant organ to eventually form advanced or metastatic melanoma. The 
overall 5-year survival rate for patients with advanced melanoma is as low as 5%. 
Encouragingly, targeted therapy and immunotherapy have achieved sensational success 
in the 2000s. Many BRAF inhibitors, MEK1/2 inhibitors, and immune checkpoint 
inhibitors have been approved by the FDA, vemurafenib, dabrafenib, trametinib, 
cobimetinib, nivolumab, pembrolizumab, lpilimumab, for instance. These drugs are more 
effective to treat advanced melanoma than traditional chemotherapy (e.g., dacarbazine 
and temozolomide). 
 
There are however problems within both targeted therapy and immune checkpoint 
inhibitors. For targeted therapy, patients are found to acquire drug-resistance after 6-
month treatment with BRAF inhibitors vemurafenib or dabrafenib; the acquired 
resistance can markedly result in the resumption of tumor progression. Melanoma cancer 
cells develop drug-resistance to targeted therapy through many mechanisms; these 
mechanisms include but are not limited to: reactivation of the MAPK pathway by 
activating mutation of the downstream or upstream of BRAF; elevation of other RAF 
subtypes; BRAF amplification; ERK1/2 mutation; RTK upregulation; and PI3K pathway 
gene mutation. For immunotherapy, irAEs are significant problems. IrAEs if not treated 
in time, can be fatal. 
 
Anticancer agents can be obtained from a natural source or through a medicinal 
chemistry program. Many of these agents are demonstrated to exhibit significant 
antitumor effects in preclinical and clinical trials, however, only a small portion of these 
agents are ultimately approved by the FDA for clinical cancer treatment. This is because 
that a large portion of antitumor agents are non-specific to tumor cells and can result in 
systemic toxicities to healthy cells. In the last decade, ADC is one of the most dynamic 
fields in drug discovery. ADC resorts to its antibody to selectively deliver cytotoxin to 
the target disease tissues or tumor cells. This can not only minimize the exposure of 
cytotoxins to healthy tissues but also maximize the concentration of cytotoxins to reach 
the tumors. Compared to cytotoxin alone, ADC generally has a broader therapeutic 
window. 
 
ADC is composed of a potent cytotoxic chemical, a linker and an antibody. The 
roles of each portion of ADC are summarized well in excellent reviews published 
recently [166-168]. In general, all the three portions in ADC and the antigen localizing on 
the surface of tumor cell are vital for a successful ADC. The antigen should be highly 
expressed in the tumor instead of in the healthy tissue. This is because, on one hand, 
expression of antigen in the normal tissue can induce the ADC to move toward normal 
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cells and thereafter result in off-target toxicity; on the other hand, expression of antigen 
in the healthy tissue will reduce the availability of ADC to the tumor and lead to reduced 
antitumor effect [245]. In addition to the specificity in tumor, the antigen should have the 
ability to internalize the ADC upon its binding to the antibody; an inability of the antigen 
to recycle ADC to extracellular environment is also desirable in order to maintain the 
concentration of the free cytotoxic chemical in the cytoplasm of tumor cell. In ADC, the 
antibody is also critical. A favorable antibody should show not only high specificity and 
affinity to the antigen on the surface of tumor cell but also pharmacokinetic stability in 
circulating blood [246]. A stable antibody can increase the level of ADC to reach the 
antigen. Similarly, a stable linker in circulating blood also increases the opportunity for 
the ADC to bind to the antigen. Currently, linkers in ADCs can be divided into two 
groups: cleavable linkers (e.g., acid-labile linkers, protease cleavable linkers, and 
disulfide linkers) and non-cleavable linkers. The cleavable linkers are not only required 
to be stable in circulating blood but also should allow rapid release of cytotoxic chemical 
upon internalization to the cytoplasm of tumor cells [247, 248]. Cytotoxic chemical in 
ADC is named payload or warhead. A successful ADC highly depends on the payload. 
An ideal payload should have functional group(s) to conjugate to the linker; the new bond 
formed after conjugation should be stable in circulating blood. In addition to the 
conjugable site(s), the payload is strictly required to have significant potency (IC50 in 
sub-nanomolar range) [249]. 
 
The FDA has approved two ADCs for clinical uses. Brentuximab vedotinin is 
approved in 2011 for the treatment of Hodgkin lymphoma and systemic anaplastic large 
cell lymphoma; trastuzumab emtansine is approved in 2013 for the treatment of HER2 
positive breast cancer. There are approximately sixty ADCs in different stages of clinical 
trials currently. The payloads applied to the construction of ADCs are limited to mainly 
two categories: DNA-damaging agents and microtubule inhibitors. The challenges to 
broaden the pool of amenable payloads for ADCs development lie in: (1) the payload 
should be linkable; (2) the payload should be hydrophilic enough to prevent the antibody 
from aggregating; (3) the payload should overcome major drug-resistance mechanisms to 
prolong the therapeutic effect of ADC. Therefore, identification of payload with 
properties mentioned above is of importance. 
 
ABI-231 is an anti-tubulin having potent antiproliferative activity (average IC50 = 
5.2 nM) against a panel of cancer cell lines. ABI-231 binds to the colchicine binding site 
in tubulin and inhibits the tubulin polymerization. Importantly, ABI-231 can effectively 
overcome P-gp mediated drug-resistance and inhibit expression of tubulin β-III isotype. 
Its in-depth SAR study was however obstructed for many years due to an inefficient 
synthesis (0.28% over five steps). 
 
In Chapter 2, we have established a novel synthetic method, which is amenable to 
SAR investigation and gram-scale synthesis of ABI-231. The synthetic strategy involves 
the synthesis of a diamine intermediate and imidazoline cyclization. Among the thirty 
new ABI-231 analogues, 4-methyl-3-indole and 4-indole analogues are the most potent 
and have average IC50s of 2.2 and 3.0 nM, respectively. The co-crystal structure of 4-
methyl-3-indole analogue in complex with tubulin reveals the existence of three H-bond 
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interactions between the ligand and receptor. In vivo efficacy evaluations of the most 
potent analogues in a subcutaneous mouse xenograft model with human A375 melanoma 
and an experimental lung metastasis model with B16F10 mouse melanoma are currently 
undergoing. 
 
In a consecutive SAR study of ABI-231 as reported in Chapter 3, we modify the 
3,4,5-TMP moiety in ABI-231. 3,4,5-TMP is one of the most common moieties in current 
tubulin inhibitors targeting the colchicine binding site. To the best of our knowledge, 
most structural modifications of CA-4 and its derivatives focus on either the double bond 
linkage or the 3-hydroxy-4-methoxy benzene moiety; rare modifications on the 3,4,5-
TMP moiety is reported. In Chapter 3, we have established a concise synthetic method to 
overcome the limitation of a potentially explosive diazide intermediate. This novel 
method involves a Suzuki coupling and Grignard reaction strategy. Eight new ABI-231 
analogues modifying the 3,4,5-TMP moiety are synthesized. Among these analogues, 3-
methoxy-benzo[4,5]-dioxene analogue exhibits the most potent activity (average IC50= 
1.9 nM); 3-methoxy-benzo[4,5]-dioxole analogue shows equipotent activity (average 
IC50= 4.9 nM) to ABI-231. To our best knowledge, 3-methoxy-benzo[4,5]-dioxene 
analogue represents the most successful instance modifying the 3,4,5-TMP moiety in 
CA-4 and its derivatives isosterically. Currently, mechanistic study and in vivo efficacy 
evaluation of these novel ABI-231 analogues are under investigation. 
 
During our exploration of gram-scale synthesis of ABI-231 analogues, a reaction 
that can generate a substructure of RABI scaffold in 24% yield is observed. Based on this 
observation, a concise synthetic method involving a strategy of Grignard reaction/Suzuki 
coupling reaction is established to access twelve novel RABI analogues in Chapter 4. 
Among the twelve analogues, 4-indole RABI analogue (average IC50 = 3.5 nM) exhibits 
significantly more potent activity than that of MX-RABI; the strongest antiproliferative 
activity is observed in the 4-indazole RABI analogue, which has an average IC50 of 0.8 
nM. The 4-indazole RABI analogue is the first CBSI showing sub-nanomolar range 
activity in the related scaffolds. Effort on investigating the mechanism of action and co-
crystal structures in complex with tubulin protein for the potent 4-indazole RABI 
analogues is currently undergoing.  
 
In Chapter 5, the SAR study of UC-112 is conducted by modifying the benzyloxy 
moiety. Thirty-six UC-112 analogues are synthesized. Several of the substituted indole 
analogues exhibit equipotency to that of UC-112 and MX-106. The novel indole 
analogues display significant abilities to overcome multidrug-resistance mediated by P-
gp overexpression. In the future study, obtaining a co-crystal structure of one the indole 
analogues in complex with survivin protein is warranted to confirm the therapeutic target. 
 
In Chapter 6, we have established an efficient total synthesis of biologically active 
20S-(OH)D3. This method involves divergent generation of key intermediates from a 
common starting material VD2, stereoselective formation of the 20S-hydroxyl scaffold 
through Grignard reaction, as well as Wittig-Horner coupling to construct VD3 core 
structure. This synthetic strategy provides an alternative for the synthesis of 20S-(OH)D3 
analogs rather than through UVB irradiations [250-253]. 
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In Chapter 2-4, we have modified the indole and 3,4,5-TMP in ABI-231. We have 
discovered several novel ABI-231 analogues showing more potent activities than the 
prototype ABI-231. For future structural modification of the ABI-231 scaffold, it can 
commence with the imidazole moiety in ABI-231. The co-crystal structure of 4-methyl-3-
indole analogue in complex with tubulin suggests the existence of a α-ASN101 residue 
nearby the imidazole moiety. By introducing functional groups such as amine, amide or 
heterocycles to the imidazole in ABI-231, it is potential to observe new H-bond 
interactions between these functional groups with α-Asn101 residue. Based on this 
hypothesis, two ABI-231 analogues with modifications of the imidazole moiety are 
proposed in Figure 7-1. A molecular modeling study of the proposed analogues has been 
performed on the platform Schrodinger 2015 molecular modeling suite (Schrodinger, 
Inc., New York, NY) using the co-crystal structure of 4-methyl-3-indole analogue in 
tubulin. The docking result is shown in Figure 7-1. 4-methyl-3-indole analogue shows a 
perfect conformational overlap with the original crystal structure and has a docking score 
of 12.0. The proposed analogues fit the pocket in a similar manner to that of 4-methyl-3-
indole analogue. Except the H-bond interactions between the imidazole NH and carbonyl 
with nearby residues α-Thr179 and β-Asp249, the modeling result also reveals the 
existence of extra H-bond interactions between the newly introdueced amino functional 
group on imidazole with nearby α-Asn101 and α-Thr 179 residues. Both proposed 
analogues have similar docking scores to that of 4-methyl-3-indole analogue. 
 
One of the proposed analogues has been synthesized by following Scheme 7-1 
and its in vitro antiproliferative activity is tested. As shown in Table 7-1, the amino 
analogue 5 is equipotent to colchicine while two intermediates 3 and 4 exhibit slightly 
decreased activities. This suggests that the 4-position on the imidazole is tolerable for 
modification. Future structural optimization can commence with relatively larger 
functional groups such as amide or imidazole ring because the molecular modeling result 
indicates the pocket in the vicinity of imidazole is broad enough to accommodate bulkier 
groups. 
  
Besides modification of the ABI-231 scaffold, RABI scaffold is also worthy 
investigating. An in-depth structural optimization of the most potent RABI analogue (15i, 
in Chapter 4) may provide a good chance to generate analogues having IC50s within 
picomolar range. Obtaining the co-crystal structure of 15i in complex with tubulin is 
therefore important and helpful for designing new generations of tubulin inhibitors. 
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Figure 7-1. Docking study of proposed ABI-231 analogues in co-crystal structure 
of 4-methyl-3-indole analogue in complex with tubulin 
 
 
 
 
 
 
Scheme 7-1. Synthesis of proposed ABI-231 analogue 5 
Reagents and conditions: (a): 3,4,5-trimethoxybenzoyl chloride, i-PrMgCl(LiCl), THF, rt; 
(b): NaOH(40% in H2O), MeOH, reflux; (c): TFA, DCM; (d): NaN3, DMSO, reflux; (e): 
H2, Pd/C, EtOAc-MeOH, rt (1:1). 
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Table 7-1. In vitro growth inhibitory effect of proposed analogue and its 
intermediates 
 
 
 
 
 
  
Compound A375 M14 RPMI7951 
3 18.9±1.1 16.4±0.9 21.5±1.3 
4 17.1±1.4 18.6±1.0 27.0±1.1 
5 12.7±0.9 11.9±1.4 17.2±2.0 
Colchicine 14.5±0.7 14.2±1.0 10.5±0.8 
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